[{"article": "\"I hope that people will respect the rigorous methodology used in this blinded, randomized, controlled trial and accept the result,\" study researcher Deirdre Lyell, MD, assistant professor of obstetrics and gynecology at Stanford University School of Medicine, says in a news release.\nThe researchers say 63% of the women who received depression-specific acupuncture reported a significant reduction in symptoms, compared to 44% of women in the other two groups combined.\nMany pregnant women who have symptoms of depression worry that taking antidepressants might harm their unborn babies -- so they stop taking their medications, say researchers at the Stanford University School of Medicine.\nAll of the women received therapy for eight weeks and were interviewed at the four- and eight-week marks by someone who did not know which treatment they were getting.\nSome received depression-specific acupuncture treatments, others had needles inserted in acupuncture points not known to relieve depression, and a third group received massage therapy.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "While acupuncture is generally safe, the story should have mentioned that 21 women in the study reported transient pain at the site of needle insertion and 1 woman experienced bleeding. ", "answer": 0}, {"article": "Hamilton, ON July 19, 2016 -- The first steps towards developing a vaccine against an insidious sexual transmitted infection (STI) have been accomplished by researchers at McMaster University.\nThe next step is more testing for effectiveness against different strains of Chlamydia and in different formulations.\n\"Vaccine development efforts in the past three decades have been unproductive and there is no vaccine approved for use in humans,\" said Bulir, who just finished his PhD in medical sciences at McMaster.\n\"The vaccine would be administered through the nose.\nTrachoma is an eye infection caused by chlamydia and is the leading cause of preventable blindness affecting millions of people in many resource-poor regions of the world.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "There is no mention of harms in the release. Did any of the mice die or develop sterility or pelvic inflammatory disease?", "answer": 0}, {"article": "People with painfully damaged knees and hips have increasingly turned to \"minimally invasive\" joint-replacement surgery. But these relatively new procedures, though they promise shorter recuperation times, are raising concerns about potential complications.\n\nMany surgeons in recent years have performed joint replacements with ever smaller incisions. In minimally invasive surgery, the incision is typically about three to four inches long, roughly half that of traditional surgery. By cutting less of the surrounding tissue...", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "\nThe article provides ample reporting on the potential harms of minimally invasive surgery (e.g., \u201cuneven leg lengths, broken hip bones, slightly off-kilter knee joints and pain in the knee because of hardened cement left in the wound\u201d).", "answer": 1}, {"article": "The study was to be presented Sunday at the Alzheimer's Association International Conference in Washington, D.C.\n\"This is a very preliminary study with a small number of subjects and the results are far from conclusive,\" said Dr. Allison Reiss, head of the Inflammation Section at Winthrop-University Hospital in Mineola, N.Y.\n\nShe believes the current study lacks information on possible confounding factors -- things such as \"coexisting illnesses, medications, hydration state, tobacco use and multiple other variables\" that could influence what's found in the saliva samples.\nSUNDAY, July 19, 2015 (HealthDay News) -- It's still very early, but scientists say a test based on a patient's saliva might someday help detect Alzheimer's disease.\n\"Saliva is easily obtained, safe and affordable, and has promising potential for predicting and tracking cognitive decline, but we're in the very early stages of this work and much more research is needed,\" study author Shraddha Sapkota, a neuroscience graduate student at the University of Alberta in Canada, said in a news release from the Alzheimer's Association.\nIn the study, Sapkota's team tested the saliva of 22 people with Alzheimer's disease, 25 people with what's known as mild cognitive impairment (a decline in memory and thinking that's sometimes a precursor to dementia), as well as 35 people whose mental skills were normal for their age.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "While it\u2019s hard to imagine harms from spitting in a cup, the story does bring up the possibility that patients\u00a0might request the test even though they show no signs of being at risk for Alzheimer\u2019s, and as with any tests, the risk of false positives is always present. The story meets our standard here. Another issue that could have been raised pertains to screening for a disease for which we do not have great treatments, and the harm that can occur when one is told they will get Alzheimer\u2019s disease and can\u2019t do much about it.", "answer": 1}, {"article": "\"I expected the weight loss to be considerable with both therapies but we were surprised to see blood pressure improve so much more with the low-carbohydrate diet than with orlistat,\" researcher William S. Yancy, Jr., MD, an associate professor of medicine at Duke University Medical Center, says in a news release.\n\"If people have high blood pressure and a weight problem, a low-carbohydrate diet might be a better option than a weight loss medication.\"\nA new study shows that a low-carbohydrate diet was equally good as the weight loss drug orlistat (the active ingredient in Alli and Xenical) at helping overweight and obese people lose weight, but people who followed the low-carb diet also experienced a healthy drop in their blood pressure levels.\n\"It's important to know you can try a diet instead of medication and get the same weight loss results with fewer costs and potentially fewer side effects,\" Yancy says.\nResearchers say studies have already shown that the two weight loss methods are effective at promoting weight loss, but it's the first time the health effects of each have been compared head to head.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Similar to the HealthDay piece, the story provides no information about the potential adverse effects of orlistat or a low-carbohydrate diet.", "answer": 0}, {"article": "It\u2019s easy to get into the habit of popping a pill to have a good night\u2019s sleep. Insomnia, which affects a third of adults, becomes more common as we age.\n\nBut as evidence has mounted about the risks of drugging the brain to induce or maintain slumber, more doctors are steering patients away from sleep aids, including over-the-counter medications, and are offering innovative behavioral-change solutions.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The article focuses on why many doctors now recommend cognitive behavioral therapy rather than drugs as the first-line treatment for insomnia. As such, it does an excellent job of laying out all the negative potential side effects of anti-insomnia drugs, both prescription and over-the-counter. Given the seriousness of these potential harms \u2013 including fatigue, sleep-walking and -eating, impaired balance and increased risks of falls and motor vehicle accidents and possibly even dementia \u2013 this careful discussion of harms\u00a0provides a valuable public service. Cognitive behavioral therapy does not appear to cause any harm, a point the story might have made more clearly, especially given that it describes the benefits as lasting for \u201cup to two years,\u201d which could lead some readers to assume that CBT stops working after a relatively short time. Nonetheless, overall, the article is more than adequate in its discussion of the harms of the two approaches.", "answer": 1}, {"article": "\"There is some limited evidence from my study and others that fish oil may be good for preventing breast cancer, but there is not sufficient evidence to make a public health recommendation right now,\" cautions study researcher Emily White, PhD, an epidemiologist at the Fred Hutchinson Cancer Research Center in Seattle.\nExactly how fish oil may affect breast cancer risk is not fully understood, but it may be related to its strong anti-inflammatory properties.\nDuctal breast cancer is the most common type of breast cancer and forms in the milk ducts.\nIn the study, 880 women developed breast cancer during six years of follow-up.\n\"If you are taking fish oil now for other reasons, this is reassuring that it may have beneficial effects beside what you are taking it for,\" she says.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Not applicable.\u00a0 No harms were discussed but this is not a serious issue in this case. ", "answer": 2}, {"article": "For more information, visit http://www.\nThe most commonly reported adverse effects were dizziness (9.7 percent) and dry mouth (7.1 percent).\nAfter six months of treatment, more than 93 percent of 901 respondents reported their pain dropped from a median of eight to four on a 10-point scale.\n\"While older patients represent a large and growing population of medical cannabis users, few studies have addressed how it affects this particular group, which also suffers from dementia, frequent falls, mobility problems, and hearing and visual impairments,\" says Prof. Victor Novack, M.D., a professor of medicine in the BGU Faculty of Health Sciences (FOHS), and head of the Soroka Cannabis Clinical Research Institute.\nThe researchers in the study also include, Ran Abuhasira, a BGU Ph.D. candidate working in the Soroka Clinical Research Center, Lihi Bar-Lev Schleider of \"Tikun Olam,\" and Prof. Raphael Mechoulam of Hebrew University.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The news release mentions the \u201cmost commonly reported side effects were dizziness (9.7%) and dry mouth (7.1%).\u201d\nIt would have been useful to include this information from the study: Among the roughly 900 subjects who took the follow-up questionnaire at six months, almost one-third \u201creported at least one adverse event.\u201d For about 10 percent of these subjects, they reported this adverse event as a 7 out of 10 on the severity scale.", "answer": 1}, {"article": "And this creates economic issues.\nWith the anterior approach, Bollinger says, \u201cwe can take\n\nX-rays during the operation, to see if the new hip is placed correctly and adjust it, when necessary.\u201d Many surgeons use a special operating table that makes this possible.\nFor this reason, new techniques are adapted slowly with extreme care, and in some cases, not at all.\u201d\n\nUnger adds that surgeons are naturally cautious and typically wait to see results from many studies before they switch methods.\nThe surgery is extensive: As its name suggests, it involves removing the joint \u2014 the damaged bone and cartilage \u2014 and replacing it with prosthetic parts made of metal, plastic or ceramics.\nAlthough agencies and hospitals don\u2019t track hip replacements by the type of procedure used, Unger says that, based on statistics from the American Association of Hip and Knee Surgeons, only 20 percent of its members choose the anterior approach.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The only mention of harms in this story is by way of showing that the more \u201cinvasive\u201d method of hip surgery is more damaging to muscle and tissue. Again, the story is framed as a risk-free operation that most surgeons are ignoring and an awful, damaging technique that leaves people teetering like Charlie Chaplin.", "answer": 0}, {"article": "The team recruited 45 healthy participants aged 21-70 years who were either obese or overweight.\nModerate-fat diet with one avocado a day lowered 'bad' cholesterol by 13.5 mg/dL\n\nThe researchers found that participants' levels of low-density lipoprotein (LDL) - referred to as the \"bad\" cholesterol - were an average of 8.3 milligrams per deciliter (mg/dL) lower after following the lower-fat diet without an avocado and 7.4 mg/dL lower after following the moderate-fat diet without an avocado, compared with their baseline average.\nIt is well known that avocados are high in fat, but the majority of an avocado's fat is monounsaturated, which is deemed a \"good\" type of fat.\n\"That is not the real-world,\" says Kris-Etherton, \"so it is a proof-of-concept investigation.\"\nKris-Etherton adds:\n\n\"We need to focus on getting people to eat a heart-healthy diet that includes avocados and other nutrient-rich food sources of better fats.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story mentions that avocados are typically consumed in the U.S. as guacamole, which is often eaten with corn chips that are high in calories and sodium. We\u2019ll call that good enough for a satisfactory rating on this criterion. The story could have gone one step further, as NBC did, and note that consumers should compensate for the extra calories from avocados by reducing intake of\u00a0nutrient-poor calories. Otherwise they\u2019re likely to gain weight.", "answer": 1}, {"article": "The George Institute is now looking at strategies to maximise uptake of the study results.\nThe Triple Pill, consisted of the blood pressure medications telmisartan (20 mg), amlodipine (2.5 mg), and chlorthalidone (12.5 mg).\nA trial led by The George Institute for Global Health revealed that most patients - 70 per cent - reached blood pressure targets with the 'Triple Pill', compared to just over half receiving normal care.\nCompared with patients receiving usual care, a significantly higher proportion of patients receiving the Triple Pill achieved their target blood pressure of 140/90 or less (with lower targets of 130/80 for patients with diabetes or chronic kidney disease).\nDr Ruth Webster, of The George Institute for Global Health, said this was a major advance by showing that the Triple Pill was not only more effective than standard care, it was also safe.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "One of the goals of the approach using reduced dosage is to reduce the likelihood of side effects, but the side\u00a0 effects reported in the study were not mentioned in the news release, and include:\nOverall, 419 adverse events in 255 patients (about 38% for the triple pill and 35% for usual care)\nOf note, both groups experienced similar rates of musculoskeletal pain (roughly 7%), but the triple pill group had much more dizziness and fainting (5.2% vs. 2.8%) as well.\nIt should have been mentioned that combination antihypertensive (blood pressure lowering) medications are well known to have dozens of \u201cmajor\u201d drug interactions, and can also cause swelling and metabolic disturbances.", "answer": 0}, {"article": "Flavonoids have been found to relax blood vessels and thereby improve blood flow, inhibit platelets from sticking together in the blood, and have a beneficial antioxidant effect. What still is not known is whether regularly eating dark chocolate, especially with its high sugar and fat content, eventually will lead to an unhealthy weight gain that would erase the beneficial effects of the flavonoids found in the cocoa.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story notes that chocolate is laden with fat and calories, potentially harmful in people who are already overweight or obese.\n", "answer": 1}, {"article": "Khandaker said that five of the 20 studies focused on one specific cytokine.\nAnti-cytokine drugs \"dampen down inflammation by blocking the actions of specific inflammatory cytokines ... with 'surgical precision' and are now routinely used for treating patients who respond inadequately to standard treatments for inflammatory conditions such as rheumatoid arthritis, psoriasis and Crohn's disease both in the US and Europe,\" explained Dr. Golam Khandaker, a clinical lecturer in Cambridge's department of psychiatry and lead author of the new study.\n\"The findings suggest that inflammation may contribute to the pathogenesis of depression,\" Khandaker said.\n(CNN) In the future, a new class of anti-inflammatory drugs could be used to treat depression, say University of Cambridge researchers.\nLooking to the future\n\n\"Evidence at this point suggests that cytokine antagonists -- which are much more specific in their anti-inflammatory effects than drugs like aspirin -- show modest antidepressant effects in individuals with depression and increased inflammation,\" said Raison, who did not participate in in Khandaker's research.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Except for a modest reference to clinical trials \u201cstill testing their efficacy and safety\u201d for human use, and a sentence saying that \u201cside effects must also be investigated,\u201d the\u00a0discussion of harms in this story would leave readers with the impression that these drugs don\u2019t have any notable, already-well-known side effects. But they do.\nA quick check of one of the drugs (etanercept) for example, currently prescribed for some autoimmune conditions, notes that serious side effects may include heart failure, lethal blood disorders and serious infections brought on by the suppression of the immune system by way of reductions in inflammation.\nSeeking the input of an independent source to discuss these harms and risks as they compare to standard antidepressant treatment would have been helpful, too.", "answer": 0}, {"article": "But that may be changing.\n\"You need to be monitored by your surgeon during that period of time.\u201d\n\nOne downside: the implants aren\u2019t covered by insurance or Medicare, says Hamilton, adding \u201cthe cost is around $4,000 to $5,000.\u201d\n\nThere are other risks with the procedure, but they are rare, according to clinical trials.\nIt\u2019s functioning in your day-to-day life.\u201d\n\nEkstadt has the privilege of being the first person in the nation to get the Raindrop outside of a clinical trial.\nThe most recent to receive approval, the \u201cRaindrop\u201d, is made mostly from water and works by reshaping the cornea helping the eye to focus better on close-up objects.\n\u201cSo the other eye needs to have good distance vision without glasses,\u201d Hamilton says, adding that sometimes people have laser surgery to improve the distance vision in the eye that won\u2019t be getting an implant to improve vision close-up.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story does include an important sentence about how all surgery has risks. Here is that sentence.\n\u201cAny time you do surgery there is a risk of infection\u2014about one in 2,000,\u201d Hamilton says. \u201cAnd an infection in the cornea can cause scarring that can affect your vision.\u201d\nBut we wish the story had included the entire context for a patient considering one of two implants mentioned: What were the measured rates of side effects in the research? The story mentions that because the implants only correct vision for near objects in one eye, the other eye sometimes has to be operated on to give it perfect\u00a0distance\u00a0vision. We also wanted to know more about the impact of having two eyes with grossly different visual function.", "answer": 1}, {"article": "It also found that the protective effect increases with age.\nDec. 6, 2010 -- Taking aspirin over a long period of time can substantially cut the risk of dying from a variety of cancers, according to a study showing that the benefit is independent of dose, gender, or smoking.\nThis 20-year follow-up established that the risk of cancer death remained 20% lower among those who had been allocated aspirin than those in the control group for all solid cancers, including lung, prostate, brain, bladder, and kidney cancers, and by 35% for gastrointestinal cancers.\nA previous study by the same authors showed that low doses of aspirin (75-300 milligrams) reduced the number of cases of colorectal cancer by a quarter and deaths caused by the disease by more than a third.\nFor instance, it only became apparent after about five years for esophageal, pancreatic, brain, and lung cancer; about 10 years for stomach and colorectal cancer; and about 15 years for prostate cancer.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Unlike the NPR Shots story, this one failed to provide a clear number about harms. It says, \u201cPrevious research has linked aspirin with reductions in heart attacks and strokes, but doctors have been wary when recommending whether people should take daily doses of aspirin because of the risk of gastric bleeding. Rothwell says, \u201cThe size of the effect on cancer I think is such that it does more or less drown out those sorts of risks.\u201d\u201d ", "answer": 0}, {"article": "MONDAY, June 6, 2011 (HealthDay News) -- There's too little evidence to say definitively whether treating early, localized prostate cancer with radiation is a better option than \"watchful waiting,\" new research finds.\n\"What all of these analyses have found is there is very limited data that allows us to determine which of these approaches in the best approach,\" said Dr. Durado Brooks, director of prostate cancer for the American Cancer Society.\n\"We just don't have sufficient information to say much of anything,\" said Dr. Stanley Ip, an assistant professor of medicine at Tufts University Medical Center.\nRadiation, he noted, may be the best option for men whose tumors have spread outside the gland, since simply removing the prostate gland surgically is not likely to be as effective, he said.\nIt is usually recommended when doctors feel someone's advanced age will allow them to outlive the generally slow-moving cancer or when someone has other conditions that are more likely to prove lethal.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story did state:\u00a0\u201cRetrospective studies, however, found that radiation treatments were associated with increased urinary or bowel problems, compared with no treatment or no initial treatment.\u201d\u00a0 We wish it had provided more detail, but we\u2019ll give it the benefit of the doubt.", "answer": 1}, {"article": "DURHAM, N.C. - Most high-risk lung cancer patients might not need annual low-dose computed tomography (LDCT) screenings if they are cleared of disease in their initial test, according to a study led by a Duke Cancer Institute researcher.\nAn additional 75 patients (0.4 percent of the initial negative group) were diagnosed with lung cancer between the first and second annual screening.\n\"Not screening patients annually could save millions in health care costs and spare patients the radiation exposure and the downstream effects of false positive screenings.\"\nPatients were ages 55-74 who had smoked for the equivalent of 30 years (one pack a day for 30 years, two packs a day for 15 years, etc.).\nThey then compared those patients to other CT-scan recipients whose screenings detected an abnormality to assess any differences in lung cancer incidence and lung cancer-specific deaths.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "Excessive radiation exposure and risk of false positives were both mentioned.", "answer": 1}, {"article": "\"CMS made the right decision,\" said John Petrini, a Santa Barbara, Calif., gastroenterologist who heads the American Society for Gastrointestinal Endoscopy.\nAt issue is whether virtual colonoscopy will enhance quality or whether it is, in the words of one physician blogger, \"a proxy for high-tech excesses.\"\nThe prospects for significant expansion of the procedure, which is covered by a growing number of insurance companies, have collided with a large and unexpected roadblock.\nCurrently about half of Americans over 50 are screened for the disease; some shun traditional colonoscopy, which is the only way to remove polyps, because of its invasive nature.\nHis wife had undergone a colonoscopy, the gold-standard exam that costs about $1,500, but Rowe's internist recommended an alternative that was less invasive and expensive: a virtual colonoscopy, which uses three-dimensional images from a CT scan to detect benign polyps or cancers.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story does a good job of describing the potential harms of the procedure, including radiation exposure (250 times that of a chest x-ray), missing small or flat polyps, and incidental findings that might lead to unnecessary treatments. The story could have also emphasized that about 20% will require a follow-up colonoscopy because of suspicious findings.", "answer": 1}, {"article": "He emphasizes he is not against the use of gastric band surgery, but that based on his study results, patients who opt for the procedure should know there's a good chance they will need a follow-up procedure and they may have less weight loss and more complications than those who choose other weight loss surgeries.\nHis study findings, he tells WebMD, are ''a reality call.\"\nThe average weight loss was below what experts consider good results.\nNearly half of the 82 patients followed for 12 years or longer required removal of the bands and about 40% had major complications, the researchers found.\nEven so, a majority of the patients in their small study said they were satisfied with the procedure.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story did a good job providing information about the common harms, along with the percentage of individuals affected.", "answer": 1}, {"article": "It is sort of a window into the lung.\u201d\n\nCigarette smoke causes 90 percent of all cases of lung cancer, which kills 1.2 million people a year globally.\nThe main gene is called PI3K and it affects a pathway of other genes, Bild, Avrum Spira of Boston University and colleagues reported.\nAnd it can be found in the windpipes of smokers, meaning they do not need more dangerous and uncomfortable lung tests.\nAnd the second group was taking the natural supplement, myo-inositol, to try to prevent lung cancer.\n\u201cWhether it is going to save millions of people, who knows?\u201d\n\nSpira said he is working with Boston-based Allegro Diagnostics, which is halfway through a 60-patient clinical trial of the test.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "       \n \nUnfortunately, the story does not mention harms or lack thereof associated with myo-inositol. And are there any harms from collecting cells from the windpipe with a brush? The story didn\u2019t address this question. \n ", "answer": 0}, {"article": "Responding to the research, Yale Child Study Center director Fred Volkmar told WebMD: \u201cThe question remains, \u2018Is fluoxetine better than risperidone for this symptom?\u2019 It would be interesting to see studies comparing these two drugs head to head.\u201d\n\nHollander has previously received funding from pharmaceutical companies, but the current study was paid for by a grant from the Food and Drug Administration\u2019s \u201corphan\u201d drug program.\n\u201cThe clinicians could tell that people were doing better not only in terms of OCD symptoms but overall distress and ability to function.\u201d\n\nMORE: Why Are So Many Foster Care Children Taking Antipsychotics?\nThey\u2019re more able to go outside their comfort zone and to better resist their habits and rituals.\u201d One participant in Hollander\u2019s study was previously too anxious to take the subway or eat in a restaurant, but, when taking Prozac, was able to tolerate these unpredictable environments.\nFor example, they like to line up their toys and they get very bent out of shape if there is any deviation.\u201d\n\nMORE: What Does a 400% Increase in Antidepressant Use Really Mean?\nA previous, larger study of a similar medication, Celexa (citalopram), in autistic children did not find a reduction in repetitive behaviors, but the drug did reduce irritability and was superior to placebo among children who had the highest levels of irritability.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story does say that, \u201cSide effects were mild to moderate and participants taking Prozac did not show increases in suicidal thoughts or ideas.\u201d\u00a0 It could have noted, though,\u00a0 that 12 weeks may not be long enough for side effects to emerge.", "answer": 1}, {"article": "Mental skills acquired earlier in life persist well into old age, he said.\nThe results, being published today in the Journal of the American Medical Association, are heartening, but Willis and Marsiske cautioned that the biggest challenge lies ahead, in getting people to apply the findings to their lives.\nFor someone who likes to solve crossword puzzles, it is important to make sure the puzzles get harder with time -- or to start playing chess.\nIf anything, the study suggests, there is a bigger payoff to mental exercise, because the brief training sessions seemed to confer enormous benefits as many as five years later.\n\"If you think you have come to a time in your life when new learning is impossible and there are no benefits of continuing mental activity, the study shows that for a large number of people that this is not true,\" added Marsiske, a clinical and health psychologist at the University of Florida at Gainesville.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "There was no discussion of possible harms or comparisons of the harms between three cognitive training activities examined in this study.\u00a0 Perhaps there were none, but the story did not address the issue.\u00a0 The story included the example \"Knowing how to figure out directions and find a new route on a map, for example, could allow someone to retain mobility even after their night vision deteriorates\" though maintenance of this cognitive component might give someone false security about driving under conditions where they are physiologically not up to the tasks.", "answer": 0}, {"article": "While studies have highlighted the short-term benefits of CBT, until now question marks have been raised about whether it can have long-term effects.\nThe study, one of the largest randomised control trials to be held in the developing world, followed women diagnosed with depression mid-pregnancy in 40 communities in rural Pakistan.\n\u201cThese findings on the longer-term benefits at seven years post-treatment are really exciting,\u201d Bhalotra said.\nWithin a year, more than half of the women in a control group (58%) were still depressed, whereas only a quarter of the mothers who had been treated with CBT reported depression.\nThe study found that women who had least social support such as those who were not living with or near their mother or mother-in-law, benefited most from the therapy intervention, both in the short and long term.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story does not make any statement on the risks or drawbacks of this intervention. However, given the relatively low-risk profile of cognitive-behavioral therapy, we\u2019ll rate this N/A.", "answer": 2}, {"article": "The longer people took the drugs, and the higher the dose, the greater the anticancer benefit.\nIt\u2019s not the first study to show a potential anticancer effect of aspirin and other similar painkillers \u2014 a class of medications known and nonsteroidal anti-inflammatory drugs, or NSAIDs.\n\u201cGiven the high skin cancer incidence and the widespread and frequent use of NSAIDs, a preventive effect of these agents may have important public health implications,\u201d the authors, led by Sigrun Alba Johannesdottir from Aarhus University Hospital in Denmark, wrote.\nBut given the growing body of data linking aspirin use to lower cancer risk, the researchers say it may be worth factoring in the drugs\u2019 anticancer effects when patients and doctors discuss options for pain relievers.\n(One COX-2 inhibitor, Vioxx, was voluntarily pulled from the market by its maker in 2004 after it was linked to an increased risk of heart disease.)\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story mentions that aspirin and NSAIDs can cause bleeding and are associated with adverse cardiovascular effects. However, maybe these important caveats should have come sooner than paragraph eight of a nine-paragraph story. Moreover, the story could have provided some sense as to how frequently these adverse events occur and if they are common enough to counterbalance the apparent decrease in cancer associated with these drugs.", "answer": 1}, {"article": "Obese women should gain even less.\nWhile the new study generally did not show fewer complications in the diet and exercise group, Dr. Loralei Thornburg told Reuters Health that it\u2019s good that there was no increase in complications.\nOther benefits may include a lower risk of cesarean delivery, excessive birth weight, and respiratory\n\nproblems in the newborn, \u201cparticularly for high-risk women receiving combined diet and exercise interventions,\u201d add the researchers, led by Benja Muktabhant of Khon Kaen University in Thailand.\nThere was no clear benefit among the women in the diet and exercise groups when the researchers looked at other complications, such as cesarean delivery, but it did look like there may be some benefit, they write.\nAfter including the new studies, the new review found \u201chigh-quality evidence\u201d to show diet, exercise or both can reduce the risk of excessive weight gain during pregnancy, write the researchers in The Cochrane Library.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "This one was borderline but ultimately deemed Not Satisfactory. The story addresses harms through quotes from an independent source who specializes in high-risk pregnancy. She says it \u201cwas very reassuring that [the paper says] there wasn\u2019t an increased risk of preterm birth with moderate exercise.\u201d However, we\u2019d note that the paper itself says that, while there was no difference between groups with regard to preterm birth overall, \u201cLimited evidence suggested that [the effect] may differ\u2026with a trend towards an increased risk for exercise-only interventions.\u201d That\u2019s not quite as reassuring as the source suggests, and we think the result deserved some discussion. In several places, the study authors noted that the issue of preterm birth needs more research so that safe guidelines can be established.\nA related concern is that there\u2019s no acknowledgment of the increased risk of low gestational weight gain seen in the diet and exercise groups or the associated harm that inadequate weight gain could potentially cause. Only the benefits of reducing excessive weight gain are discussed. To the story\u2019s credit, it does state the importance of talking to your doctor before starting a diet or exercise regimen.", "answer": 0}, {"article": "Actually, nitrous is making a comeback in U.S. maternity circles. It has remained a staple of childbirth in Canada, Australia, and Britain \u2014 Catherine, Duchess of Cambridge (the former Kate Middleton), who welcomed her third royal baby, Louis Arthur Charles, last month, reportedly has used it. But it basically disappeared in the United States in the 1970s. American women preferred to be numbed below the waist with epidural anesthesia, or at least that became the gold standard for pain relief.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "It\u2019s mentioned:\n\u201cNitrous comes with some caveats. It can cause nausea and dizziness. It also interacts with vitamin B12, so women with a deficiency of the nutrient shouldn\u2019t use the gas \u2026 but studies \u2014 and generations of use worldwide \u2014 have not found complications or long-term problems.\u201d\nThis is enough for a satisfactory rating. However, we\u2019re left asking: where\u2019s the evidence? Some research findings to support a midwife\u2019s statement in a review that nitrous is \u201csafe for the mother, fetus, and neonate\u201d would be salient for many expecting mothers.\nIt\u2019s also important to point out that if you Google \u201cnitrous oxide & harms\u201d you will come across a much larger list of harms, some of them quite ominous. But most of these occur in the setting of the prolonged and extensive abuse of recreational nitrous oxide (aka \u201cwhippets\u201d). But, presumably, the obstetric use of nitrous \u2014 which is a brief exposure to limited doses \u2014 would pose much less risk. Mentioning this would help clarify things.", "answer": 1}, {"article": "Galvin agrees that more research is necessary before any conclusive results can be reported.\nThe MEND protocol, outlined in a 2014 study in the journal Aging, calls for interventions to treat conditions that could be associated with Alzheimer's such as inflammation, stress and diabetes.\nThe study noted that some of the patients who had to quit working as a result of their memory decline, were able to return to work after adopting MEND and participants who were struggling at their jobs reported an improvement in job performance.\nA cure for Alzheimer's disease (AD), a condition marked by progressive, debilitating cognitive decline that affects more than 5.4 million Americans, is the holy grail in disease research.\nFor example, an MRI of one patient showed hippocampal volume at the 17th percentile for his age range prior to MEND.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story does not mention any potential risks of any aspect of the protocol. It does say that MEND \u201crequires the use of supplements which are not well studied and do not require FDA approval.\u201d It does not mention what supplements these are and what risk they might present.\nAlso, the authors of the study suggest testing for the\u00a0APOE\u00a0gene,\u00a0and that those with a certain gene variance be treated with this protocol. The majority of those with the variance, though, will not get Alzheimer\u2019s, so this is potential overtreatment and exposure to harms for little-to-no benefit. Several of the 10 people in the study did not complete the protocol, and some of that might have been due to adverse effects, but that was not mentioned.", "answer": 0}, {"article": "\u201cThis isn\u2019t a magic bullet.\nThat kind of approach could be risky.\u201d\n\nNutt said the results showed that psilocybin \u201cis safe and fast acting, so may - if administered carefully - have value for these patients.\u201d\nWe\u2019re just learning how to do this treatment.\u201d\n\nMagic mushrooms grow worldwide and have been used since ancient times, both for recreation and for religious rites.\nThe World Health Organization estimates that some 350 million people worldwide are affected by depression, a common mental disorder characterized by sadness, loss of interest or pleasure, tiredness, feelings of guilt or low self-worth, disturbed sleep and appetite, and poor concentration.\nBlood pressure, heart rate and the self-reported intensity of the effects of psilocybin were monitored during each session, and the patients were seen by a psychiatrist the next day and one, two, three and five weeks after the second dose.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Potential risks\u00a0of using hallucinogenic drugs, including anxiety and paranoia, are mentioned.\nThe story also could have mentioned that inducing hallucinosis can result in other self-harm and is potentially much more dangerous.", "answer": 1}, {"article": "Their editorial accompanies the Marban report in the Feb. 14 advance online issue of The Lancet.\n\"We have been trying as doctors for centuries to find a treatment that actually reverses heart injury,\" Eduardo Marban, MD, PhD, tells WebMD.\n\"These findings suggest that this therapeutic approach is feasible and has the potential to provide a treatment strategy for cardiac regeneration after [heart attack],\" write University of Hong Kong researchers Chung-Wah Siu and Hung-Fat Tse.\n\"That is what we seem to have been able to achieve in this small number of patients.\nThe finding, just in time for Valentine's Day, is the clearest evidence yet that literally broken hearts can heal.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "There is no mention of harms in the story. Bloomberg BusinessWeek reported on the same study and said, \u201cA year after the procedure, six patients in the stem cell group had serious side effects, including a heart attack, chest pain, a coronary bypass, implantation of a defibrillator, and two other events unrelated to the heart.\u201d\n\u00a0", "answer": 0}, {"article": "A total of thirty 10-minute conversations were recorded.\nA relationship is obviously so much more than that.\u201d\n\nMembers of Williams\u2019s research team visited 15 couples in their home once a week for 10 weeks.\nIn analyzing the recordings, Williams identified 10 communication patterns that caregiving spouses used to connect with their partners and show affection.\nPrevious research has found that communication decline among people with dementia is a significant source of stress to caregivers, and most say they need education about communication.\nThey included sharing news about friends or relatives or plans for the day as a way to involve their spouse in day-to-day events; waiting patiently and keeping eye contact while spouses searched for words; and finding alternate ways to communicate \u2014 for example, singing songs together when attempts to engage the spouse in certain topics failed.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "We\u2019ll rate this category as Not Applicable since the study, and the story, were observational. The authors\u2019 conclusions are based on how they interpreted the actions of caregivers during conversations with spouses that seemed to result in more favorable communications.", "answer": 2}, {"article": "At the molecular level, genes related to the cells lining blood vessels were turned on.\nThe researchers conclude that their study, recently published in the journal Brain Stimulation, provides the first experimental evidence that whole-brain LIPUS therapy markedly improves cognitive dysfunctions without serious side effects by enhancing specific cells related to dementia's pathology.\n\"The LIPUS therapy is a non-invasive physiotherapy that could apply to high-risk elderly patients without the need for surgery or anaesthesia, and could be used repeatedly,\" says Shimokawa.\nBut there are currently no curative treatments available for vascular dementia or Alzheimer's disease, the most common causes of dementia.\nThe team, led by cardiologist Hiroaki Shimokawa, found that applying low-intensity pulsed ultrasound (LIPUS) to the whole brain of the mice improved blood vessel formation and nerve cell regeneration without having obvious side effects.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release notes there were no \u201cobvious side effects\u201d in the mice. But we really have no idea if there would be harms in humans or even primate models. Ultrasound applied to the head has been shown to warm up tissues in the brain, though what possible harm this may cause is uncertain. High-energy frequencies (greater than those used by LIPUS) can cause a raft of detrimental effects, though, including temporary suppression of brain cell function and brain damage.\nThe study goes into further detail on harms in the mice models by stating \u201cLIPUS-treated mice showed no signs of cramps, paralysis, cerebral hemorrhage, hypothermia, hyperthermia, or increased mortality compared with control mice.\u201d However, you can\u2019t ask a mouse how it feels, and it\u2019s uncertain how often LIPUS may be needed in a mouse, let alone a person, to reap any potential benefits.", "answer": 0}, {"article": "\u201cDr.\n\u201cHere at Valley, we are proud to offer this option for our patients and are excited about its potential for vastly improving patient care for women with breast cancer.\u201d The technique involves placing tissue expanders (interim implants) under the skin on top of a woman\u2019s pectoralis muscles after her breast tissue has been removed.\n\u201cIt is very rewarding as a reconstructive surgeon to continuously refine these procedures for our patients.\u201d\n\nMs. Burt chose the Valley breast surgery team after carefully researching her treatment options for DCIS (ductal carcinoma in situ), a diagnosis that is often debated among clinicians as to whether it should be classified as breast cancer at all.\n\u201cIt\u2019s important to listen to each woman\u2019s needs and then to decide together what is the best approach to treatment, so that in the end the cancer will be gone and the woman can move on with her life,\u201d says Dr. Wilson.\nIn addition to exceptional cosmetic results, the technique is likely to improve clinical outcomes as evidenced by ongoing research that shows women who undergo this procedure experience less pain and a shorter recovery period.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "As a 2013 New York Times Well blog post highlights, about one-in-four nipple-sparing surgeries (promoted by\u00a0this release) lead to dead tissue \u201cin the areola or in nearby skin\u201d \u2014 and additional surgeries to remove that dead tissue.\nThe risks or necessity\u00a0of mastectomy and reconstructive breast surgery aren\u2019t mentioned, either. Mastectomies (as compared to lumpectomies or avoiding surgery altogether) may not lead to better outcomes for many women. Also, implants can leak, cause infections, and lead to other complications. We\u2019re also not told how radiation and chemotherapy \u2014 two extremely common treatments in conjunction with breast cancer surgeries \u2014 affect results.\nThe one saving grace of this release is its last word, which makes a case for approaching each woman\u2019s diagnosis and treatment on an individual basis.", "answer": 0}, {"article": "Bochner and his colleagues Drs.\nIf the results are favorable, the next step would be to get funding to actually test whether taking a BTK inhibitor will improve the ability of food-allergic adults to eat foods they're allergic to.\n\"The hope is that drugs like BTK inhibitors will protect people with food allergies from having anaphylaxis, or at least increase how much of that food they can eat without reacting,\" Bochner said.\nCurrently, the study is being expanded to adults with food allergy to see if their skin test and basophil activation test responses show a similar reduction with just a few doses of ibrutinib and how long such benefits might last.\nWhile the study was small - only two patients qualified out of about 35 that were screened for allergies - the implications are much larger for later phases of this study.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "Readers of this release get no alert that the labeling of ibrutinib warns of potentially life-threatening bleeding, infections, decreased blood cell counts, heart rhythm problems and also that patients commonly suffer diarrhea. The release not only fails to mention any of these risks and side effects, it projects an unsupported aura of safety by describing the drug as an FDA-approved \u201csuccessful and less-toxic alternative to chemotherapy.\u201d", "answer": 0}, {"article": "It also has a very low rate of false positives - it is 98% accurate at ruling out RA.'\nThis latest research provides the basis of tests that could improve diagnosis and, importantly, detect disease at a very early stage, with the promise even that people at risk of developing rheumatoid arthritis can be followed before the disease begins.\n'When we looked at results from more than 2000 patients we found that testing for antibodies that target citrullinated tenascin-C (cTNC) could diagnose RA in around 50% of cases, including some cases not identified by CCP.\nThe Kennedy Institute's Professor Kim Midwood said: 'What is particularly exciting is that when we looked at samples taken from people before their arthritis began, we could see these antibodies to cTNC up to 16 years before the disease occurred - on average the antibodies could be found seven years before the disease appeared.\nWhile tests for individual proteins usually have a relatively low diagnostic sensitivity, a more general test called CCP, that detects synthetic citrullinated peptides, identifies a lot more RA cases.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release briefly notes that the test carries a very low rate of false positives. However, the harms from screening tests are well-known. A false positive can result in additional tests, unnecessary treatment, anxiety and financial strains. A major concern is using the test in asymptomatic individuals who may be at risk for future development of symptoms due to rheumatoid arthritis. If the test isn\u2019t 100% specific, it means we\u2019re telling some patients who are otherwise fine that they\u2019re going to develop something bad in the future \u2013 when in fact they won\u2019t. Oops! Second, it isn\u2019t clear that treating such asymptomatic patients may benefit them long-term. Remember the drugs for rheumatoid arthritis all have side effects \u2013 some of which can be quite serious. These potential harms are not mentioned at all.", "answer": 0}, {"article": "\"I was lucky,\" he said.\nThe odds are that the person is having cardiac arrest - the heart suddenly stops - which can occur after a heart attack or be caused by other heart problems.\nOne person who's been spreading the word about hands-only CPR is Temecula, Calif., chiropractor Jared Hjelmstad, who helped save the life of a fellow health club member in Southern California\n\nHjelmstad, 40, had read about it in a medical journal and used it on Garth Goodall, who collapsed while working out at their gym in February.\nIn a major change, the American Heart Association said Monday that hands-only CPR - rapid, deep presses on the victim's chest until help arrives - works just as well as standard CPR for sudden cardiac arrest in adults.\nThe last update, in 2005, put more emphasis on chest pushes by alternating 30 presses with two quick breaths; those \"unable or unwilling\" to do the breaths could do presses alone.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The American Heart Assocation recommendations and the Circulation report provide contraindications for compression-only CPR, which the segment properly notes.\nThe report and recommendations cite no other risks of compression-only CPR. The published study cites the possibility that some unidentified subgroup of patients may benefit from traditional CPR, but says no research has demonstrated this.\nRib fractures are a potential harm, and the story could have mentioned this. Nonetheless, we\u2019ll give the story the benefit of the doubt on this criterion. \u00a0 ", "answer": 1}, {"article": "Researchers from the United Kingdom conducted a randomized controlled trial on the effectiveness of advice from primary care physicians to use nasal irrigation and/or steam inhalation for chronic sinusitis.\n\"We have found that even a very brief intervention of a video showing patients how to use saline nasal irrigation can improve symptoms, help people feel they do not need to see the doctor to manage the problem, and reduce the amount of over-the-counter medication they need to use,\" said Dr. Paul Little, Primary Care and Population Sciences Unit, University of Southampton, Southampton, United Kingdom.\n\"We found potentially important changes in other outcomes; in particular, fewer participants in the nasal irrigation group than in the no-irrigation group had headaches, used over-the-counter medications and intended to consult a doctor in future episodes,\" write the authors.\nThe study involved 871 patients from 72 primary care practices in England who were randomly assigned to 1 of 4 advice strategies: usual care, daily nasal and saline irrigation supported by a demonstration video, daily steam inhalation, or combined treatment with both interventions.\nAdvising patient with chronic sinus congestion to use nasal irrigation - a popular nonpharmacologic treatment - improved their symptoms, but steam inhalation did not, according to a randomized controlled trial published in CMAJ (Canadian Medical Association Journal).\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "There is no mention of harms. While considered to be safe, there are risks to nasal irrigation that include a potential failure to seek appropriate medical attention as well as infection, headache and nosebleed, according this consumer fact sheet by the FDA.", "answer": 0}, {"article": "Within one month of the emergency department visits, 727 heart attacks or death in patients occurred.\n\"We have developed a simple lab score that is superior to using cardiac troponin alone for the identification of patients at low and high risk for heart attack or death at emergency department presentation,\" say Dr. Peter Kavsak, McMaster University, Hamilton, Ontario.\n\"Adoption of the clinical chemistry score algorithm would standardize reporting of high-sensitivity cardiac troponin test results, how the tests are interpreted in the normal range, and represent an option less susceptible to both analytical and preanalytical errors.\nThe score, published in CMAJ (Canadian Medical Association Journal), can also identify patients at risk of subsequent heart issues after discharge.\n\"Clinical chemistry score versus high-sensitivity cardiac troponin I and T tests alone to identify patients at low or high risk for myocardial infarction or death at presentation to the emergency department\" is published August 20, 2018.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The text is specific about the number of heart attacks that would have been missed by the scoring system (1 out of 727) in this population of 4000+ patients who went to emergency rooms with possible symptoms.\nThis indicates a high sensitivity, which is good because it means that the test is not missing people likely to have a heart attack or die within 30 days. \u00a0However, the other potential harm from a diagnostic test is from false positive results \u2014 which could lead to unnecessary hospitalizations and treatments. \u00a0This statistic is not addressed in the release, though it is presented in the study.", "answer": 1}, {"article": "Seventy-four subjects with type 2 diabetes were randomly assigned to follow either a vegetarian diet or a conventional anti-diabetic diet.\nThe vegetarian diet consisted of vegetables, grains, legumes, fruits and nuts, with animal products limited to a maximum of one portion of low-fat yoghurt per day; the conventional diabetic diet followed the official recommendations of the European Association for the Study of Diabetes (EASD).\nUsing magnetic resonance imaging, Dr. Kahleov\u00e1 and colleagues then studied adipose (fat-storage) tissue in the subjects' thighs to see how the two different diets had affected subcutaneous, subfascial and intramuscular fat (that is, fat under the skin, on the surface of muscles and inside muscles).\nLosing muscle fat improves glucose and lipid metabolism so this finding is particularly important for people with metabolic syndrome and type 2 diabetes, says lead author, Dr. Hana Kahleov\u00e1, Director of Clinical Research at the Physicians Committee for Responsible Medicine in Washington DC.\nThis finding is important for people who are trying to lose weight, including those suffering from metabolic syndrome and/or type 2 diabetes.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release may encourage people to embark on a vegetarian diet without enough knowledge of the potential downsides. Without careful meal planning, people on vegetarian diets risk not getting enough protein, vitamin B-12, iron, zinc, omega-3 fatty acids. A brief mention of these challenges would have been helpful.", "answer": 0}, {"article": "For more information, visit http://www.\n\"The aim is to target the thinking abnormality we see in patients with MDD - that of perseverating, ruminating, obsessing, dwelling on the negative - by activating these two nodes (emotion processing and cognitive control) simultaneously.\nThe underlying mechanism for MDD that the intervention targets involves an imbalance in the activity of specific brain regions: individuals with MDD show hyperactivity of neural systems involved in emotion processing, such as the amygdala, coupled with decreased activity of systems involved in cognitive control and emotion regulation, such as the prefrontal cortex.\nIn the trial, the therapeutic reduced MDD symptoms by 42 percent in the experimental group after six weeks compared to 15.7 percent in the control group, which was given a similar task using simple shapes instead of emotions.\nErik Lium, PhD, Senior Vice President at MSIP, said, \"We strongly believed in the potential of this technology based on early trials at Mount Sinai, and are pleased with our commercial partnership with Click Therapeutics.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "We found just one comment.\u00a0Excerpt: \u201cThe initial results demonstrate that the efficacy of this digital therapeutic is comparable to drug therapy, with a highly favorable safety profile.\u201d\nEach drug shows different efficacy, so we\u2019re not sure how this was established. Also, it\u2019s standard to track\u00a0adverse events in trials. For this one, what adverse events did the researchers find? We\u2019re not told.", "answer": 0}, {"article": "This study -- Propentofylline inhibits glioblastoma cell invasion and survival by targeting the TROY signaling pathway -- also was funded by the National Institutes of Health under grants NS86853 and P50 CA108961.\nOnly 5 percent of patients survive more than 5 years.\nWorking with collaborators in the scientific and medical communities literally worldwide, TGen makes a substantial contribution to help our patients through efficiency and effectiveness of the translational process.\nTGen found that PPF works to limit the spread of glioblastomas by targeting and knocking down the expression of the TROY protein.\nOne of the fundamental challenges in treating brain cancer with drugs is what is known as the blood-brain barrier that separates circulating blood from the brain extracellular fluid in the central nervous system.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "Not only does the release fail to mention any potential harms, it dismisses such concerns with a quote about \u201cminimal side effects.\u201d", "answer": 0}, {"article": "\u201cThe treatment of cachexia just doesn\u2019t exist.\n\u201cThis same calcium signal also activates signaling pathways to increase skeletal muscle endurance and also skeletal muscle size.\u201d\n\nSah\u2019s research team hypothesized that low level calcium cycling induced by these natural compounds might promote improved exercise capacity and overall metabolic health associated with healthy muscle mass.\nThe discovery was a \u201cserendipitous finding\u201d in the lab of Rajan Sah, M.D., Ph.D., assistant professor of Internal Medicine and Molecular Physiology and Biophysics at the University of Iowa.\nIn pre-clinical studies, compounds in thyme and oregano have demonstrated a greater than 37 percent increase in exercise tolerance and a 15 percent increase in muscle mass of certain body muscles.\nThe intellectual property associated with this discovery was recently licensed by the UI Research Foundation to Innovus Pharma, an over-the-counter consumer goods and specialty pharmaceutical company that commercializes non-prescription medicine and consumer care products.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "There is no mention of harms from these mysterious, unnamed\u00a0compounds.\u00a0 And without their identification, readers are left clueless about any risks that might be involved. The inference is that since oregano and thyme are common, edible spices that they would present no harms once prepared in over-the counter products.", "answer": 0}, {"article": "Cooper and his colleagues looked at 29,507 births to women covered by Medicaid in Tennessee between 1985 and 2000.\n\"I think it is safe to say that not a lot is known about the options for women in pregnancy,\" said Sandra L. Kweder of the FDA's Center for Drug Evaluation and Research.\n\"It would be important for a pregnant woman and her health-care provider to be aware of this, so they can identify an alternative medicine to treat her hypertension,\" said William O. Cooper, a pediatrician at Vanderbilt Children's Hospital who headed the study, published in today's New England Journal of Medicine.\nThe alternatives that clinicians might want to consider are diuretics, alpha-methyldopa, some beta-blockers, and the calcium-channel blocker nifedipine, according to the FDA officials and an editorial accompanying the study.\nThe fraction of babies with defects was 7.1 percent in the ACE-inhibitor group; 1.7 percent in the other anti-hypertensive group; and 2.6 percent in the group taking no blood-pressure medication.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The harms to the fetus of treating a mother with an ACE inhibitor during the first trimester of pregnancy are plainly mentioned. However the risks of NOT using ACE inhibitors in some women (congestive heart failure, diabetes) are not mentioned. This study was not done in a high risk group and the risks of undertreatment may be greater in some populations. So, for example, women with diabetes and renal dysfunction or those with congestive heart failure would have gotten an incomplete picture from the article.", "answer": 0}, {"article": "Cedric Garland, meanwhile, hews just as strongly to the opposite view \u2014 that vitamin D supplements confer a slew of benefits, including warding off colon cancer, breast cancer, even Type 1 diabetes.\nI just don\u2019t know which one.\u201d\n\nHurley is a science journalist and author of \u201cNatural Causes: Death, Lies and Politics in America\u2019s Vitamin and Herbal Supplement Industry\u201d (Broadway Books, 2007).\n\u201cBut keep in mind, there isn\u2019t yet evidence that taking those higher amounts will confer any benefits beyond the recommended daily allotment of 600 to 800 IU.\u201d\n\nSome studies, she noted, have even found evidence that very high levels of vitamin D circulating in the blood might be just as unhealthful as very low levels.\n\u201cIt\u2019s just preposterous to say it\u2019s not proven.\u201d\n\nIn January 2014, Autier published a statistical analysis of results from hundreds of studies of vitamin D. He concluded: \u201cUnfortunately, there is probably no benefit to expect from vitamin D supplementation in normally healthy people.\u201d\n\nGarland, on the other hand, is the co-author of dozens of studies showing a strong, inverse association between vitamin D levels and seemingly every disease under the sun.\n\u201cThe higher your latitude and the greater your area\u2019s average cloud cover, the higher your rates of cancer.\u201d Since he and his late brother, Frank Garland, published the first study, in 1980, revealing that relationship, hundreds of other studies have explored the link between vitamin D, including supplements, and health \u2014 but none were large enough, long enough or designed well enough to convince the skeptics.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Research has shown risks from high levels of vitamin D. We were glad the story included the following:\n\u201cA 2014 study, for instance, found that people with the highest levels of vitamin D in their blood (more than 60 nanograms per milliliter) were significantly more likely to die in the three months following a hospitalization as were people whose levels were between 30 and 49.9 ng/mL.\u201d\nAnother possible harm that the story could have examined is people downing pills and thinking they have \u201cprevented\u201d some future problem. Does taking a vitamin pill reassure them and delay or forestall established preventive measures such as diet and exercise, known to help prevent type 2 diabetes and heart disease?", "answer": 1}, {"article": "For further information, please visit: http://www.\nBethan Hughes, from Wellcome's Innovation team said: \"This innovation has the potential to transform lives for those who suffer loss of sight through glaucoma, and offers hope of a breakthrough in early diagnosis of other neurodegenerative diseases.\n\u2022 Link to paper: The following link will go live at the time the embargo lifts: https:/\n\u2022 For embargoed copies of the BRAIN paper and for media enquiries please contact Maggie Stratton: m.stratton@wellcome.ac.uk +44 (0)20 7611 8609/ +44 (0)787 211 2656\n\u2022 For further information about DARC technology please contact Emma Alam: e.alam@uclb.com +44 (0)207 679 9000/ +44 (0)7896 058667\n\nUCL Business PLC (UCLB) is a leading technology transfer company that supports and commercialises research and innovations arising from UCL, one of the UK's top research-led universities.\nIn clinical trials, the pioneering diagnostic -- developed by researchers at University College London (UCL) and the Western Eye Hospital -- allowed doctors to see individual nerve cell death in the back of the eye.\nProfessor Philip Bloom, Chief Investigator at Western Eye Hospital, part of Imperial College Healthcare NHS Trust, added: \"Treatment is much more successful when it is begun in early stages of the disease, when sight loss is minimal.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release states only that the initial trials established the safety of the test in patients. The published research says that \u201cANX776 [the florescent marker or dye injected into patients] was found to be safe and well-tolerated with no serious adverse events, and a short half-life (10\u201336 min).\u201d If there were non-serious side effects, readers deserve to know what they are.", "answer": 0}, {"article": "For more information about NIH and its programs, visit www.nih.gov.\nThe new study, supported by NIH\u2019s Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), provides strong evidence that even a partial course can have some benefit.\nSteroids improve survival and reduce the chances of certain birth defects for extremely premature infants, even if the treatment course is not finished before delivery, according to a study funded by the National Institutes of Health (NIH).\nAbout the National Institutes of Health (NIH): NIH, the nation's medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services.\nThe study team also found evidence that the better outcomes likely were due to lower rates of bleeding in the brain and of a brain injury called cystic periventricular leukomalacia.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "Every intervention carries risks, and antenatal steroid therapy is no exception. Although this therapy is generally deemed to be safe, some studies have reported undesired effects on the mother\u2019s immune system and metabolism, as well as reduction of fetal heart rate and breathing movements. A multiple course of antenatal steroids might even slow fetal intrauterine growth and lower neonatal birth weight.\nSince harms were not addressed, we give the news release a Not Satisfactory rating.", "answer": 0}, {"article": "Researchers used CAR-T to treat a man with brain cancer to some success\n\nGlioblastoma is one of the deadliest cancers \u2014 an illness that responds to few treatment options, and often poorly. But a single case study that uses an experimental immunotherapy to treat these brain tumors might give oncologists a new way to approach the disease.\n\nThe therapy, called CAR-T, is controversial and has faced hurdles in clinical trials. It has shown great promise in treating blood cancers like leukemia and lymphoma \u2014 but has proven challenging in treating other forms of the disease, including solid tumors.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "This was a tough call, but we\u2019re leaning toward satisfactory.\nOn one hand, the STAT story\u00a0does acknowledge the downsides, so far, of CAR-T therapy, by referring to the adverse events as \u201cnotorious\u201d and providing a link for more information.\nOn the other hand, the story only mentions that severe side effects have occurred\u00a0without telling us any of\u00a0those side effects and what the side effects (if any) were for the one patient treated. Instead it says the patient\u2019s side effects were \u201cfairly innocuous\u201d and quotes a researcher early in the story saying \u201cit\u2019s amazing how safe it was.\u201d Yet, this hardly proves it\u2019s safe.\nSee our tips for\u00a0reporting accurately about the harms, side effects and risks of immunotherapy.", "answer": 1}, {"article": "Other New York counties took similar actions after New York City\u2019s measure was enacted.\n\u201cHere we find on a population level when we restrict them, it benefits society by reducing heart attacks and strokes.\u201d\n\nThe findings suggest the FDA\u2019s action will lead to health benefits across the country, he added.\nBrandt and colleagues write that in 2015, the U.S. Food and Drug Administration (FDA) removed manufactured trans fats from its list of safe food additives.\n\u201cNew York City was progressive and they enacted restrictions on trans fats, but no one looked to see if this made measurable changes to outcomes,\u201d said study lead author Dr. Eric Brandt, of Yale University in New Haven, Connecticut.\nWhile admissions for heart attacks and strokes fell after 2002 in all the counties, the drop was more substantial in those that enacted trans fat restrictions, the authors found.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The concept of harm/side effects does not seem relevant here.\nHowever, we did want to note: When trans fats were first introduced, they were supposed to be a healthy alternative to tropical oils with lots of saturated fat. Now that they are being removed, it\u2019s worth discussing what they will be replaced with and whether that change could have negative health consequences, too.", "answer": 2}, {"article": "Esketamine received Breakthrough Therapy Designations from the U.S. FDA in November 2013 for treatment-resistant depression and in August 2016 for the indication of major depressive disorder with imminent risk for suicide.4\n\nAbout Major Depressive Disorder\n\nMajor depressive disorder affects nearly 300 million people of all ages globally and is the leading cause of disability worldwide.5 Individuals with depression, including major depressive disorder, experience continuous suffering from a serious, biologically based disease which has a significant negative impact on all aspects of life, including quality of life and function.5 Although currently available antidepressants are effective for many patients, about one third of patients do not respond to treatment and are thought to have treatment-resistant depression.6\n\nAbout the Janssen Pharmaceutical Companies of Johnson & Johnson\n\nAt the Janssen Pharmaceutical Companies of Johnson & Johnson, we are working to create a world without disease.\nThe reader is cautioned not to rely on these forward-looking statements.\nThese statements are based on current expectations of future events.\nWe are Janssen.\nWe bring together the best minds and pursue the most promising science.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release discusses adverse effects.", "answer": 1}, {"article": "The women ranged in age from 18 to 86.\nTwo commercial tests based on markers of DNA chemical changes called methylation, released in Europe last summer, require Pap smears or swabs of cervical tissue, and show 64 percent sensitivity in identifying similar lesions, according to senior investigator Rafael Guerrero-Preston, Dr.P.H., M.P.H., assistant professor of otolaryngology-head and neck surgery at the Johns Hopkins University School of Medicine and member of the Johns Hopkins Kimmel Cancer Center.\nThe new study builds on the Johns Hopkins team's previously published work, in which investigators identified three genes associated with cervical cancer or abnormal-looking cells known to become cancerous: FKBP6, INTS1 and ZNF516.\nIn a proof-of-concept study, described online in Cancer Prevention Research on November 8, the investigators say their genetic markers test showed a \"sensitivity\" or accuracy rate of 90.9 percent in identifying so-called CIN2 lesions -- cervical lesions with abnormal cells likely to not only develop into cancer, but also to develop into cancers likely to spread.\n\"If further studies confirm these findings, we see a significant use of urine screening as a way to quickly and inexpensively determine if a biopsy is warranted, or if physicians can use a 'watch and wait' approach before intervening,\" says Guerrero-Preston.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release does make\u00a0it clear that this small urine test study correctly identified those without cancer 83% of the time, a considerable improvement over the false positive rate of the more traditional Pap test.\nBut the real risk of this new test is that it may indicate a false negative \u2014 suggesting all is well \u2014 when it isn\u2019t. Under the best of scenarios, the new test gets it wrong 10 in 100 times. When applied to a more usual practice setting, it gets it wrong 15 to 25 in 100 times. Here getting it wrong may mean missing an advanced pre-cancerous lesion or even a cancerous one. One can argue that even 1 in a 100 times is too much, but in developing countries this may be better than current practice. However, we don\u2019t believe the risk of false negatives has been clearly or addressed.", "answer": 0}, {"article": "Eye and Ear specializes in ophthalmology (eye care) and otolaryngology\u2013head and neck surgery (ear, nose and throat care).\n\u201cThe development of cochlear implants, for example, didn\u2019t really accelerate until someone placed an electrode in the cochlea of a patient and found that the patient heard a frequency of some type.\u201d\n\nSmell loss, or anosmia, has an estimated prevalence of 5 percent of the general population.\nIn the elderly, of whom there are estimates that greater than 50 percent of the population over the age of 65 has experienced smell loss, it can be difficult to get proper nutrition, as the sensation of flavor is closely tied to the sense of smell, and as flavor diminishes, appetite decreases in this population.\nThis breakthrough in human patients opens the door for a \u201ccochlear implant for the nose\u201d to be developed \u2014 though the study authors caution that the concept of an olfactory stimulator is more challenging than existing technologies.\n\u201cThere\u2019s currently so little that we can do for these patients, and we hope to eventually be able to reestablish smell in people who don\u2019t have a sense of smell,\u201d Dr. Holbrook said.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "As with cost, it is far too early to create a laundry list of potential side effects associated with nerve stimulation to induce sensations of smell. However, there are things that could be said. For example, the study itself found that volunteers reported discomfort and occasional pain associated with the electrode stimulation. And the potential for inducing olfactory hallucination needs to be considered. \u00a0Dysosmia may be less desirable than anosmia.", "answer": 0}, {"article": "P.S.A.\nBut even with this uncertainty, prostate cancer specialists say, most men who are treated would not have died of prostate cancer, and that is especially true for elderly men, in particular those who are frail and have a limited life expectancy.\nThe cancer can be lethal, but it usually grows so slowly that men die with it, not because of it.\nPathologists can distinguish between cancers that look particularly aggressive and those that do not, but there is a real possibility that even if tissue obtained at a biopsy has only less aggressive tumor cells, more aggressive cells might still be lurking in the prostate.\nBut if a man has been screened year after year, it can be hard to suggest he stop because he may not live much longer.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The article does address the harms of overdiagnosis and treatment, though does not provide quantitative data. We\u2019ll give it the benefit of the doubt.", "answer": 1}, {"article": "A popular new type of prenatal test intended to find genetic flaws in a fetus can in rare cases also reveal previously undiagnosed cancer in the mother.\n\nThe unexpected finding emerged in a study involving eight women who initially had abnormal results from the prenatal blood test, but for whom a subsequent assessment showed their babies were normal. When the mothers\u2019 DNA was reanalyzed, researchers said, the anomalies were linked to cancer in each of the women.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The WSJ article very explicitly notes that there are harms from invasive prenatal tests, although it does not give rates of miscarriage; and it goes into welcome detail about the challenges of giving women genetic risk information for themselves or their infants based on the noninvasive blood test, noting \u201cthere is no consensus on when or how to inform\u201d patients of such findings. On the other hand, the story explains, if maternal tumor DNA is detected, the need to inform the mother may be urgent and life saving.", "answer": 1}, {"article": "Researchers recommend large-scale clinical trials to confirm that nighttime fasting results in favorable changes to biomarkers of glycemic control and breast cancer risk.\n\u201cNew evidence suggests that when and how often people eat can also play a role in cancer risk.\u201d\n\nWomen in the study reported eating five times per day with a mean nighttime fasting of 12 hours.\nIt may have a big impact on public health without requiring complicated counting of calories or nutrients.\u201d\n\nWomen who fasted for longer periods of time overnight had significantly better control over blood glucose concentrations.\nNewswise \u2014 A decrease in the amount of time spent eating and an increase in overnight fasting reduces glucose levels and may reduce the risk of breast cancer among women, report University of California, San Diego School of Medicine researchers in the journal Cancer Epidemiology, Biomarkers & Prevention.\nThe data shows that each three hour increase in nighttime fasting was associated with a 4 percent lower postprandial glucose level, regardless of how much women ate.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "There was no discussion of any potential harms associated with increasing the time periods between eating and decreasing overall calorie consumption. The\u00a0mean duration of nighttime fasting in the study was 12 hours, with discussion of \u201ceach three hour increase in nighttime fasting\u201d being associated with a lower glucose level. \u00a0It makes one wonder \u2013 but the release doesn\u2019t address this \u2013 just how long some women in the study fasted.", "answer": 0}, {"article": "\u201cIt\u2019s reasonable to screen for something that\u2019s common, dangerous and has a treatment that\u2019s effective and safe.\u201d\n\nDr. William Cooper, a pediatrics and preventive medicine professor at Vanderbilt University, called it \u201can innovative approach\u201d that finds not just kids at risk but also parents while they\u2019re still young enough to benefit from preventive treatment, such as cholesterol-lowering statin drugs.\nIn the US, cholesterol tests cost around $80 and usually are covered by health insurance though much lower prices often are negotiated.\nThe study also revealed parents who had the condition but didn\u2019t know it, and had passed it on to their children.\nThe study authors in England estimated that if cholesterol testing costs $7 and gene testing costs $300, it would cost $2,900 for every person identified as having the disorder.\nOne in 270 children had the gene mutations; others were identified through cholesterol levels alone.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The harms of screening including false positives and negatives, overdiagnosis, overtreatment, inappropriate disease labelling and so on are not mentioned.", "answer": 0}, {"article": "Otto tracked 755 patients who died from breast cancer from 1995 to 2003 and another 3,739 control patients matched by age and other measures.\nNearly 36 percent of these women had never had a mammogram.\nThe routine screening also lowered the chances of being diagnosed with an advanced cancer, she said.\nIt's not clear, for instance, whether the women who died of cancer got less aggressive treatment or refused treatment.\nThe study appears online Dec. 6 in the journal Cancer Epidemiology, Biomarkers & Prevention.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The article refers briefly to \u201covertreatment\u201d but fails to explain this or other potential harms.", "answer": 0}, {"article": "For more information about NIH and its programs, visit www.nih.gov.\n\u201cThe technique used by researchers in this study enables very early detection of metastatic spread, which would allow adaptation of treatment more quickly and hopefully lead to better outcomes in the future.\u201d\n\nThe study, published online in the Aug. 12, 2015, issue of Nature Communications, was led by Zheng-Rong Lu, Ph.D., CWRU M. Frank Rudy and Margaret Domiter Rudy Professor of biomedical engineering and an expert in molecular imaging for cancer and other diseases.\nThese are two things that potentially can make a big impact on clinical practice and also management of cancer.\u201d\n\nOne-third of patients diagnosed with breast cancer eventually develop metastases in distant organs, with an increased risk of death.\n\u201cBy also binding with the magnetically tagged peptide, the biomarker is enhanced, generating enough signal for MRI detection of small, high-risk cancer and micrometastases.\u201d\n\nThe researchers tested the approach in mice into which they had introduced breast cancer cells.\nAbout the National Institutes of Health (NIH): NIH, the nation's medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release seems overly optimistic here. It says testing by the researchers \u201cshowed that the agent is readily cleared from the body and has a low level of retention in tissues. Therefore, they expect it will be safe if ultimately developed for clinical use.\u201d \u00a0We think it would be best to conduct the necessary studies before commenting optimistically on the potential safety of the agent \u2014 after all, the point of conducting the studies is that we don\u2019t know yet if the agent is safe or not. And even if it does turn out to be safe, there could be potential side effects that patients should know about. Also, the experiments involved mice, and it\u2019s not clear if this technique would require a patient to submit to a whole body MRI in order to find metastases.", "answer": 0}, {"article": "WASHINGTON -- A U.S. Food and Drug Administration panel of outside medical experts backed a Novartis AG drug, Exelon, for treatment of dementia in patients with Parkinson's disease.\n\nExelon is currently on the market to treat mild to moderate Alzheimer's disease. The FDA said it wasn't sure whether dementia associated with Parkinson's was much different than dementia associated with Alzheimer's. Dementia is a condition that typically first presents itself as memory loss greater than what would be expected as part of the normal...", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story reports the panel believes the drug to be \u201csafe\u201d but does not describe any side effects or harms of rivastigmine. These may include nausea/upset stomach, vomitting, loss of appetite, and headaches. ", "answer": 0}, {"article": "He was fascinated by certain powerful cells of the immune system \u2014 T cells.\n\"It's a new modality for treating cancer,\" Dr. Samuel Broder, a former director of the National Cancer Institute, says now of Allison's pioneering research.\nIt might be too early to say we're going to cure cancer, Allison says, \"but we're going to cure certain types of cancers.\nA clinical trial to study the drug \u2014 now called ipilimumab, or Ippy for short \u2014 was set up at Memorial Sloan Kettering Cancer Center in New York City.\nStill, the approach offers promise to some people that other therapies can't, and has transformed the way doctors think about cancer treatment.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Harms are not mentioned, which is a significant oversight. We understand that this is a story about a man and his accomplishments in developing a tool to fight cancer. But to paint a full picture, you have to describe the tool. And it\u2019s impossible to discuss ipilimumab without discussing either its cost or its potential harms. The manufacturer\u2019s own website states that ipilimumab \u201ccan cause serious side effects in many parts of your body which can lead to death. These serious side effects may include: intestinal problems (colitis) that can cause tears or holes (perforation) in the intestines; liver problems (hepatitis) that can lead to liver failure; skin problems that can lead to severe skin reaction; nerve problems that can lead to paralysis; hormone gland problems (especially the pituitary, adrenal, and thyroid glands); and eye problems.\u201d\nJust as with costs of the drug, we don\u2019t expect a story to offer a thorough inventory of potential adverse health effects, but failure to acknowledge them in any way is a significant oversight \u2014 particularly when they can be this severe.", "answer": 0}, {"article": "To place an electronic embedded link to these articles in your story These links will be live at the embargo time: http://jama.\nEditor's Note: The author has completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest and none were reported.\n\"The results reported by Willett et al demonstrate that most unstable ankle fractures in older patients can be treated with a cast without the need for surgery,\" writes David W. Sanders, M.D., M.Sc., F.R.C.S.C., of Western University, London, Ontario, Canada, in an accompanying editorial.\nAmong older adults with an unstable ankle fracture, the use of a modified casting technique known as close contact casting (a molded below-knee cast with minimal padding) resulted in similar functional outcomes at 6 months compared with surgery, and with fewer wound complications and reduced intervention costs, according to a study appearing in the October 11 issue of JAMA.\n\"Close contact casting was delivered successfully for most participants, substantially reducing the number of patients requiring invasive surgical procedures at the outset and additional operations during a 6-month period,\" the authors write.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "A release devotes a fair amount of space to harms from casting as compared with surgery:\n\u201cRadiologic malunion (abnormal healing of a fracture) was more common in the casting group (15 percent vs 3 percent for surgery). Casting required less operating room time compared with surgery. There were no significant differences in other secondary outcomes: quality of life, pain, ankle motion, mobility, and patient satisfaction.\u201d", "answer": 1}, {"article": "For example, a poor test grade or bad performance evaluation might lead to feelings of \"I'm not good enough,\" but the lessons encourage more positive thinking about \"how many exams have you passed, to put this failure in a more accurate light,\" Guille said.\nShe said she became very depressed but had little time to seek help.\nLuckily, her depression subsided when that rotation ended.\nSuicidal thoughts were much less common in new doctors who had four half-hour online sessions before starting their first year of training, compared with those who got no therapy.\nInterns who got the sessions were 40 percent less likely to have suicidal thoughts during that first year compared to those who received four weekly emails with information about depressions and where to seek help.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "It is hard to imagine harms associated with this approach so we will rate it as not applicable.", "answer": 2}, {"article": "For more information about Pitt Public Health, visit the school's Web site at http://www.\nThe analysis, published today in the journal Stroke, determined that resuming anticoagulation therapy after a person suffers a major bleeding event was associated with a higher likelihood of stroke-free survival than discontinuing anticoagulation.\nThe risk of dying from any cause or having a stroke was 23 to 34 percent higher in patients who discontinued anticoagulation therapy compared to those who resumed it.\n\"If a patient who is on an anticoagulant to avoid a stroke has a major bleeding event, doctors are faced with a catch-22: Discontinue the anticoagulant to avoid future bleeding, but again place their patient at increased risk of stroke; or resume the anticoagulant to continue avoiding a stroke, but then have to worry about another bleeding event,\" said lead author Inmaculada Hernandez, Pharm.D., Ph.D., an assistant professor in Pitt's School of Pharmacy, who completed this work as a doctoral student at Pitt's Graduate School of Public Health.\n\"It causes a lot of uncertainty for physicians, especially because patients at highest risk of recurrent bleeding also are at highest risk of stroke,\" said co-author Yuting Zhang, Ph.D., associate professor of health policy and management at Pitt Public Health, and Hernandez's doctoral dissertation committee chair.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The news release deals with bleeding, which is the most concerning adverse effect of blood thinners. But there are other harms including joint pain, bruising and dizziness. Warfarin requires dietary restrictions and regular monitoring with blood tests.", "answer": 1}, {"article": "The robot-surgeon team might not have outperformed the surgeon alone because the procedure was a relatively simple one.\nWith the surgeon alone, \u201cthe incision is smaller (and) the manipulations are more controlled,\u201d Dr. Ceana Nezhat, an author on the study and the chair of Obstetrics & Gynecology at Northside Hospital in Atlanta, told Reuters Health.\nBut all I need to do is add 5 and 5.\u201d\n\nEspecially in a time of concern over rising medical costs, \u201cwe should not simply use the highly sophisticated technology just because it\u2019s there,\u201d Falcone said.\n\u201cWe were surprised that (surgery with the robot) did not have better outcomes than (the surgeon alone), as we have always believed if you can see more and see better you can do more and do better,\u201d the authors write.\nRather, surgeons move electronic instruments that are linked to the movement of other instruments inside the body, while they watch a three-dimensional image of what\u2019s going on inside.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story says that there were no complications in either group and goes on to say that the robotic surgeries took longer, making it more likely that surgeons would make mistakes (although they did not, apparently, make any mistakes.) It says in passing that \"the incision is smaller (and) the manipulations are more controlled\" when a surgeon works without a robot, a counter-intuitive piece of information that merited at least an additional sentence of explanation, even in a story this short.", "answer": 1}, {"article": "Lozano acknowledges that retrieving childhood memories, which he says has occurred in about one-third of his patents \u2014 requires lofty voltages that he would be uncomfortable sending patients home on.\nLast year they published a study in Molecular Psychiatry in which four of six patients either remained cognitively stable or improved in response to DBS, as measured by the ADAS-cog.\nReferring to Lozano's second clinical study, Dr. Nader Pouratian, a neurosurgeon and DBS researcher at UCLA, comments, \"The recent deep brain stimulation trial for Alzheimer's disease clearly demonstrates the safety of this approach for trying to treat the progression of disease.\nA 2012 study published in the New England Journal of Medicine reported that in seven patients receiving DBS to a brain region called the entorhinal cortex, spatial memory improved \u2013 meaning they could more easily remember the locations of newly learned landmarks.\nThe technique is also approved for obsessive-compulsive disorder and is being looked at for a number of other brain disorders, including depression, chronic pain and, as in Lozano's work, dementia.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story states that the study showed \u201cboth the surgery itself and DBS of the fornix appear safe\u201d and \u201cno serious, long-term side effects were seen in either patient group, supporting further research in the field.\u201d\nBut the story doesn\u2019t mention that 26 (61.9%) of the 42 patients in the study experienced one or more adverse effects. Five patients (11.9%) experienced one or more serious adverse effects, and four of those patients required a return to surgery.", "answer": 0}, {"article": "The U.S. Centers for Disease Control and Prevention has more about healthy eating for a healthy weight.\nOn the opposite end of the list, the Whole30 diet -- a 30-day program that bans processed foods, legumes, grains, dairy, alcohol and added sugar -- ranked as the worst overall diet on the list, the new report said.\nWhen it comes to speedy weight loss, the HMR program and Biggest Loser diet shared the top ranking, followed by the Atkins diet in second place and Weight Watchers in third.\nThe DASH diet scored highest when it comes to healthy eating, followed by the TLC diet.\nThe MIND diet includes some features of the DASH diet and Mediterranean diet, such as high consumption of fruits, vegetables and fish, but focuses on foods that promote brain health.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Potential harms of the DASH diet are negligible, so we won\u2019t ding the story for not mentioning them. We\u2019d note, however, that USN&WR\u2019s online summary of the \u201ccons\u201d of the diet include \u201cLots of grunt work\u201d and \u201csomewhat pricey.\u201d\u00a0 The implication of these drawbacks is that well-meaning people will not be able to adhere to the diet.\u00a0We would have appreciated a delve into what \u201cLots of grunt work\u201d refers to.", "answer": 2}, {"article": "The Society is based in Oak Brook, Ill. (RSNA.org)\n\"The nerve root is a sensitive structure that when pinched becomes inflamed and causes pain,\" said lead investigator Alessandro Napoli M.D., Ph.D., an interventional radiologist at Sapienza University of Rome.\n\"The probe delivers a gentle electrical energy, so there's no thermal damage,\" Dr. Napoli said.\n\"The body reacts with muscle constriction, which decreases the distance between vertebrae, and a vicious cycle is created.\"\nMost back pain is short-term, but about 20 percent of people affected by acute low back pain go on to develop chronic low back pain lasting a year or more.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release does mention side effects, saying, \u201cDr. Napoli said no patients experienced side effects after receiving the minimally invasive outpatient treatment.\u201d\nBut just because there were no side effects in this small study, does that mean there is no risk of such side effects for anyone? That seems like downplaying the risks. The release would have been more thorough had it mentioned that any invasive treatment such as this one carries a risk of infection.  ", "answer": 1}, {"article": "The Food and Drug Administration gave Keytruda accelerated approval for melanoma in 2014.\nThere are side-effects, including fatigue, itchiness and rash.\nIt was bad enough for 8 percent of patients that they stopped taking it.\nAnd 61 of the patients, or 9 percent, have stopped taking the drug after their tumors went away.\nOn average, the patients lived two years and 40 percent of them are still alive three years later.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Side effects are described \u2014 fatigue, itchiness, and rashes \u2014 and even notes the dropout rate of 8%.", "answer": 1}, {"article": "Cigarette smoking is responsible for 90 percent of all lung cancer cases in the United States.\n\"We were looking at the activity of genes in the cells that we obtained from the windpipe or airways of smokers at risk for lung cancer,\" said study senior author Dr. Avrum Spira, a critical care physician at Boston Medical Center and associate professor of medicine, pathology and bioinformatics at Boston University School of Medicine.\nIt turned out that gene activity in the PI3K pathway was \"off the chart\" in smokers with lung cancer versus those without the disease.\n\"It's incredibly, incredibly exciting,\" said Dr. Patrick Nana-Sinkam, a lung cancer expert with the Ohio State University Comprehensive Cancer Center, who was not involved with the new study.\n\"This drug inhibits the pathway that's activated in smokers.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "No potential harms are discussed. Bronchoscopy can be risky, especially in those with already compromised lung function such as smokers.", "answer": 0}, {"article": "Investigators in the Netherlands report the results of a three-year follow-up of a randomized controlled trial that compared three noninvasive treatments that included imiquimod and fluorouracil cream.\n\"Based on our findings, both imiquimod and fluorouracil are effective noninvasive treatments in most primary, low-risk superficial BCC, but the data provide no definite evidence for superiority of imiquimod to fluorouracil,\" commented Dr. Roozeboom.\n\"The main advantages of noninvasive treatments are good cosmetic outcome, preservation of surrounding tissue, and potential for home application of either creams,\" explained lead investigator Marieke Roozeboom of the Department of Dermatology, Maastricht University Medical Center in the Netherlands.\nA three-year randomized controlled clinical trial has found that two topical creams are effective in most primary, low-risk superficial BCC, comparing favorably with photodynamic therapy (PDT), as reported by investigators in the Journal of Investigative Dermatology.\nA total of 601 patients with a superficial BCC participated in this study: 202 patients were treated with methylaminolevulinate photodynamic therapy (MAL-PDT), 198 with imiquimod cream, and 201 with fluorouracil cream.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The news release makes no mention of the side effects of either drug.\nThe news release does note that, between 1- and 3-year follow-up, \u201cmore recurrences were diagnosed in the fluorouracil group compared with the imiquimod group.\u201d It would have helped to know how many more recurrences.", "answer": 0}, {"article": "\"What we found was a very coherent pattern of less cervical cancer among people who\u2019ve used the IUD based on thousands of women \u2014 and the pattern wasn't subtle at all, it was stunning,\" Dr. Victoria Cortessis, the study's lead author and associate professor of clinical preventive medicine at the Keck School of Medicine at the University of Southern California, told BuzzFeed Health.\n\nIUDs are small, T-shaped devices that are placed in the uterus to prevent sperm from reaching an egg. They are a highly effective form of birth control and they can offer protection against pregnancy for up to three, five, or ten years.\n\nThe study is the first of its kind to combine and analyze data from multiple studies to look at the issue. \"We went through all of the relevant human epidemiological data on this topic and narrowed it down to 16 high-quality observational studies of over 12,000 women from all over the world,\" Cortessis says.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Although this story did a great job on most counts, it didn\u2019t mention potential harms of IUDs. Cramping, spotting between periods, and heavier periods are all possible side effects. The bigger issue that the story could have mentioned, though, is that IUDs don\u2019t protect against other STIs.", "answer": 0}, {"article": "The new beds, Fuh said, are much different than similar beds made 20 years ago where patients would lie on their stomachs, put a strap around their pelvis and \u201chold onto handle bars for dear life.\u201d\n\n\u201cThe table now, you just lay on your back, and the machine does all of the work.\nSome of them returned to Earth 1 inch to 2 inches taller.\nIt is less than half the cost of surgery but is rarely covered by insurance.\nIt is designed for patients who have not had surgery.\nThe space agency noticed astronauts, who did not have gravity compressing their spines in space, reporting the disappearance of neck and back pain.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story does not mention any potential harms of this approach. ", "answer": 0}, {"article": "[1]\n\nWriting in a linked Comment, Dr Nahid Bhadelia from Boston University School of Medicine and Boston Medical Center, Boston, USA says, \"[This study] validates the accuracy of the ReEBOV RDT in patients who are well into their illness...suggesting it could be used to triage this subset of patients if RT-PCR is not available, particularly in those with a high index of clinical suspicion for a differential diagnosis...the data presented provide crucial information about the point of-care function of this rapid diagnostic test, such as ease of use, quality of samples taken at the bedside, and the concordance with venous samples...the results raise caution regarding the performance of the widely used altona RT-PCR assay, which the authors suggest might have underperformed because of laboratory specific technical and performance factors.\"\n106 suspected Ebola patients admitted to two treatment centres in Sierra Leone (run by the Ministry of Health and Sanitation of Sierra Leone and supported by the non-governmental organisation Partners In Health) during February 2015 were tested by both RDT (performed on a fingerstick blood sample at the point-of-care) and by standard RT-PCR (performed on plasma in the laboratory).\nThe study is the first to show that a point-of-care EVD test (ReEBOV Antigen Rapid Test; Corgenix) is faster than and as sensitive as a conventional laboratory-based molecular method used for clinical testing during the recent outbreak in Sierra Leone.\nA new test can accurately predict within minutes if an individual has Ebola Virus Disease (EVD), according to new research published in The Lancet.\nThe altona RT-PCR assay failed to detect a small number of EVD cases that tested positive by both RDT and by an alternative RT-PCR test (Trombley), all with relatively low amounts of virus.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release explains how not having a rapid-diagnostic test could expose people who are otherwise healthy to Ebola.\u00a0But there are some less obvious harms\u00a0this release probably should have addressed. For example, there\u2019s only brief mention of how\u00a0the new test missed some early\u00a0cases of EVD. Waiting a few minutes for a result is better than hours or days, of course, but letting infected patients with a false-negative test out of quarantine is a serious concern.\u00a0It would also be useful to talk about the impact of a false-positive result (since specificity was 92%). What are the consequences of telling someone they have Ebola when they don\u2019t, in fact, have the infection?", "answer": 0}, {"article": "The work builds on the success of the team's pioneering research to tackle antimicrobial resistance over the past 18 months.\nImportantly, the two new simplified forms of teixobactin have also proven to have identical potency against superbugs as the natural form of teixobactin.\nWith this new knowledge, synthesised versions of teixobactin can be more easily developed, taking the process from up to 30 hours to just ten minutes for a single coupling step - a significant step towards turning teixobactin into a viable new drug.\nHe explained: \"When teixobactin was discovered it was ground breaking in itself as a new antibiotic which kills bacteria without detectable resistance including superbugs such as MRSA.\nThe development of new antibiotics which can be used as a last resort when other drugs are ineffective is therefore a crucial area of study for healthcare researchers around the world.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release does not address potential harms. This omission is another reason the release should have made clear that although the researchers performed some laboratory tests for potential toxicity, teixobactin has not been tested in people, so its potential adverse effects are not known.", "answer": 0}, {"article": "People with Type 2 diabetes get an earful of grim lectures about their health prospects and endure much hardship to manage their condition well. But new research offers those who do so a rare reward. A glass of wine every day not only won't hurt, says a new study: It can actually improve cardiac health, help manage cholesterol and foster better sleep.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Although the researchers did not report adverse events in their journal article, they described at length how they excluded several categories of participants, including smokers, pregnant women, those with a family history of addiction, women with close relatives who had breast cancer, anyone under 40 and others, in order to minimize the potential risks of drinking alcohol. Other risks of alcohol include less common\u00a0events such as falls, which may not be apparent in a smaller study over only 2 years. In addition,\u00a0the public tends to generalize, and the take away from this story for some readers might be that red wine is good for everyone with diabetes. \u00a0In fact, this study was only among well controlled type 2 diabetics who were either on oral agents or insulin no more than once daily. The researchers explicitly warned about the potential risks of recommending that people with diabetes drink wine. That concern about harming people who might be vulnerable to adverse effects of alcohol was left out of the story.", "answer": 0}, {"article": "In a twist in the debate about the safety of menopause hormones, new research suggests the real problem may not be the hormone itself, but the fact that it's typically swallowed as a pill.\n\nThis week, the medical journal Circulation offers some of the strongest evidence yet that the risks of hormones are dramatically reduced when the drugs are absorbed through the skin in patches and gels rather than taken as pills. The study by French researchers showed that one of the most serious risks associated with hormone use -- blood...", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story mentions blood clots, stroke and breast cancer as potential harms of hormone therapy. ", "answer": 1}, {"article": "J&J also said Cosentyx demonstrated quicker effectiveness than Tremfya during the study.\nWith $2.1 billion in sales in 2017, Cosentyx has become one of the top revenue earners for Novartis and is expected to make up for falling revenue from its blood cancer treatment, Gleevec, whose patent expired two years ago.\nAfter 48 weeks of therapy, 84.5 percent of the 1,048 participants treated with Tremfya showed 90 percent improvement in disease symptoms, as measured by the Psoriasis Area Severity Index, compared with 70 percent on Novartis\u2019s Cosentyx, J&J said.\nTremfya, first approved in July 2017 as a plaque psoriasis treatment in the United States, is also being tested as a for psoriatic arthritis and Crohn\u2019s disease.\n\u201cThese results imply that Cosentyx remains a good option for moderate-to-severe psoriasis patients that want to achieve more rapid skin clearance,\u201d brokerage Jefferies wrote in a note following the results.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Since Tremfya is known to weaken the immune system, it places patients at an increased risk of bacterial, fungal, and viral infections.\nPeople taking this drug, and other immunosuppressives like it, must be screened for tuberculosis, since it could dramatically accelerate the disease.\nNone of this was mentioned.", "answer": 0}, {"article": "DOI: 10.5435/JAAOS-D-17-00318\n\"This is the first comprehensive mixed-comparison analysis comparing best-evidence scientific research and excluding lower quality studies that can bias the outcomes,\" said lead author and orthopaedic surgeon David Jevsevar, MD, MBA.\nAlthough the use of NSAIDs for arthritic conditions such as knee OA has potential risks, including heart attack and stroke, existing evidence indicates that naproxen has less potential for adverse cardiovascular events.\nAccording to a network meta-analysis research article published in the May 1, 2018 issue of the Journal of the American Academy of Orthopaedic Surgeons (JAAOS), the nonsteroidal anti-inflammatory drug (NSAID) naproxen was ranked most effective in individual knee OA treatment for improving both pain and function, and is considered a relatively safe and low-cost treatment method.\n\"Using a statistical ranking technique, we worked to provide evidence regarding which of the most common NSAIDs are most likely to decrease pain and improve function, and we attempted to fill in the gaps in evidence for more inconclusive treatments such as HA, PRP, and corticosteroids.\"\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The news release does refer to some potential harms of nonsteroidal anti-inflammatory drugs, including naproxen and ibuprofen. However, it does not quantify these risks and it does not address any of the potential harms of the other treatments in the analysis.", "answer": 0}, {"article": "NEW YORK (Reuters Health) - Taking multivitamins may help women without cardiovascular disease to ward off a heart attack, new research shows.\nAmong the women with heart disease, 13 percent of the non-supplement-users had heart attacks, compared to 14 percent of women who took multivitamins only, which wasn\u2019t a statistically significant difference (meaning it could have been due to chance).\nFor the women without heart disease at the study\u2019s outset, taking a multivitamin for less than five years reduced heart attack risk by 18 percent compared with non-users of supplements.\nTo investigate the relationship between vitamin use and heart disease in women, Rautiainen and her team followed 31,671 women with no history of heart disease and 2,262 women who did have cardiovascular disease for about 10 years.\n\u201cEven if we have controlled for many of those factors that are associated with a healthy behavior we cannot exclude the possibility that we might measure a healthy lifestyle via multivitamin use.\u201d\n\nIn industrialized countries, Rautiainen and her team note in the American Journal of Clinical Nutrition, multivitamin use is widespread.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "\u00a0There was no discussion of possible harms associated with the use of multivitamins. \u00a0In an era where so very many foods are fortified with various nutrients, the consumption of yet another source of micronutrients may not be without potential down sides.", "answer": 0}, {"article": "Which sounds worse to you?\nThe study, published in the Pediatric Infectious Disease Journal, looked at the published data about effects from the vaccine and found that it has a \u201cfavorable safety profile.\u201d This study comes after many other previous studies that show essentially the same thing.\nFor example, a young girl died tragically not long after getting the vaccine, and it got a lot of press, but it was later found that she died of a completely unrelated cause.\nEven more frustrating about this vaccine is that it\u2019s being fought by an unusual group of people; while most anti-vax leanings are not affiliated with any particular political persuasion, Gardasil gets attacked additionally by conservatives who think that girls getting it will become more promiscuous, because HPV is a sexually transmitted disease.\nThere is no correlation between getting the Gardasil vaccine and seriously adverse effects such as \u201cautoimmune diseases (including Guillain-Barre Syndrome and multiple sclerosis), anaphylaxis, venous thromboembolism, and stroke.\u201d\n\nMind you, all these things and more have been used by people who attack vaccines as an argument against it.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story notes the vaccine is not associated with serious adverse effects sometimes attributed to it (e.g. multiple sclerosis). It mentions that syncope and possibly skin rash are thought to be side effects of the vaccine.\u00a0Ideally, the story would have provided more information about how frequently these effects are seen (the main objective of the study being reported on).", "answer": 1}, {"article": "\u201cI had terrible pangs of sadness and despondency.\nI was missing my husband so badly.\u201d\n\nEven after seeing a therapist, which helped, she suffered from nightmares and couldn\u2019t bear to hear arias from their favorite operas.\n\u201cI had many interests.\u201d She traveled and even tried dating again.\nAfter he died in 2002, she sold the Long Island house they\u2019d loved and shared, finding it too filled with memories, and moved to their country home in upstate New York.\n\u201cBut I wasn\u2019t really doing well,\u201d said Ms. Schomaker, 73.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story does not come out and discuss the general topic of harms vs. benefits of \u201ccomplex\u201d therapy. But it does manage to clear our bar by quoting skeptic Jerome Wakefield, who says that labeling of people might result in over-treatment.\n\u201cBy diagnosing complicated grief just six months after a death, he said, \u201cyou\u2019ll get a lot of normal people receiving treatment they don\u2019t need,\u201d including drugs.\nWe\u2019ll give the benefit of the doubt here, although it\u2019s debatable whether a single quote about the controversy of labeling covers enough ground on this issue.", "answer": 1}, {"article": "\u201cBut this is a small study, a proof of concept.\n\u201cWe can\u2019t yet say that this study means that DHEA is a viable alternative to HRT, but ... we should be looking to do larger studies to confirm these initial results.\u201d\n\nDHEA, or dehydroepiandrosterone, is a natural steroid hormone mostly made in the adrenal glands and has a variety of therapeutic uses.\nAt the start of the trial, all groups had similar sexual activity, but after the year, those taking calcium and vitamin D scored an average of 34.9 on the questionnaire scale, while those taking DHEA had a score of 48.6, showing that those on DHEA had more sexual interest and activity.\nItalian researchers writing in the journal of the International Menopause Society, Climacteric, said they had found the first robust evidence that low doses of DHEA can help sexual function and menopausal symptoms, suggesting it may one day become an alternative to hormone replacement therapy (HRT).\nThe results for the HRT group were similar, and both the HRT DHEA groups showed a higher level of sexual intercourse in comparison to the control group, the researchers said.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story explains the potential harms involved in taking hormone treatments, saying, \u201csales of HRT drugs have fallen sharply since a large study in 2002 found higher rates of ovarian cancer, breast cancer and strokes in women who took the pills, and the search has since been on for alternatives.\u201d But the story does not address any potential harms of DHEA, which was the subject of the story.\n\u00a0", "answer": 0}, {"article": "The other trial had nearly identical results.\n\"The ability of these potential drugs to treat individuals with a single F508del mutation means that more people than ever before could benefit,\" said Dr. Michael Boyle, senior vice president for therapeutics at the foundation.\nThen there's the 30 percent of CF patients who carry only one copy of F508del, plus another defect known as a \"minimal-function\" mutation.\nNow the questions are whether the improved lung function can be sustained, and whether the drugs prevent symptom exacerbations and other complications, wrote Dr. Fernando Holguin, of the University of Colorado, Aurora.\nThis is the first time, Rowe said, that CFTR modulator therapy has \"pushed the needle\" for patients with one F508del mutation.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story reported: \u201cSo far, the treatments appear safe. Most side effects in the four-week trials were \u2018mild to moderate,\u2019 the researchers said, and included cough, headache and increased sputum.\u201d\nThe story should also have said that three patients in the VX-445 trial discontinued treatment, due to severe adverse events including intestinal blockages intestines and temporary worsening of lung function. Another three had to temporarily stop treatment due to signs of liver damage, muscle weakness and constipation. Considering the small size of the trial overall, these numbers are important.", "answer": 0}, {"article": "After a two-week break, they moved, round-robin style, to another arm of the trial.\nVinson, whose research focuses on plant polyphenols and their effects on human health, said it appears that green coffee bean extract may work by reducing the absorption of fat and glucose in the gut; it may also reduce insulin levels, which would improve metabolic function.\nBut he said nutrition experts would want assurances that green coffee beans do not cause \"malabsorption\" within the human gut \u2014 a condition that would lead to weight loss as well as malnutrition, heart arrhythmias and other problems because vitamins and minerals are not passing through the intestine.\nIf green coffee extract were a medication seeking approval from the Food and Drug Administration, these results would make it a viable candidate \u2014 more than 35% of subjects lost more than 5% of their body weight, and weight loss appeared to be greater while subjects were taking the pills than when they were on the placebo.\nThough Vinson identified polyphenols and chlorogenic acid as the agents that appear to promote weight loss, Grollman said that claim needed further study.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Better than the HealthDay story on this criterion, quoting an expert on a specific concern about malabsorption within the gut \u2013 \u201ca condition that would lead to weight loss as well as malnutrition, heart arrhythmias and other problems.\u201d", "answer": 1}, {"article": "AstraZeneca PLC's cholesterol drug Crestor sharply lowered risk of heart attacks among apparently healthy patients in a major study that challenges longstanding heart-disease prevention strategies. The findings could substantially broaden the market for statins, the world's best-selling class of medicines.\n\nHeart experts said the findings, presented Sunday at the annual scientific meeting of the American Heart Association in New Orleans, could reshape cholesterol-treatment guidelines used for more than a decade to fight cardiovascular...", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story indicated that there was an increased number of people taking Crestor who developed diabetes during the study.", "answer": 1}, {"article": "CHICAGO (Reuters) - A new analysis of evidence used by a U.S. advisory panel to roll back breast cancer screening guidelines suggests it may have ignored evidence that more frequent mammograms save more lives, U.S. researchers said on Tuesday.\n\u201cIt is not a small difference,\u201d said Dr. Mark Helvie of the University of Michigan Health System, who worked on the study published in the February issue of the American Journal of Roentgenology.\nBreast cancer is the second-leading cause of cancer death among U.S. women, after lung cancer.\n\u201cIt\u2019s like a weather man using a computer model to see what the weather is rather than looking outside the window,\u201d Lee said in a telephone interview.\nThose guidelines recommended against routine mammograms for women in their 40s and said women in their 50s should get mammograms every other year instead of every year.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The article does not include information about the potential harms resulting from routine, annual mammography beginning at age 40.\u00a0 Readers, especially women who may decide to begin annual screening at age 40, need to be told about the possibility of false positives and unnecessary biopsies. Authors such as Welch and Esserman have referred to overdiagnosis and overtreatment.", "answer": 0}, {"article": "\"If five types of the disease exist, how does this change popular medical opinion on prostate cancer screening?\n\"These findings could lead to more optimized diagnostic testing on all aspects of the prostate cancer diagnosis process and brings full circle the coming approach to cancer being an individual disease based very much on the patient's individual genetic profile,\" said Dr. Samadi.\nFor men with a family history of the disease, contact Dr. Samadi to learn more about your risk factors and to get a baseline PSA blood test.\n\u2022 In 2015, it is estimated that there will be more than 27,500 deaths from prostate cancer.\nThis may mean that each type of the disease needs its own approach to screening, diagnosis, treatment and even recurrence,\" noted Dr. Samadi.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The main potential harm from the test is risk misclassification (which could happen when the gene tests are applied in a larger, unselected population) resulting in either under- or over-treatment of prostate cancer. \u00a0This is not addressed in the news release.", "answer": 0}, {"article": "Estrogen stimulates the growth of ER+ tumors.\nAfter the four months of estrogen-lowering therapy, the research team found that 82 percent of those women in the marginal group were, in fact, able to undergo successful breast-conservation surgery.\nThe women were classified into three groups as the study began: \"marginal\", meaning that the women were eligible for a lumpectomy to conserve the breast, but that it would be disfiguring or require several operations; \"mastectomy-only\", meaning a lumpectomy was not considered possible; and \"inoperable\", meaning that doctors believed that even a mastectomy would not completely remove the cancer.\nThe most common form of breast cancer, ER+ accounts for about three-quarters of all breast cancer cases in the United States, the authors noted.\nThe 352 women who participated were monitored for tumor growth before and after being placed on a 16-week regimen of aromatase inhibitors -- estrogen-lowering agents -- before any surgery.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "There is no\u00a0discussion of any potential harms from\u00a0aromatase inhibitors.\u00a0These drugs can cause joint pain and sexual problems which lead many women to discontinue using them.\u00a0There also is concern that these estrogen-lowering drugs may decrease bone density and increase the risk of osteoporotic fractures.\u00a0This is an outcome\u00a0that\u00a0can\u00a0have severe health consequences for older women.", "answer": 0}, {"article": "Learn more about brain health at http://www.\nThe study found that people whose diets adhered more closely to the Dietary Approaches to Stop Hypertension (DASH) diet were less likely to develop depression than people who did not closely follow the diet.\nOn the other hand, the more closely people followed a Western diet--a diet that is high in saturated fats and red meats and low in fruits and vegetables--the more likely they were to develop depression.\n\"Depression is common in older adults and more frequent in people with memory problems, vascular risk factors such as high blood pressure or high cholesterol, or people who have had a stroke,\" said study author Laurel Cherian, MD, of Rush University Medical Center in Chicago and a member of the American Academy of Neurology.\nMINNEAPOLIS - People who eat vegetables, fruit and whole grains may have lower rates of depression over time, according to a preliminary study released today that will be presented at the American Academy of Neurology's 70th Annual Meeting in Los Angeles, April 21 to 27, 2018.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release does not address potential harms. However, there are few (if any) harms associated with adopting a well-balanced diet that is high in fruits and vegetables. While it is always wise to consult a physician before making significant lifestyle changes, we feel that this is not necessarily something that a news release needs to state explicitly. With that in mind, we give this a satisfactory rating.", "answer": 1}, {"article": "But are they receiving it?\nA briefing posted on the site specifically states: \u201cCompared to tobacco products, electronic cigarettes are significantly safer.\u201d\n\nIn their paper, the researchers note that information on comparative risks is common for other products and activities, like over-the-counter medicines and even safety ratings of vehicles.\nThe day after the article was released, the Mayo Clinic removed the headline, replacing it with the still misleading statement that smokeless tobacco was \u201cnot a safe product.\u201d\n\n\u201cPeople can only make as good a decision as the information available to them allows,\u201d said Sweanor, an adjunct professor in the University of Ottawa\u2019s Faculty of Law who has spearheaded the development of world-leading tobacco control initiatives in Canada since the early 1980s.\nIn the case of providing information on differential health risks of nicotine products, \u201cThe evidence to date does not come close to establishing that there would be a loss to public health from making this information widely available from credible sources,\u201d Kozlowski says.\n\u201d\n\nBUFFALO, N.Y. \u2013 Millions of people visit the websites of the Mayo Clinic, American Cancer Society and the Centers for Disease Control and Prevention, among others, seeking authoritative health information.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "It is all well and good to say that smokeless products are far less lethal than cigarettes, but it behooves the news release to point out what, if any, drawbacks they may pose. But this release doesn\u2019t give us any actionable information to show why substitute tobacco products are safer. We are instead told,\nThe news release needs to tell readers what those risks are so they can make informed decisions about their own use \u2014 or not \u2014 of smokeless tobacco products. The CDC says the use of smokeless products:\nStill relatively new on the scene, but exploding in popularity, vaping delivers many unknown elements and chemicals to the lungs. Compared to Canada and the UK, the US severely lags in safety studies that compare harms from vaping and traditional tobacco products.", "answer": 0}, {"article": "July 30, 2012 -- If it weren't for routine PSA prostate cancer screening, an extra 17,000 Americans each year would learn that they had the worst form of the disease, a new study suggests.\nThe new study seems to make a powerful argument in favor of PSA testing.\nMicroscopic cancers already have seeded his body.\nBut he would not yet have symptoms or detectable metastatic disease, so he'd be diagnosed with earlier-stage disease.\nThat kind of prostate cancer -- metastatic prostate cancer, in which the cancer spreads to the bone or other parts of the body -- is rapidly fatal, usually within two years or less.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story lists some of the potential harms of screening at the very end.", "answer": 1}, {"article": "The remaining subjects were divided randomly into four groups.\nThe good news, according to a Brazilian study published by the journal PLoS One, is that two relatively simple measures can help to reduce the incidence of POCD: administering a small dose of the anti-inflammatory drug dexamethasone immediately before an operation and avoiding profound anesthesia during the operation.\nIf so, the use of an anti-inflammatory drug may have a protective effect,\" said Maria Jos\u00e9 Carvalho Carmona, a professor of anesthesiology at the University of S\u00e3o Paulo's Medical School (FM-USP) and principal investigator for the study.\n\"The results reinforce recent evidence of the importance of avoiding deep anesthesia,\" Carmona said.\nThe researchers evaluated 140 patients aged between 60 and 87 who underwent surgery under propofol-induced general anesthesia at the Central Institute of Hospital das Cl\u00ednicas, FM-USP's teaching hospital, in most cases for removal of gallstones.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "While the release refers in general to the risks inherent with both deep and superficial anesthesia, it does not mention any of the potential side effects associated with its recommended intervention, dexamethasone. And there is no shortage of information on dexamethasone available. According to the U.S. National Library of Medicine\u2019s Medline Plus page on dexamethasone, the drug\u2019s side effects range from vomiting to insomnia to depression. The page indicates that dexamethasone may also interact with a\u00a0 variety of other widely-used drugs. In addition, giving patients steroids, of which\u00a0dexamethasone is one, increases the risk of infection or worsening severity of existing infections. We don\u2019t expect a release to provide an exhaustive list of side effects, but acknowledging that there are known risks associated with the drug is important.", "answer": 0}, {"article": "Genomic Health Inc. has struck a deal to commercialize a new blood test that can help advanced prostate cancer patients decide whether to try costly new-generation drugs or rely on much cheaper traditional chemotherapy to improve their chances for survival.\n\nThe test, developed by closely held Epic Sciences Inc., San Diego, detects a mutation associated with a poor response to two new drugs, Xtandi from Medivation Inc. and Astellas Pharma Inc. of Japan, and Zytiga from Johnson & Johnson.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story does not explain harms.\u00a0However, diagnostic tests are only as good as their sensitivity and reliability, so it would have been good for readers to get an impression of whether the test catches every case of AR-V7, and the likelihood of false positives or false negatives. Even if that information is not yet available, it is important for readers to be made aware of the issue that a false result could lead to the wrong therapy being given.", "answer": 0}, {"article": "Senator Arlen Specter, a Pennsylvania Democrat and longtime advocate for cancer screening, said in an interview: \u201cAnd this Pap smear guideline is yet another cut back in screening?\nThere are 11,270 new cases of cervical cancer and 4,070 deaths per year in the United States.\nIn addition, women who have a total hysterectomy (which removes the uterus and cervix) for a noncancerous condition, and who had no severe abnormalities on previous Pap tests, can quit having the tests entirely.\nThe guidelines also say that women can stop having Pap tests between 65 and 70 if they have three or more negative tests in a row and no abnormal test results in the last 10 years.\nDr. Carol L. Brown, a gynecologic oncologist and surgeon at Memorial Sloan-Kettering Cancer Center, said the new guidelines should probably not be applied to all women, because there are some girls who begin having sex at 12 or 13 and may be prone to develop cervical cancer at an early age.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story mentions the harms of not catching cervical cancers early. It devotes some attention to the harms of over-treatment that follow unnecessary screening, particularly in low-risk younger women. \nThe story should have mentioned the likelihood of these risks.\n\u00a0", "answer": 1}, {"article": "This test might help.\nIn a subgroup of women, the test accurately classified 4 of 5 preterm deliveries as being at-risk, and incorrectly suggested that 3 of 18 women who had a full-term pregnancy were at risk for early labor.\nHowever, a new blood test \u2014 which is still experimental and not yet available outside of a research lab \u2014 can pick up on gene activity in the body that suggests a pregnancy is at risk for preterm delivery, according to a study published Thursday in the journal Science .\nThey identified seven cfRNAs that seemed to be associated with premature birth, and in a test of 38 women, they found that they could predict premature birth up to two months in advance.\n\"Those molecules will circulate in the blood for some time, they can be measured, and you can see the contributions from essentially every tissue in the body,\" senior investigator Stephen Quake told BuzzFeed News.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Readers don\u2019t get a sense of what harms a false-positive test might expose a mother and her child too, and the rate here (nearly 17%) is rather high. Based on studies of the alternative test method \u2014 i.e. ultrasound \u2014 the risks of false-positive test/misdiagnosis include\u00a0high stress and anxiety, depression, expensive and unnecessary treatments, and other possible harms. (The most common interventions for increased risk of preterm birth include progesterone supplements and bedrest.)", "answer": 0}, {"article": "Neither treatment prompted significant side effects, the authors said.\nHowever, while this approach is often successful in younger children (between the ages of 3 and 7), it is successful among only about a third of older children (between the ages of 7 and 12).\nMONDAY, Dec. 13, 2010 (HealthDay News) -- Acupuncture may be an effective way to treat older children struggling with a certain form of lazy eye, new research from China suggests, although experts say more studies are needed.\nAnd while theorizing that the apparent success of this alternative approach may have something to do with stimulating blood flow, retinal nerve growth and visual cortex activity, the authors acknowledged that the exact mechanism by which it works remains poorly understood.\n\"However, I think it's worth considering or trying,\" Chang added, \"because nothing else seems to work very well for patients of that age, including patch therapy.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story states that neither treatment produced significant side effects in the study, which is accurate.\u00a0It also\u00a0goes into some detail about the potential adverse effects reported previously with\u00a0patch treatment, but it doesn\u2019t mention any of the drawbacks of acupuncture that\u00a0patients might encounter outside of a study.\u00a0Notably, the\u00a0frequent treatments required by the study protocol might require taking children out of school\u00a0and cause\u00a0disruption to their education as well as the parent\u2019s employment.\u00a0The researchers\u00a0were able to\u00a0avoid\u00a0this by scheduling all appointments after school,\u00a0but parents outside of a study might not have this\u00a0much flexibility. We\u2019ll call this a satisfactory, but more detail would have been useful.", "answer": 1}, {"article": "The F.D.A.\nThe other ingredient, sacubitril, inhibits an enzyme known as neprilysin, a new mechanism of action for a heart failure drug.\nIt said there were also cases of angioedema, an allergic reaction that usually results in swelling of the lips or face but can be life threatening if swelling interferes with breathing.\nAfter about 27 months, 21.8 percent of those taking Entresto had either died from cardiovascular causes or had been hospitalized for worsening heart failure, compared with 26.5 percent for those taking enalapril.\nNovartis said that about 2.2 million Americans would be eligible for the drug, which was approved for patients with so-called Class II to Class IV chronic heart failure with so-called reduced ejection fraction.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story addresses both common side effects and severe ones, while also noting which patients may be at increased risk of those side effects. The coverage would have been even stronger with some mention of the rate at which these problems occurred.", "answer": 1}, {"article": "The research is part of a larger University of Exeter study called PRO-BONE.\nAdolescence is the key period for bone development, and poor development at this stage is linked to reduced peak bone mass (the amount of bone mass at the end of the skeletal maturation, around age 30), increased fracture risk and osteoporosis later in life.\nDr Gracia-Marco said: \"The sports we studied are the three most popular in the UK, and it's important to know what effects they have in relation to bone health.\nFor example, footballers' BMC was 7% higher than that of cyclists at the lumbar spine, and 5% higher at the femoral neck.\nOne innovative aspect of the study was the measurement of bone texture of the lumbar spine using trabecular bone score (TBS) - the first use of this technique in adolescent athletes.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The news release included no discussion of the potential harms of playing soccer, especially in a highly competitive environment. In a 2010 report on soccer injury risks, the American Academy of Pediatrics noted that soccer \u201chas a higher injury rate than many contact/collision sports such as field hockey, rugby, basketball and (American) football.\u201d Lower leg and foot injuries are most common, and the rate of concussions is similar to those suffered by American football and hockey players.", "answer": 0}, {"article": "\"We now feel pretty confident that, in many children with autism, there are alterations either in structure growth or connectivity of the brain, but we really don't understand the implications of that for core features of autism, one of which is problems with communication,\" Amaral said.\n\"We're focusing on this earliest time period, when the brain is still developing and still changing,\" explained study author Lisa Eyler, an assistant professor of psychiatry at the University of California, San Diego.\n\"This is probably not going to be used for wide-scale screening but it could be used for children who we have some sense that they have autism and want to gather more information,\" said David Amaral, president of the International Society for Autism Research and research director of the University of California Davis MIND Institute.\nThey have a long way to go before they're actually able to implement a test like this,\" said Keith Young, vice chairman of research in psychiatry and behavioral science at the Texas A&M Health Science Center College of Medicine in Temple.\nIn the youngest children, the activation was about equal in both the right and left hemisphere, while in the older children, activity became more pronounced on the left side, which is similar to adult patterns and to be expected, Eyler explained.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "It makes a pass at this by saying the screening may inadvertently detect other brain problems and lead to misdiagnoses,\u00a0but it\u00a0doesn\u2019t develop the theme. Although fMRI does not use ionizing radiation, the procedure is long and the subject\u2019s head need to be restrained for the scans to be taken,\u00a0 In addition, the scan itself produces a good deal of noise (loud thumping)\u00a0requiring the subject to wear protective earphones.\u00a0 And, the test will take up to one hour to complete. ", "answer": 0}, {"article": "The page may no longer exist or may have moved to another web address. Try again to locate what you want by choosing a section from the navigation menu at left, viewing our Site Map or using the search box below.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story states that hypnosis comes with no known risks, unlike hormone replacement therapy.", "answer": 1}, {"article": "Higher soy intake was also associated with less reported fatigue.\nWASHINGTON -- Consuming soy foods (such as soy milk, tofu and edamame) and cruciferous vegetables (such as cabbages, kale, collard greens, bok choy, Brussels sprouts, and broccoli) may be associated with a reduction in common side effects of breast cancer treatment in breast cancer survivors, say a team of scientists led by Georgetown Lombardi Comprehensive Cancer Center.\nWhether the reduction in symptoms accounts for longtime use of soy and cruciferous vegetables needs further investigation, says the study's senior author, Judy Huei-yu Wang, PhD, of Georgetown Lombardi's Cancer Prevention and Control Program.\nThe lead author on the study, Sarah Oppeneer Nomura, PhD, of Georgetown Lombardi, said that while further research is needed in larger study populations and with more detailed dietary data, this project addresses an important gap in research on the possible role of lifestyle factors, such as dietary habits, in relation to side effects of treatments.\nCo-authors of the study include Chiranjeev Dash, MBBS, MPH, PhD, Leena Hilakivi-Clarke, PhD, and Yun-Ling Zhen, MPH, PhD, from Georgetown Lombardi; Yi-Tin Hwang, PhD, from National Taipei University, Taiwan; Scarlett Lin Gomez, MPH, PhD, from the Cancer Prevention Institute of California; Teresa T. Fung, MS, ScD, from Harvard T. H. Chan School of Public Health; Shu-Lan Yeh, PhD, from Chang Shan Medical University, Taiwan; and Serena Phillips, RN, MPH, from Milken Institute School of Public Health, George Washington University.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release responsibly devotes some attention to harms. It notes that in preclinical animal studies, \u201cbiologically active compounds present in both soy and cruciferous vegetables cause breast cancer cells to grow, but have opposite effects in animals that consume these compounds well before cancer is diagnosed and continue consuming them during and after cancer treatments.\u201d\nIt also cautions that breast cancer patients shouldn\u2019t start eating soy now if they haven\u2019t consumed it previously, noting that more research is needed to understand potential risks.\nNumerous studies have examined the impact of soy-based foods on women with breast cancer \u2014 with conflicting results \u2014 and we expect this debate will continue. Some recent studies suggest that eating soy, benefits women with breast cancer, particularly at the low rate it is consumed in the American diet.", "answer": 1}, {"article": "\"It's meaningless, and it could very easily introduce real confusion.\"\nPreviously, the only tests for breast cancer risk were for relatively rare genes, leaving most women with no way to assess their individual genetic predisposition.\n\"There is concern about the validity of many genetic tests that are being offered,\" said Joan Scott, deputy director of the Center for Genetics and Public Policy at Johns Hopkins University.\n\"There is at least a significant chance this test will could falsely reassure some women and alarm others,\" said Eric Winer, a breast cancer expert at Harvard Medical School and a spokesman for the American Society of Clinical Oncology.\nAn FDA spokeswoman said the agency had just become aware of the new test and could not say whether it would take any action, though she noted that in August the agency sent a letter expressing concern to another company marketing a questionable genetic test for ovarian cancer.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story provides appropriate caveats for women who are considering this test. Namely, a lower than average score might suggest a woman could forgo screening.\u00a0 Women with a higher than average risk score could experience unnecessary anxiety and possibly choose treatments they do not need (such as prophylactic mastectomy).\u00a0 ", "answer": 1}, {"article": "SOURCE: bit.ly/AhalBY\n\u201cDietary magnesium intake is inversely associated with risk of stroke, specifically ischemic stroke,\u201d wrote lead author Susanna Larsson, a professor at the Karolinska Institute in Stockholm, Sweden.\nMore in-depth studies are needed before researchers can say that the magnesium was what actually reduced the stroke risk, she added.\nThe United States recommends that men and women over age 31 eat 420 and 320 milligrams of magnesium daily, respectively.\n\u201cIt\u2019s a diet that\u2019s rich in fruits, vegetables and grains.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Harms weren\u2019t discussed, but we\u2019re not sure there any substantial harms of a diet rich in leafy green vegetables, nuts and beans worth mentioning.", "answer": 2}, {"article": "Medical researchers are well aware that the dummy pills used in clinical trials often provide as much relief as the actual drugs being tested. This is what's known as the placebo effect, and it's quite common in people with Parkinson's, a movement disorder that causes tremors, stiffness and balance problems. A 2008 meta-analysis found that placebos used in clinical trials of Parkinson's treatments improved symptoms by an average of 16%.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story did not discuss potential harms. From a bioethics standpoint, there is concern that\u00a0the use of a placebo without the patient\u2019s knowledge may undermine trust between the physician and patient, thereby leading to medical harm. (More background on these concerns in this Science-Based Medicine post.) In addition, patients receiving placebo treatments in clinical studies commonly complain of adverse drug reactions. The story also could have discussed the potential for harm resulting from the participants\u2019 interruption of active drug therapy for the study.", "answer": 0}, {"article": "Harvard T.H.\nIn 1991, the women--ages 27-44 at the time--filled out questionnaires about their food intake, and did so every four years after that.\nAmong all the women, there was a strong inverse association between fiber intake and breast cancer incidence.\n\"We now have evidence that what we feed our children during this period of life is also an important factor in future cancer risk.\"\nThey also completed a questionnaire in 1998 about their diet during high school.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "No harms are mentioned but we wouldn\u2019t expect any in a release touting the benefits of a high fiber diet.", "answer": 2}, {"article": "So, is kiwi the new \"wonder\" fruit?\nThe study was to be presented Tuesday at the American Heart Association's annual meeting in Orlando, Fla.\n\nCardiologists were quick to caution that there is no single magic food or ingredient that is the key to heart health, but they all agreed that kiwi may have a place in the five daily servings of fruit and vegetables that are currently recommended as part of a heart-healthy diet.\n\"There is biological plausibility, but I would not go and grab three kiwis a day,\" said Dr. Nehal Mehta, a preventive cardiologist at the Hospital of the University of Pennsylvania in Philadelphia.\nThey are rich in lutein, a potent antioxidant, and this may be what is responsible for their blood pressure-lowering powers, said researchers who were led by Mette Svendsen of Oslo University Hospital in Norway.\nResearchers measured blood pressure via 24-hour ambulatory monitoring, which is thought to be more precise than measuring it during a single point in time.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "There\u2019s an odd cautionary quote that even 3 kiwis a day \u201cdoesn\u2019t sound like moderation and I would caution against eating that much.\u201d\u00a0 But the story never explains why.\u00a0 Is there a harm?\u00a0 This point was just left hanging unexplained.\nHere\u2019s some of the explanation that could have been given.\u00a0 Kiwi is rich in potassium, which may be one of the ways it helps lower blood pressure. People with kidney disease or other metabolic disorders predisposing them to high potassium could get into trouble with high intake of the fruit (theoretically). See Medlineplus for information about potassium-rich diets.", "answer": 0}, {"article": "This was not statistically different.\nThe critical care specialists who make up the American College of Chest Physicians favor heparin to reduce the risk of blood clots, while the American Academy of Orthopaedic Surgeons guidelines state that no one drug is better than another for preventing clots.\nSince then, the shift has become even more distinct: Aspirin prescribing has risen to 70 percent among Michigan surgeons, says Hallstrom, who is co-director of the initiative and a health services researcher at U-M's Institute for Healthcare Policy and Innovation.\nThe study suggests most patients can have just aspirin without increasing the risk for venous thromboembolism, but doctors need to consider factors such as a patient's history of clots, obesity and ability to mobilize after surgery when determining the best measure for clot prevention, Hallstrom adds.\nSome doctors choose powerful anti-clotting drugs like heparin (Lovenox) and rivaroxaban (Xarelto), but it hasn't been clear whether these expensive prescription drugs work any better than cheap, readily available aspirin.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "\u201cGood old aspirin\u201d implies that aspirin is benign and without potential harms, which is not accurate, even if the harms of aspirin are typically less than those of anticoagulants. There are two potential harms that were examined: bleeding and formation of clot. \u00a0While the report notes that aspirin was \u201cnot inferior\u201d to other anticoagulants, it was silent on the incidence of bleeding.", "answer": 0}, {"article": "\"This result suggests that adequate pain management should be an important goal of care, even after minor outpatient surgery, and that more effective pharmacologic and nonpharmacologic strategies should be explored,\" writes Dr. Naveen Poonai, Clinician Scientist, Lawson Health Research Institute, and Associate Professor, Emergency Medicine, Department of Paediatrics, Schulich School of Medicine & Dentistry, Western University, with coauthors.\nOral morphine use at home has not been previously studied in children who have had minor surgery nor has it been compared with ibuprofen.\nIn the first 24 hours, more than 80% of the children in the study needed pain relief at home.\nPain scores for children in both the oral morphine and ibuprofen groups were similar, but the children receiving oral morphine reported more adverse effects, such as nausea, vomiting, drowsiness, dizziness and constipation.\n\"Oral morphine versus ibuprofen administered at home for postoperative orthopedic pain in children: a randomized controlled trial\" is published October 10, 2017.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "Side effects from the drugs were listed as nausea, vomiting, drowsiness, dizziness and constipation.", "answer": 1}, {"article": "A flu drug \u2014 shown to reduce the duration of symptoms \u2014 could upend treatment in U.S.\n\nNext winter, there may be a new drug for people who contract influenza \u2014 one that appears to be able to shut down infection quickly and, unlike anything else on the market, can be taken as a single dose.\n\nThe Food and Drug Administration on Tuesday said that it would give the drug, baloxavir marboxil, a priority review, and approval has the potential to upend the way influenza is treated.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The news release issued by Genentech about the FDA\u2019s decision to grant priority review describes baloxavir marboxil\u2019s most common side effects: diarrhea, bronchitis, nausea and sinusitis. The news release also states that overall incidence of adverse events seen in patients taking baloxavir marboxil were lower than those seen in both the placebo group and the group taking Tamiflu.\nThe STAT News story does not mention any potential harms.", "answer": 0}, {"article": "Now, a groundbreaking study suggests that not all C-sections are equally risky.\nDr. Mairead Black, the University of Aberdeen obstetrician who led the study, said that as cesarean births had increased in Scotland and worldwide, the researchers wondered what, if anything, children born by C-section \u201care missing out on.\u201d\n\n\u201cOur thinking was: If a baby is born naturally, it comes into contact with bacteria from the mother, which might help with immune system development,\u201d Dr. Black said.\nThe finding suggests that the arduous experience of labor \u2014 that exhausting, sweaty, utterly unpredictable yet often strangely exhilarating process \u2014 may give children a healthy start, even when it\u2019s interrupted by a surgical birth.\nThe step is just one of a cascade of physiological changes that take place in mother and baby during the labor process, including surges in stress hormones and reproductive hormones like oxytocin that may help the fetus adapt during labor, preserve blood flow to the organs, and keep the baby alert and prepared for breast-feeding.\nThe results showed that babies born by planned C-section had a 35 percent higher risk of Type 1 diabetes compared with babies born by emergency C-section, after adjusting for differences among the mothers.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story is a comparison of harms and it did a reasonable job of describing relatively slight differences between the study groups: planned C-sections, unplanned C-sections and vaginal deliveries.\nThe headline overstates what the story describes carefully. In the excerpt below, italics by editor.\n\u201cOver all, the differences between a scheduled C-section and an emergency C-section were slight. However, the data do begin to shed light on why babies born through vaginal birth may have fewer health risks than babies born by C-section.\nThe biggest difference between babies born by scheduled and unscheduled C-section appeared in risk for Type 1 diabetes. The results showed that babies born by planned C-section had a 35 percent higher risk of Type 1 diabetes compared with babies born by emergency C-section, after adjusting for differences among the mothers.\u201d\nAs noted above, the risk sounds much higher when given in relative terms, but since we\u2019ve already docked points for that concern above,we\u2019ll award a Satisfactory rating here.", "answer": 1}, {"article": "Results of the regenerative medicine study published in the journal Nature Nanotechnology.\nWe have shown that skin is a fertile land where we can grow the elements of any organ that is declining,\" said Dr. Chandan Sen, director of Ohio State's Center for Regenerative Medicine & Cell Based Therapies, who co-led the study with L. James Lee, professor of chemical and biomolecular engineering with Ohio State's College of Engineering in collaboration with Ohio State's Nanoscale Science and Engineering Center.\nOur technology keeps the cells in the body under immune surveillance, so immune suppression is not necessary,\" said Sen, who also is executive director of Ohio State's Comprehensive Wound Center.\nResearchers at The Ohio State University Wexner Medical Center and Ohio State's College of Engineering have developed a new technology, Tissue Nanotransfection (TNT), that can generate any cell type of interest for treatment within the patient's own body.\nIn lab tests, this technology was also shown to reprogram skin cells in the live body into nerve cells that were injected into brain-injured mice to help them recover from stroke.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "While we are told that the \u201cprocedure is non-invasive,\u201d and that \u201cthe cargo is delivered by zapping the device with a small electrical charge that\u2019s barely felt by the patient,\u201d this implies a safety that may not exist. The release should have described how well the \u201cpatients\u201d (in this case pigs and mice) tolerated the treatment and what types of problems they might have developed. More importantly, it should also have warned that this experiment in a small number of animals might not uncover problems that would occur when used in a large number of people.", "answer": 0}, {"article": "The main side effects, Vertex said, were headache, upper respiratory tract infections, nasal congestion, rash and dizziness.\n\u201cI\u2019ve been doing clinical trials for 30 years in C.F.\nVertex has not said how much it will charge for VX-770.\nNow, 22 years later, a drug that tries to compensate for the genetic defect might be nearing the market.\nThe company is hoping that by late May it will win approval to sell a new type of drug for hepatitis C, which analysts expect will be a blockbuster.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "", "answer": 1}, {"article": "Visit the Mayo Clinic News Network.\nWhile twice-daily injections of low-molecular-weight heparin has been the traditional treatment of choice for cancer patients who suffer a venous clot, Dr. McBane notes that there are numerous limitations to this therapy.\nDr. McBane says quality of life surveys, which were taken monthly throughout the six-month trial, showed that patients markedly preferred oral apixaban over injectable dalteparin.\n\"As a class, these drugs have a number of advantages, including oral delivery, lack of interactions with foods or other medications, and the lack of a need for monitoring drug levels.\"\nThe drug was associated with fewer major bleeding events and fewer recurrent blood clots, compared to low-molecular- weight heparin.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "While a lot of emphasis was placed on potential benefits of apixaban, no harms were mentioned. The release talks about the limitations of the comparator but not apixaban. It certainly seems that there are fewer side effects from apixaban than heparin, particularly because there are no injection-related issues (such as bruising, pain and swelling) from the oral medication. Yet this does not mean that apixaban is completely harmless; like other anti-coagulant medications, one of the side effects is major bleeding which can quickly become dangerous if not treated. \nIn this study, patients receiving apixaban had fewer subsequent blood clots and didn\u2019t appear to have higher rates of bleeding \u2014 the main complication of any blood thinner. Several caveats should be mentioned: first, this was a relatively small trial and included a range of different cancers. Follow-up studies are needed to confirm these results in more patients across a range of different cancers. Second, though it wasn\u2019t statistically significant, more patients in the apixaban group had died at 6 months (15.9% vs. 10.6%). Future studies should examine this further.", "answer": 0}, {"article": "Saper says yoga likely works by strengthening core and lower back muscles and helping with mind-body relaxation.\nOpiate overdoses are now the leading cause of death for adults under age 50 -- an especially compelling reason to find approaches to chronic pain that don't involve narcotics.\n\u2022 None New guidelines outline how to handle back pain \n\n\n\nIn the study, 320 adults with moderate to severe back pain received one of three approaches over 12 weeks:\n\u2022 Education about how to cope with back pain\n\n\n\nYoga was just as effective as physical therapy -- and both groups were about 20 percent less likely to use pain medication than patients receiving education alone.\n\"I feel, the more that one can do for one's self and not depend on medication, the healthier it is for your body,\" Zaborowski said.\n\"Yoga makes me think about my back and how I'm standing and if I'm standing properly, then I can function better.\"\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story could have included some statement of potential harms from yoga. While it may seem that yoga is innocuous, that\u2019s not exactly the case: In a 2017 Cochrane review of 12 different research studies on yoga and chronic back pain, they included potential harms, including the risk of \u201cincreased back pain.\u201d", "answer": 0}, {"article": "Analytics firm GlobalData has forecast that CGRP antibodies will generate combined sales of $4 billion by 2026.\nSimilar drugs are under development at companies including Eli Lilly & Co and Teva Pharmaceutical Industries Ltd, but Amgen emphasizes that Aimovig is the only one that targets the CGRP receptor pathway, rather than CGRP itself.\nLOS ANGELES (Reuters) - A late-stage trial of Amgen Inc\u2019s experimental drug Aimovig found that it reduced episodic migraines by at least half in 30 percent of patients who had failed up to four previous treatments, while 14 percent of placebo patients achieved that goal, the company said on Tuesday.\nAimovig, currently under review by the U.S. Food and Drug Administration, is likely to be the first drug in a new class designed to target calcitonin gene-related peptide (CGRP), which plays a key role in migraine activation.\nAmgen has partnered with Novartis AG to co-commercialize Aimovig in the United States, while Amgen has rights to the drug in Japan and Novartis has rights to commercialize in rest of world.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story says \u201cno Aimovig patients stopped treatment due to side effects, while around 1 percent of placebo patients discontinued because of side effects.\u201d\nAlthough this is helpful information, it doesn\u2019t give any insight into what side effects did occur or how frequently. Just because patients didn\u2019t discontinue treatment, that\u2019s not an assurance that the drug didn\u2019t cause meaningful adverse effects.\nMoreover, the story should have cautioned that there are concerns about the long-term effects of this type of therapy \u2014 particularly risk of cardiovascular disease \u2014 which can\u2019t be assessed with a 12-week study. MedPageToday shed some light on those concerns in its coverage.", "answer": 0}, {"article": "Grams of carbohydrate and total weight of the foods were not significantly different.\nThe statistically significant results of the randomized, controlled crossover study (n=47) showed that a 250-calorie instant oatmeal serving (with an additional 113 calories of skim milk) enhanced satiety and feelings of fullness, reduced the desire to eat and may even lead to a lower caloric intake at lunch, compared to a 250-calorie serving of cold, oat-based cereal, also served with an additional 113 calories of skim milk.\nResearch in the Journal of the American College of Nutrition suggests that eating a hearty portion of instant oatmeal for breakfast -- versus a popular oat-based cold cereal -- leads to lower calorie intake at lunch\n\nCHICAGO, IL, August 19, 2015 - A new study revealed that your cereal choice at breakfast might have an impact on how much you eat for lunch.\n\"The recent 2015 Dietary Guidelines for Americans Committee Report emphasized the importance of eating breakfast for all Americans - and we know that instant oatmeal is a popular and convenient choice,\" comments Marianne O'Shea, PhD, Director of the Quaker Oats Center of Excellence.\n\"When we took it a step further and evaluated the intake four hours post-breakfast, we found that after consuming instant oatmeal, the participants chose to eat significantly less at lunch compared to those who ate the oat-based, cold cereal.\"\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "Direct harm from consumption of these products isn\u2019t likely, so we\u2019ll rate this Not Applicable. However, the study itself does note that a bowl of Honey Nut Cheerios has a lot more sugar than unsweetened oatmeal. In fact, one serving had about 20 grams, which is nearly as much as some experts say women should eat in an entire day.", "answer": 2}, {"article": "Panel Says Aspirin Lowers Heart Attack Risk For Some\n\nMillions of Americans take baby aspirin every day to prevent a heart attack or stroke.\n\"With all the good therapies, better blood pressure control, better cholesterol control, all the things we do in modern medicine,\" he says, \"over the last couple of decades, we've had nearly a 50 percent reduction in the rate of cardiovascular disease.\"\nIf people don't have a significantly increased risk of having a heart attack or stroke over the next decade, Nissen says, they may be \"causing more harm than benefit.\"\n\"It's just not prudent or safe,\" he says, noting that bleeding in the abdomen or brain is extremely dangerous and can be fatal.\nSeveral groups including the American Heart Association offer online calculators to help people figure out their risk, which, along with discussion with a health care provider, can help determine whether daily aspirin might be useful.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The\u00a0article highlights the risks of taking aspirin daily, in particular the risk of bleeding. The article even brings in an independent source, Dr. Nissen, who discusses the bleeding risks. The story would have been stronger had it helped the reader/listener understand the likelihood of those harms, as the ubiquity of aspirin use in our culture may lead individuals to downplay the medicine\u2019s possible harms. However, the story does enough to clear our bar here.", "answer": 1}, {"article": "Gontero noted that cognitive behavioral therapy might help build confidence in some men.\n\"However, most men complaining of inadequate penile size do have associated sexual problems even if their penile dimensions fall within the normal range -- so-called dysmorphophobic penis,\" said Gontero, an associate professor of urology at the University of Turin.\n\"All procedures aimed to increase the penile girth should be considered unsafe, leading to potentially poor cosmetic and functional results,\" Gontero added.\nIn a review of five evidence-based surgical studies of 121 men and six non-surgical studies of 109 men published between 2000 and 2009, the researchers found that penile extenders -- which stretch the organ over a period of months through traction -- were the most effective among non-invasive methods.\nStudy co-author Dr. Paolo Gontero said urologists are constantly approached by men concerned about their penis size, despite the fact that the majority are average, with a flaccid length of 1 to 4 inches.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Harms are mentioned here, and we appreciate that. We do think, though, that some hard numbers should have been put to the risks associated with more of the enhancement procedures. We give it a pass, though, for at least providing harms data for the penile extenders that are touted as the method with the biggest benefit. It says, \u201cMore than 70 of them used penile extenders, with six experiencing minor problems such as bruising, pain and itching. These devices yielded average flaccid length increases of between 0.2 inches and 1 inch, Gontero said, and men achieving better results noted their satisfaction.\u201d", "answer": 1}, {"article": "This data is clinically significant.\n\"The migraine brain is hyperexcitable, and basic science studies have demonstrated modulation of neuronal excitability with this treatment modality,\" says Amaal Starling, M.D., a Mayo Clinic neurologist, who is first author of the study.\nThe eNeura SpringTMS Post-Market Observational U.S. Study of Migraine study, also known as ESPOUSE, instructed participants to self-administer four pulses with the device in the morning and four pulses at night over three months to prevent and treat migraine attacks as needed.\n\"The sTMS may be a great option for these patients and allow doctors to better meet their unique needs.\"\n\"For certain patients, treatment options for migraines, such as oral medications, are not effective, well-tolerated or preferred,\" Dr. Starling adds.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The news release establishes in the first paragraph that TMS is \u201ceasy-to-use\u2026noninvasive\u2026safe,\u201d but does not mention any side effects. These include worsening headaches, transient mood disturbances, and very rarely seizures. Importantly, given how new this treatment is, studies on potential long-term side effects are lacking at this time.\nThe procedure cannot be used in people who have metal in their head such as stents, aneurysm clips, metallic ear/eye devices, and bullet fragments.", "answer": 0}, {"article": "To learn more about the Society and the field of endocrinology, visit our site at http://www.\n\u2022 Smoking cessation, weight loss (if indicated), limiting or avoiding alcohol, maintaining adequate levels of vitamin D and calcium, eating a healthy diet, and regular physical activity are suggested for all women with prior breast cancer\n\u2022 Non-pharmacologic therapies for VMS such as cognitive behavioral therapy, hypnosis, and acupuncture may be helpful as are vaginal lubricants and moisturizers\n\u2022 Several emerging approaches such as selective estrogen receptor modulators (SERMs), Tissue selective estrogen complex (TSECs), estetrol, and neurokinin B inhibitors show promise as useful agents to expand options for symptom relief with less breast cancer risk but have not yet been tested to confirm safety in women with prior breast cancer\n\nOther authors of the study include: Cynthia A. Stuenkel of the University of California, San Diego in La Jolla, Calif.; Susan R. Davis of the School of Public Health and Preventative Medicine, Monash University in Australia; JoAnn V. Pinkerton of the University of Virginia in Charlottesville, Va.; Ann Gompel of Paris Descartes University in France; and Mary Ann Lumsden of the University of Glasgow School of Medicine, Dentistry, and Nursing in Scotland.\nThe most important thing to remember is that therapy must be individualized based on each woman's needs and goals.\"\nMenopause is a normal part of a woman's aging process but pre-menopausal women treated with chemotherapy can also develop premature menopause, and consequently, severe menopausal symptoms including sleep disorders, vulvovaginal atrophy (VVA), vasomotor symptoms (VMS), mood changes, depressive symptoms, cardiovascular disease, osteopenia, and osteoporosis.\nThe study, \"Managing Menopausal Symptoms and Associated Clinical Issues in Breast Cancer Survivors\" is published online at https:/ , ahead of print.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "No harms were mentioned in the release. The only nod to harms was the recommendation that women who were treated with chemotherapy for breast cancer should not be treated with hormone therapy.", "answer": 0}, {"article": "For more information about NIH and its programs, visit www.nih.gov.\nAbout the National Institutes of Health (NIH): NIH, the nation's medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services.\nThe group, led by NIH\u2019s National Institute of Allergy and Infectious Diseases (NIAID), tested 60 cerebral spinal fluid samples, including 12 from people with Parkinson\u2019s disease, 17 from people with dementia with Lewy bodies, and 31 controls, including 16 of whom had Alzheimer\u2019s disease.\nThe NIAID group continues to adapt the RT-QuIC assay to detect additional types of neurological diseases with greater accuracy using the least invasive patient sample possible \u2014 whether that is blood, skin, nasal brushings, or other samples.\nThe diseases typically progress for years before symptoms appear, and once they do, distinguishing one disease from another can be difficult.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "There\u2019s no discussion of how patients might be affected by earlier diagnosis. For example, do patients want to know whether they have one of these incurable diseases?\nAccording to the study, \u201cthe earlier the diagnosis, the earlier that any appropriately targeted therapies can be initiated before further tissue damage is done.\u201d But the news release doesn\u2019t explore that potential benefit.\nAlso, a 93 percent accuracy rate means 7 percent of patients will get a false result. According to the study, the test correctly identified those without the disease in all cases, which means the disease was not detected in some patients, which could give them a false assurance.\nThe release doesn\u2019t assess potential harms of taking spinal fluid samples, which though generally considered safe it is still an invasive test and can result in headache, back pain, bleeding, and increased skull pressure. The release states that researchers are attempting to come up with better tests for neurological diseases \u201cusing the least invasive patient sample possible \u2014 whether that is blood, skin, nasal brushings, or other samples.\u201d ", "answer": 0}, {"article": "Previously, no treatment was available for these patients.\"\nIn January, Bayer announced that the U.S. Food and Drug Administration (FDA) had granted priority review status for Stivarga (regorafenib) as a second-line systemic treatment for patients with hepatocellular carcinoma.\nThe success of this trial opens the field for testing drugs in third-line treatment of HCC and provides a rationale to test regorafenib as a first-line treatment or in combination with therapies administered directly into the tumor or diseased liver in patients in an earlier stage of HCC, according to Dr. Llovet.\n\"This study represents a breakthrough in the management of hepatocellular carcinoma, since it provides evidence for clinical benefits in an area that was an unmet medical need,\" said Josep M. Llovet, MD, founder and Director of the Liver Cancer Program and Professor of Medicine and Liver Diseases at the Icahn School of Medicine at Mount Sinai.\nThis trial provides evidence that regorafenib is the first systemic treatment for patients whose HCC progressed during treatment with sorafenib, the only other drug with proven clinical benefit.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release states only that \u201cregorafenib was well-tolerated with manageable adverse events\u201d [emphasis added]. This is an example of the disconnect that can occur between language commonly used among researchers and language that people use in everyday life. For example, of the 374 patients who received regorafenib, seven had deaths that, according to the journal article, \u201cwere considered by the investigator to be related to study drug.\u201d Few members of the lay public would be likely to automatically assume that death is a manageable adverse event, even when talking about last-ditch medical treatments for advanced cancers. Other side effects that cropped up in the study, and which could significantly affect quality of life for patients, included hypertension, pain and swelling in the hands and feet, diarrhea and severe bleeding. Fatigue was also present as a side effect but the degree of fatigue is not mentioned. ", "answer": 0}, {"article": "The page you are looking for has either moved or is not available (error 404).\n\nPlease return to the homepage or use the search box above to see if the page is available in a new location.\n\nIf you think this message is in error or need assistance, please email the webmaster.", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The news release makes no mention of possible side effects related to the use of hydroxyurea. The NIH\u00a0notes that those risks include a drop in white cell count or platelet count and, in rare cases, a worsening of anemia. According to NIH, \u201cthose side effects usually go away if a person\u00a0stops taking the medication.\u201d There were other adverse events measured in the study that should have been described as well.", "answer": 0}, {"article": "Newswise \u2014 CHAPEL HILL, NC \u2013 For patients whose hearing is considered \u201ctoo good\u201d for traditional cochlear implants, but whose hearing loss is too advanced to benefit from hearing aids, there hasn\u2019t been a device to meet their needs.\nNearly 25 percent of those ages 65 to 74 and 50 percent of those who are 75 and older have disabling hearing loss.\nNinety-two percent of participants reported an improvement in their ability to hear even among background noise, one of the most challenging listening environments for people with hearing loss.\nSYNCHRONY EAS (Electric Acoustic Stimulation) Hearing Implant System, which is manufactured by Durham-based MED-EL Corporation, received FDA approval on September 16.\n\u201cOur clinical trial participants were overwhelmingly receptive to this new technology,\u201d Pillsbury said.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release has zero information about harms, actual or potential.", "answer": 0}, {"article": "Important factors that could cause actual results to differ materially from those reflected in Vanda's forward-looking statements include, among others: the ability of HETIOZ\u00ae to provide significant benefit in the treatment of the symptoms of jet lag disorder; Vanda's ability to obtain marketing approval for the use of HETLIOZ\u00ae in the treatment of jet lag disorder; and other factors that are described in the \"Risk Factors\" and \"Management's Discussion and Analysis of Financial Condition and Results of Operations\" sections of Vanda's annual report on Form 10-K for the fiscal year ended December 31, 2017, which is on file with the SEC and available on the SEC's website at www.sec.gov.\nThis clinical design allowed for the study of HETLIOZ\u00ae without the confounding effects of sleep deprivation and variable light conditions.\nThe pre-specified primary endpoint was the amount of sleep time in the first two thirds of the night.\nThere are no adequate and well-controlled studies of HETLIOZ\u00ae in pregnant women.\nJet lag disorder symptoms are more severe during eastward travel.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The end notes attached to the release describe potential harms in clear terms. ", "answer": 1}, {"article": "Women more likely to have serious mental health problems than men, study says\n\nNIH's mental health chief on why he's leaving for Google: Technology may hold key to better diagnosis\n\nMost Americans will get a wrong diagnosis at least once in their lives\nThe research, published Wednesday in JAMA Psychiatry, is significant because major depression is one of the most common mental health disorders in the United States and one of the leading causes of disability worldwide.\nThis study \"shows a new, proven-safe treatment of depression that is probably both more effective and less expensive than drug treatment or anything else,\" said Dan Kripke, a psychiatrist and professor emeritus at the University of California, San Diego, who has studied the topic but was not involved in the latest trial.\nThere's some evidence that depression, like jet lag, occurs when the biological clock is out of sync, and light helps to correct that, Lam said.\nMost people typically receive medication and psychotherapy \u2014 but medications don't work in all cases and there's a shortage of providers in many areas.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The short story does not mention potential harms of light therapy., and it doesn\u2019t say there are few or none known. Either way, we would have liked the story to address the notion of harm\u00a0I [Editor\u2019s note: As pointed out by a commenter, the story does note that light therapy \u201ccomes with few side effects compared to medication such as antidepressants.\u201d That\u2019s more than we gave the story credit for initially, but we decided to keep the Not Satisfactory rating because the story does not say what any of those side effects are or how frequently they occur.]\nInterestingly, if you look at the table on adverse effects in the original study, it shows that close to 1/4 of those on light therapy experienced diarrhea. We can\u2019t exactly explain that strange finding but it was worth mentioning.", "answer": 0}, {"article": "Atrial fibrillation also increases the risk for dementia.\nBecause atrial fibrillation increases the risk for stroke, people with the condition are often prescribed blood thinners (also known as anticoagulants) to prevent blood clots that can cause a stroke.\nTHURSDAY, Oct. 26, 2017 (HealthDay News) -- Blood thinners may pull double duty for people with the heart rhythm disorder atrial fibrillation: New research suggests they help prevent dementia as well as stroke.\nThe findings strongly suggest that blood thinners reduce the risk for dementia in people with atrial fibrillation, but proving that would not be possible, the Swedish researchers said.\nAt the time they joined the study, about half of the participants were taking oral anticoagulants, such as warfarin, Eliquis (apixaban), Pradaxa (dabigatran), Savaysa (edoxaban) or Xarelto (rivaroxaban).\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "People stop taking these drugs for a reason, and some of those reasons might have to do with the side effects or adverse effects which can also include unstoppable bleeding. The story should have mentioned this. As the article indicates, \u201cpatients start on oral anticoagulation for stroke prevention but they stop after a few years at an alarmingly high rate.\u201d\u00a0 It would seem an important question to explore: why do approximately 15 percent of patients stop taking the drugs within the first year, and then 10 percent each year afterwards?", "answer": 0}, {"article": "Toenail fungus causes nails to become thick, yellow and brittle in a way that looks pretty ugly and can be painful.\n\u201cI\u2019ve had patients come in who have had laser procedures and not seen long-term success.\u201d\n\nFirestone also says that over-the-counter antifungal nail creams and ointments rarely work because they can\u2019t penetrate the nail root.\nIn this case, there is a chance.\u201d\n\nEven John Strisower, the founder of PinPointe USA, says patients should expect at least a minimal reinfection within five years after laser treatment.\nCompared with oral medication, he says, \u201cthe odds of success are better with the laser; plus, there\u2019s no side effects.\u201d\n\nThe most common oral treatment, Lamisil, works for about two out of three patients, according to Lamisil\u2019s FDA-approved prescribing information, but it has been associated with rare cases of serious liver problems.\nIn one small study about laser treatment for toenail fungus, which appeared last year in the Journal of the American Podiatric Medical Association, \u201c26 eligible toes (ten mild, seven moderate, and nine severe)\u201d were treated with a laser produced by Nomir Medical Technologies, which is still seeking FDA approval.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story provides absolutely no information on harms or potential harms of the laser approach. While the risk may be low, lasers do present risks. Instead, the story says, \u201cKominsky has treated 400 to 500 patients with the PinPointe laser. Compared with oral medication, he says, \u2018the odds of success are better with the laser; plus, there\u2019s no side effects.'\u201d A\u00a0doctor selling laser treatments should not be allowed to make these kinds of claims without proof. The folks at Novartis have every right to be miffed that they were held to a higher standard. We did appreciate that the story mentioned reinfection. \u201cEven John Strisower, the founder of PinPointe USA, says patients should expect at least a minimal reinfection within five years after laser treatment.\u201d", "answer": 0}, {"article": "Non-smokers without symptoms generally are not screened for lung cancer in the U.S.\n\u201cThose are some of the things I worry about.\u201d\n\nHer study showed that 300 middle-aged smokers would need to be screened with CT scans to prevent one death from lung cancer.\nBut experts say the findings likely don\u2019t apply in non-Asian countries, where the majority of all lung cancers are found in people who smoke \u2014 and where using computed tomography (CT) scans to screen for lung cancer in smokers has recently been a controversial topic.\nIn another study published by Kondo and colleagues \u2014 this one looking at lung cancer screening in smokers \u2014 five-year survival rates were also highest in those screened with CT scans.\nThat\u2019s consistent with the findings of the National Lung Screening Trial in the U.S., which in November released data \u2014 published online in the New England Journal of Medicine last week \u2014 showing that 20 percent fewer middle-aged heavy smokers died of lung cancer when they were screened annually with a CT scan compared to a standard, less detailed chest X-ray.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "No quantification of what may have been observed in the study, but adequate general caveats were given:\n\u201c\u2026 each scan exposes a person to radiation, which also slightly increases cancer risks over time with repeated scans.\nAnd screening comes with an inherent risk of false-positives \u2014 scans which suggest a lung cancer that turns out not to be there.\nDr. Christine Berg, one of the leaders of the U.S. screening studies, said that generally about a quarter of chest CT scans show some kind of abnormality \u2014 but 96 percent of those abnormal scans turn out not to be lung cancer. While doctors ruled out cancer, those patients would have undergone further tests, sometimes including biopsies, which can cause complications including infection and bleeding.\nAnd for some patients, \u201cif you really weren\u2019t going to benefit from the screening\u2026that complication is something you may not have faced,\u201d Berg said. \u201cThose are some of the things I worry about.\u201d", "answer": 1}, {"article": "The end point also shifts the paradigm from palliation to cure,\" remarked Dr. Scher.\nHowever, none achieved the primary end point of undetectable PSA with testosterone recovery at 20 months after initiation of therapy with ADT alone, although one patient had a PSA of Of the 15 patients with bone metastases, 14 (93%) reached an undetectable PSA when ADT, surgery, and radiation were used.\nThe results suggest that some men who have previously been considered incurable can possibly be cured; investigators also establish a new paradigm for testing various drug combinations in conjunction with local treatment of the prostate to determine which is the best approach (ie, has the highest undetectable disease rate).\nIn a study published in Urology\u00ae, researchers demonstrate for the first time that an aggressive combination of systemic therapy (drug treatment) with local therapy (surgery and radiation) directed at both the primary tumor and metastasis can eliminate all detectable disease in selected patients with metastatic prostate cancer.\nWhile the study is only a first step, one-fifth of the patients treated had no detectable disease, with an undetectable prostate-specific-androgen (PSA) and normal blood testosterone, after 20 months.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release doesn\u2019t mention harms at all \u2013 except to say that the combo treatment was \u201cwell tolerated.\u201d Given that the patients received a combination of drugs, surgery and radiation treatment, there are a host of potential side effects. We don\u2019t expect a release like this one to provide an exhaustive list of those potential harms, but we do expect it to acknowledge possible side effects in some sort of meaningful way. \u00a0Readers have no way of knowing what \u201cwell tolerated\u201d means in the absence of more facts.\nGranted, the published study offered very little observation in the way of harms. But in the absence of such information we encourage news release authors and journalists to seek clarification since it\u2019s a key consideration for people considering treatment options.", "answer": 0}, {"article": "Now, before anyone goes dumping tons of extra cinnamon in their egg nog in hopes of keeping holiday-season pounds at bay, Wu cautioned that further study is needed to determine how best to harness cinnamaldehyde's metabolic benefits without causing adverse side effects.\nAnd because it is already used widely in the food industry, it might be easier to convince patients to stick to a cinnamon-based treatment than to a traditional drug regimen.\nThe study is titled \"Cinnamaldehyde induces fat cell-autonomous thermogenesis and metabolic reprogramming,\" DOI: 10.1016/j.metabol.2017.08.006.\n\"Scientists were finding that this compound affected metabolism,\" said Wu, who also is an assistant professor of molecular and integrative physiology at the U-M Medical School.\nThe research was supported by the Human Frontier Science Program, Edward Mallinckrodt Jr. Foundation, National Institutes of Health and American Heart Association.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "There are no specific harms mentioned, however a disclaimer is included in the news release that \u201cWu cautioned that further study is needed to determine how best to harness cinnamaldehyde\u2019s metabolic benefits without causing adverse side effects.\u201d\nConsuming too much cinnamon can cause mouth irritation. Some people are allergic to the spice.\u00a0 According to WebMD, cinnamon can interfere with some medications, including antibiotics, diabetes drugs, blood thinners and heart medicines.", "answer": 0}, {"article": "But some cancer organizations reject the panel's advice.\n\"This study will only add to the confusion for women and their physicians,\" said Dr. Daniel B. Kopans, director of breast imaging at Massachusetts General Hospital and a radiology professor at Harvard Medical School.\n\"Mammography is not perfect; no one has claimed that it is,\" said Kopans, a member of the ACR Commission on Breast Imaging.\n\"Our observed 10 percent reduction in death from breast cancer is much lower than previously thought,\" Kalager said.\nIn an accompanying editorial, Dr. H. Gilbert Welch, a professor of medicine and community and family medicine at the Dartmouth Institute for Health Policy and Clinical Practice in Lebanon, N.H., said the Norwegian study helps to confirm that the decision to undergo screening mammography is \"a close call.\"\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "In the fourth graph, we are given this great quote from the lead author, Dr. Mette Kalager, an epidemiologist with the Cancer Registry of Norway in Oslo and a visiting scientist at the Harvard School of Public Health in Boston. \"Women should be informed that the benefit is smaller than expected, and there should be a balanced discussion on the benefit and the possible harms of screening, such as overdiagnosis, false-negative and -positive tests and psychological distress.\" Given how thorough the story was\u00a0in other areas, we hoped to see some of these potential\u00a0harms actually broken down later in the story.\u00a0What\u00a0has research shown to be the estimated\u00a0amount of overdiagnosis, false-negatives and false-positives? Some of\u00a0these numbers would have been a nice counterpoint to some of the statements\u00a0elsewhere in the story touting\u00a0the benefits\u00a0of mammograms.\u00a0", "answer": 0}, {"article": "The Mount Sinai Hospital is in the \u201cHonor Roll\u201d of best hospitals in America, ranked No.\n\u201cHealth care utilization is extremely high once cancer progresses, with hospital readmission rates as high as 40 percent and death in the acute care setting ranging from 30-50 percent \u2013 both measures of poor-quality cancer care.\u201d\n\nTo improve the quality of care, researchers at the Icahn School of Medicine developed standardized criteria or \u201ctriggers\u201d for palliative care consultation for patients admitted to the cancer unit at The Mount Sinai Hospital.\n\u201cPalliative care involvement helps patients understand their prognosis, establish goals of care, and formulate discharge plans in line with those goals, and this study is the first to confirm the impact of using standardized criteria and automatic palliative care consultation on quality of cancer care.\u201d\n\nCo-authors of the study include Kerin Adelson, MD, Division of Hematology/Oncology at Yale University School of Medicine.\n\u201cAs cancer progresses, patients are often at high risk for physical pain and emotional distress,\u201d said Cardinale B. Smith, MD, MSCR, Associate Professor of Medicine (Hematology and Medical Oncology), and of Geriatrics and Palliative Medicine, at the Icahn School of Medicine at Mount Sinai.\nPublished today in the Journal of Oncology Practice, the study also determined that a systemized process of referrals resulted in significant improvements in 30-day readmission rates, hospice referral, and receipt of chemotherapy after discharge in patients with advanced cancers.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "It\u2019s hard to imagine many harms associated with a palliative care consultation. It might be helpful to point out that\u00a0patients who are recommended for that type of consultation are still free not to choose palliative care.", "answer": 2}, {"article": "For older people who fracture a hip, the prognosis is grim: a third or more die within a year and only about 1 in 5 return to their pre-injury level of function.\n\nA new approach to care could mean it doesn\u2019t have to be that way.\n\nMore hospitals are putting hip fracture patients on a fast track from the emergency room to the operating room,...", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "There are no harms discussed in the story. We can presume that faster surgery is safer, but whether hip repair is done rapidly or after three days, all surgical patients\u00a0are at risk of harm, and so the risks should be discussed.", "answer": 0}, {"article": "In one of two related studies published Monday, Anderson and his colleagues described in the journal Nature Biotechnology how they had tested 774 variations of alginate in rodents and monkeys and identified a handful that elicited a greatly reduced foreign body response.\n\u201cOur goal is to bring that kind of biological cure across the spectrum of type 1 diabetes.\u201d\n\nThe potential of the approach has attracted interest from both small startups and large biopharmaceutical companies that are looking at stem cell-based therapies for diabetes.\nThe human beta cells survived exquisitely well.\u201d\n\nThe studies show \u201cyou can take stem cells and make a limitless supply of [human beta cells] and put them in a device and cure an entirely different species of animal,\u201d Anderson said.\nThe problem with existing alginates is that the body eventually catches on to the material as a foreign substance, suffocating the implant in a layer of scar tissue.\n\u201cThis is really the first demonstration of the ability of these novel materials in combination with a stem-cell derived beta cell to reverse diabetes in an animal model,\u201d said Julia Greenstein, vice president of discovery research at JDRF, an organization trying to end type 1 diabetes that provided some funding for the studies.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story makes a nod in the direction of harms when it notes that there was a minimal immune system response to the transplanted cells. An immune response is currently one of the harms that limits the usefulness of this procedure.\nBut the story should have gone further to describe how the transplantation procedure is performed. This is an invasive approach that is not without risks and adverse effects.", "answer": 0}, {"article": "The people who do this are specially trained.\nThe procedure must start within six hours of the onset of a stroke, which means that emergency teams and hospitals will have to move fast, Powers said.\nThe guidelines provide added incentive to quickly transfer stroke victims from a local hospital to a major stroke center capable of advanced treatment, said Powers and Dr. David Kandzari, director of interventional cardiology and chief scientific officer for the Piedmont Heart Institute in Atlanta.\nThe major risk of using the device is that it could tear an artery and cause bleeding in the brain, particularly since it will be used on people who have already received very potent blood thinners, Kandzari said.\nA number of other medical societies have endorsed the AHA's new guidelines, including the American Association of Neurological Surgeons and the Society of Vascular and Interventional Neurology.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The article meets the standard by including this sentence: \u201cThe major risk of using the device is that it could tear an artery and cause bleeding in the brain, particularly since it will be used on people who have already received very potent blood thinners, Kandzari said.\u201d\nIt also notes, \u201cclinical trials have shown that the risk of brain bleeding for people who received tPA and then went through mechanical clot removal is no greater than for people who just receive the blood thinner.\u201d Some caution about the fact that we don\u2019t know if that risk will be as low when the procedure is rolled out more widely (as opposed to being used in a highly controlled study environment) would have been welcome.", "answer": 1}, {"article": "There is also another issue.\nNow Dr. Berry, the M. D. Anderson statistician, and a group of leading cancer researchers have found that the chemotherapy benefits in those clinical trials were concentrated almost exclusively in women whose cancers were impervious to estrogen.\n\"Part of it is that this area of medicine we're practicing in is kind of a high wire act,\" said Dr. Michael Lee, an oncologist in private practice in Norfolk, Va. \"It is more comfortable to adopt things that are aggressive.\"\nThe chemotherapy question starts with American and European guidelines that say almost every woman with breast cancer that has gone beyond its earliest stages, when it is confined to the milk duct, should have the treatment.\n\"I don't know that many doctors who are comfortable giving women an option about chemotherapy,\" said Fran Visco, president of the National Breast Cancer Coalition, an advocacy group.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story does not provide enough information on the potential short-term and long-term harms of chemotherapy. There is only anecdotal evidence from one woman who developed nerve damage. Common short-term side effects of chemotherapy can include nausea and vomiting, hair loss, and fatigue. Younger women may also experience early menopause and infertility as a result of certain chemotherapy regimens. Potential, though more rare, long-term side effects are more serious and may include: bone disorders, heart problems, blood clots and nerve problems.", "answer": 0}, {"article": "Future prospective trials are needed to see what the prognostic significance of breast arterial calcification might be.\n\"Whether the best use of breast arterial calcification is to trigger additional testing or to directly inform preventive treatment decisions, either by flagging high-risk women to their providers or by reclassifying traditional (heart disease) risk estimates, is worth further discussion.\"\nEarlier research had shown a link between breast arterial calcification and atherosclerotic disease--even heart attack, stroke and other cardiovascular disease events, but researchers said these data provide a more direct relationship between the extent of calcified plaque in the mammary and coronary arteries, as well as a comparison to standard risk evaluation.\nThe study, \"Digital Mammography: Screening for Coronary Artery Disease?,\" will be presented on April 3, 2016, at 9:45 a.m. CT/10:45 a.m. ET/3:45 p.m. UTC at the American College of Cardiology's 65th Annual Scientific Session in Chicago.\n\"Even by the conservative estimate of 10 percent, approximately 4 million women nationwide undergoing screening mammography will exhibit breast arterial calcification; with 2 to 3 million of them likely to have signs of premature coronary atherosclerotic disease,\" the authors said.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release didn\u2019t acknowledge that false-positive scans can lead to additional expense, anxiety, further testing, and perhaps treatment with unnecessary medications that have unwanted side effects. Follow-up tests may also expose women to additional radiation.", "answer": 0}, {"article": "There are clear philosophical differences.\nRather, he said, the latest literature suggests that the drugs available to soften the cervix in preparation for contractions help to decrease the Caesarean risk, adding a small caveat: For a small number of first-time mothers with \u201cunfavorable, long and hard cervixes\u201d \u2014 as opposed to cervixes that are soft and receptive to induction \u2014 the risk of Caesarean is increased.\nThe question was presented in May at the yearly ACOG meeting in Washington: \u201cWhy not induce everyone at 39 weeks?\u201d Two doctors had been asked to debate: Errol Norwitz, chairman of obstetrics and gynecology at Tufts University School of Medicine, and Charles Lockwood, dean of the Morsani College of Medicine at the University of South Florida.\n\u201cBeyond adding an element of suspense, this strategy allowed us to come to unbiased conclusions.\u201d\n\nAfter Lockwood found that recent studies suggest that elective inductions at 39 weeks decrease Caesarean delivery rates and might reduce the rate of infant and maternal complications, what was supposed to be a debate proceeded as a discussion in support of induction.\n\u201cIt\u2019s obvious that a blanket policy of 39-week inductions would not affect all of the stillbirths that happen before 39 weeks,\u201d Dekker said, adding that the CDC report concludes, \u201cDespite intensive investigations, for a substantial number of fetal deaths a specific cause of death cannot be determined.\u201d\n\nAnd, Dekker said, the public has the misconception that inductions are simple, noninvasive procedures.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story quotes several opponents of earlier induced labor, who refer to risks including \u201cdecreased blood flow and oxygen to the baby,\u201d detached placenta and uterine wall tearing.\nWhile these harms are outlined in only vague and general terms, without specific numbers or citations, this at least acknowledges harms, so we\u2019ll rate as\u00a0Satisfactory.", "answer": 1}, {"article": "America needs to catch up.\nWhen asked if any test similar to BioSure\u2019s new take-home test was in development, Tara Goodin, a press officer for the Food and Drug Administration, said: \u201cThe FDA cannot confirm the existence of or comment on any current/pending product applications.\u201d\n\nThe FDA has approved two take-home HIV tests, but neither has all the strengths of the BioSure test.\nIt adjusted the raw data to mirror the demographics of the U.K. as a whole and estimated that in 2012, 22 percent of all residents with HIV were undiagnosed.\nThe U.K.\u2019s new at-home HIV test won\u2019t reach all the undiagnosed or guarantee that the people who test positive wind up receiving the care they need from a doctor, but letting people check their status quickly and accurately is likely to produce cascading positive effects, as HIV-positive people find it easier to seek care for themselves, warn past partners about exposure, and reduce risk for future partners.\nIn a 2012 study, researchers estimated that in 2008, approximately 20 percent of all HIV-positive people in the United State were undiagnosed.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "There is an egregious disregard of harms. Imagine the trauma of receiving a preliminary test indicating you may be infected with HIV, without any counseling or other support. A false positive test would inflict at least temporary anxiety, but if a person did not seek follow-up testing the trauma of an inaccurate test could be long-lasting. It\u2019s possible self-testing could harm people if it means they are less likely to seek care than if they had been tested in a setting that offers counseling. Also, the test may not detect infection that occurred within the previous three months, so a person who was recently infected, but gets a negative test result, may incorrectly believe he or she is uninfected and then expose others.\nSome of the challenges of home testing are covered in this review article.\u00a0(Dr. Ganguli is a co-author). In addition to the above, there is the issue of the test being used more by\u00a0the worried well and the affluent than by those at highest risk for the disease. In surveys, Americans report that they do not want to spend more than $15 on an HIV test.", "answer": 0}, {"article": "Led by John Weeks (johnweeks-integrator.com), the Co-founder and past Executive Director of the Academic Collaborative for Integrative Health, JACM publishes controlled trials, observational studies, scientific reviews and leading commentary intended to help medical organizations and governmental organizations optimize the use of integrative products, practices, and practitioners in patient care and in delivery and payment strategies.\nThe study design and results, which suggest further controlled studies of this intervention approach in ASD, are published in the Journal of Alternative and Complementary Medicine (JACM), a peer-reviewed publication from Mary Ann Liebert, Inc., publishers.\nIts biotechnology trade magazine, GEN (Genetic Engineering & Biotechnology News), was the first in its field and is today the industry's most widely read publication worldwide.\nThe researchers measured the effects of the intervention on factors such as the children's behavior, ability to pay attention, sleep, and aspects of parenting stress.\nCoauthors Lana Warren, EdD, OT/L and Patricia Rao, PhD, Kennedy Krieger Institute, Baltimore, MD, and David Paton, DAc, LAc, Starting Point Acupuncture and Health Services, Catonsville, MD, identified the most positive outcome of the study as the high compliance rate, with all parents of the children ages 3-10 completing the intervention.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "Potential harms aren\u2019t discussed at all. To be clear, the risks here are low. As the Mayo Clinic notes, \u201cThe risks of acupuncture are low if you have a competent, certified acupuncture practitioner.\u201d But, then again, the release also doesn\u2019t mention the importance of finding a certified acupuncture practitioner. And even with certified practitioners, there are risks, from soreness and bruising to infections. In addition, individuals with bleeding disorders are not good candidates for acupuncture.", "answer": 0}, {"article": "\"Generally, people wonder if it is worth it.\nWhile the study results are promising, much more work needs to be done, Munk said: \"The fact of the matter is that chronic lower back pain is very complex and often requires a maintenance-type approach versus a short-term intervention option.\"\n\"The study can give primary care providers the confidence to tell patients with chronic low back pain to try massage, if the patients can afford to do so,\" Munk said.\nThe study, \"Real-World Massage Therapy Produces Meaningful Effectiveness Signal for Primary Care Patients with Chronic Low Back Pain: Results of a Repeated Measures Cohort Study,\" was published online March 14 in the journal Pain Medicine.\nINDIANAPOLIS -- In the first study of its kind, researchers found real-world massage therapy to be an effective treatment for chronic low back pain.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "We hesitate to suggest that any harm could come from a massage. But the release could have included a statement of there being \u201cno evidence of harms\u201d during the study, if that were the case.\nDepending on the cause of the back pain, is there a potential risk that some patients might experience a worsening of pain after a massage? The release doesn\u2019t say whether people with injuries should avoid massage and seek help from a back specialist. This is especially important if people are seeking therapy on their own, without seeing a physician.", "answer": 0}, {"article": "An estimated 104,000 Americans quit smoking for good as a result of the 2014 campaign.\n\u201cThe money spent in one year on Tips is less than the amount the tobacco industry spends on advertising and promotion in just 3 days.\u201d\n\nThe most recent Surgeon General\u2019s Report, The Health Consequences of Smoking\u201450 Years of Progress, called for airing effective messages such as the Tips ads with high frequency and exposure for 12 months a year for a decade or more.\nWith a year-round campaign we could save even more lives and money.\u201d\n\nTips, the first federally funded anti-smoking paid media campaign, features former smokers talking about their smoking-related illnesses.\nThe latest outcomes measuring the impact of CDC\u2019s national tobacco education campaign are as strong as those achieved in its first year, and suggest that three years into the campaign, the ads were still having a significant impact.\n\u201cThe Tips campaign is an important counter measure to the $1 million that the tobacco industry spends each hour on cigarette advertising and promotion,\u201d said Corinne Graffunder, Dr.P.H., director of CDC\u2019s Office on Smoking and Health.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "Intuitively, it may be hard to consider the possibility that there could be harms attributable to an anti-smoking campaign. However, some assessments of other public health education programs have found that to be the case, and we wish this summary had at least addressed the possibility.\nIn 2008, for example, ABC News reported on a large Congress-mandated study of the effectiveness of a $1 billion anti-drug campaign that launched in 1998. The report was published in the American Journal of Public Health.\n\u201cThe study\u2019s authors,\u201d ABC reported, \u201cassert that anti-drug ads may have unwittingly delivered the message that other kids were doing drugs, inadvertently slowing measured progress that was being made to curb marijuana use among teenagers.\u201d\n\u201cOverall, the campaign was successful in achieving a high level of exposure to its messages; however, there is no evidence to support the claim that this exposure affected youths\u2019 marijuana use as desired,\u201d the report said.\u201d", "answer": 0}, {"article": "She agreed to the memory testing for the study.\nThe team then statistically analyzed the results and found that people scored slightly higher than usual on words when stimulation arrived during a low or foggy state \u2014 and worse, when the pulse arrived in a high state.\nThis study used data from 150 patients, and had 20 collaborators from institutions around the country, including Emory University, the University of Washington, the Mayo Clinic and the University of California, San Francisco.\nThe preoperative \u201cevaluation\u201d is a fishing expedition of sorts, in which doctors sink an array of electrodes through the top of the skull and wait for a seizure to occur, to see whether it\u2019s operable.\nThe new study is the latest chapter in an extraordinary, decades-long collaboration among cognitive scientists, brain surgeons and people with severe epilepsy being evaluated for an operation.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story explains that brain stimulation can weaken memory formation, and notes how brain implants require \u201ca delicate procedure\u201d to pull off. However, the risks of brain implant devices aren\u2019t discussed \u2014 and they\u2019re significant.\u00a0According to Johns Hopkins University, surgery to implant electrodes in the brain carries a number of risks, including bleeding in the brain, leaking of spinal fluid into the brain, infection stroke, and more. After surgery, brain implants can cause tingling in the face and limbs, problems with speech or vision, dizziness, and other side effects.", "answer": 0}, {"article": "Nucleix Ltd. develops, manufactures and markets innovative, non-invasive, molecular cancer diagnostic tests.\n\"Lung cancer is the leading cause of death from cancer worldwide due to the high incidence of the disease, and the low rate of diagnosis at early and more curable stages,\" stated Prof. Mina Gaga, the President of the European Respiratory Society (ERS) and a lead investigator in the study.\nIn particular, in the non-small-cell lung carcinoma group (n=162), the most prevalent type of lung cancer affecting about 85% of lung cancer patients, Lung EpiCheck was able to identify correctly approximately 70% of patients.\nThe reason for the high mortality rate is that currently most cases are detected when the patient becomes symptomatic, which is usually at late stages of the disease.\n\"We are very excited to present the best published clinically validated results of a blood test for the early detection of lung cancer,\" said Opher Shapira, PhD, CEO of Nucleix.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "There\u2019s no discussion on the potential harms of the screening test. \u00a0False positives can result in invasive and potentially\u00a0dangerous procedures and false negatives can give a false sense of security, which can prevent or delay other interventions such as smoking cessation.\nThe potential for false positives and negatives are very high for this blood test, according to the results presented in the release:\nIn particular, in the non-small-cell lung carcinoma group (n=162), the most prevalent type of lung cancer affecting about 85% of lung cancer patients, Lung EpiCheck was able to identify correctly approximately 70% of patients. With a correct identification of 59% of stage I patients, 77% of stage II, 76% of stage III and 83% of stage IV patients.\nOf note, low dose\u00a0CT scanning for lung cancer has reported false-positive rate that is lower than the rate reported for this blood test \u2014 and yet according to recent real-world experience, it still returns some 2,749 false positives for every lung cancer death averted.", "answer": 0}, {"article": "The other 10 received a fake treatment.\nDuring transcranial magnetic stimulation (TMS), a doctor places a large magnetic coil against the patient\u2019s scalp, which creates electric currents to stimulate nerve cells.\nResearcher Giacomo Koch, MD, PhD, of the Santa Lucia Foundation in Rome, Italy, and colleagues point out that the changes could be the combined effects of the mental tasks and the TMS.\nThe tests also measured activities of daily living affected by neglect, such as dialing numbers on a phone, reading a menu, and sorting coins.\nThis condition often occurs after a stroke on the right side of the brain and is typically treated with a combination of physical therapy and brain retraining or mental tasks using a pen and paper or computer.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Although TMS used for depression is associated with a low rate of adverse effects (mostly headache), we don\u2019t know if other problems might emerge when using it on patients who\u2019ve had a stroke. The story didn\u2019t discuss the potential for adverse effects or mention whether any adverse effects were seen in this study. Any new treatment \u2013 however theoretically safe \u2013 may cause unexpected harms in such a clinically fragile population. That is one of the limitations of a study of such a small number of highly selected individuals.", "answer": 0}, {"article": "Intrarosa is marketed by Quebec-based Endoceutics Inc.\nIntrarosa is the first FDA approved product containing the active ingredient prasterone, which is also known as dehydroepiandrosterone (DHEA).\nThe U.S. Food and Drug Administration approved Intrarosa (prasterone) to treat women experiencing moderate to severe pain during sexual intercourse (dyspareunia), a symptom of vulvar and vaginal atrophy (VVA), due to menopause.\nThe FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices.\n\"Pain during sexual intercourse is one of the most frequent symptoms of VVA reported by postmenopausal women,\" said Audrey Gassman, M.D., deputy director of the Division of Bone, Reproductive, and Urologic Products (DBRUP) in the Office of Drug Evaluation III in the FDA\u2019s Center for Drug Evaluation and Research (CDER).\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "Every intervention carries its own sets of risks. For Intrarosa, the most common side effects include vaginal discharge and an abnormal pap smear, according to the news release. But it doesn\u2019t detail what \u201cabnormal\u201d means or explain what the implications are for women who receive such a result. It also doesn\u2019t quantify the potential harms, including how many women experienced these adverse effects.\nFurthermore, the clinical trials cited in this release lasted for only 12 weeks, meaning long-term effects were not investigated. According to the US National Library of Medicine, the active ingredient DHEA may be unsafe if taken in high doses or long-term. Researchers also say DHEA may cause decreased breast size, a deep voice, increased genital size, irregular periods, oily skin and unnatural hair growth in women.\nSince the news release doesn\u2019t describe potential harms or talk about the drug\u2019s long-term effects, we give it a Not Satisfactory rating here.", "answer": 0}, {"article": "Previous research has shown that taking aspirin or other non-steroidal anti-inflammatory drugs (NSAIDs) every day may help reduce prostate cancer risk.\n\u201cThe walking had to be brisk for men to experience a benefit.\u201d\n\nThe researchers said the effect of brisk walking persisted independent of age, diagnosis, type of treatment and characteristics of disease.\nAnother potential source of the associated reduction was reduced inflammation due to a lower circulation of interleukin-6, high levels of which \u201cpredicted a 73% increased risk of dying from prostate cancer among normal-weight men,\u201d the researchers wrote.\nThe authors theorize that the same may be true of acetaminophen; while not an NSAID, it does have anti-inflammatory properties.\nIn the first study, published Monday in the journal Cancer Epidemiology, Biomarkers and Prevention, scientists found that men who took a daily dose of acetaminophen (Tylenol) for five years had a 38% lower risk of developing prostate cancer, compared with other men.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "No drug \u2013 not even acetaminophen \u2013 is without risk.\u00a0 So, when the story starts in cavalier fashion \u2013 \u201cPop a Tylenol\u2026\u201d it should also find time and space somewhere to mention that popping pills comes with some risk \u2013 especially given that the safe daily maximal dose of acetaminophen has been lowered in recent years.", "answer": 0}, {"article": "Rather, they will suggest that doctors focus on changes in levels over time.\nBut, he added, \u201cIf we biopsied every man with a PSA below 4, we\u2019d be looking at a sea of cancers that would never grow to be life threatening.\u201d\n\nThese facts and the results of a recent study by Dr. Carter, among others, indicated that rather than acting on the basis of a single PSA test, the rate of change in levels over time is a better indicator of who might have a serious cancer.\n\u201cPSA testing of men over 70 is not rational.\u201d\n\nHe pointed to a Scandinavian study showing that among men older than 65, to prevent one death from prostate cancer over 10 years, 330 men would have to have prostate surgery.\nAside from cancer and prostatic growth with age, factors that can change PSA measurements include inflammation or infection of the prostate; a decline in testosterone levels or the drug finasteride, taken for hair loss, both of which lower the PSA; and variations in laboratory assays and in the inherent biology of a person.\n\u201cWe don\u2019t want to miss the possibility of a life-threatening disease, but we end up diagnosing and treating disease that would never have caused harm.\u201d\n\nThe new guidelines will lower the PSA level at which a biopsy should be considered, because, as Dr. Carter put it, \u201cthere\u2019s no level below which we can tell a man he doesn\u2019t have prostate cancer or life-threatening prostate cancer.\u201d\n\nAs one important trial showed, among men with a very low PSA \u2014 that is, a reading below the current cutoff of 4 \u2014 biopsies found that 15 percent had prostate cancer.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Specific harms of screening and its downstream consequences are not mentioned.\u00a0 For instance, the article only states prostate cancer surgery is debilitating, without stating why or how and without recognizing that other prostate cancer treatments, like radiation, can also have debilitating side effects, like problems with erections, leaking urine, and problems with bowel function (which is not stated).\u00a0 The article doesn't tell readers how severe these problems could be or how frequently they might occur.\u00a0 There is also harm in managing the many false positive test results that occur, which is not mentioned; the biopsies can be painful, are often not definitive because they are random, and there are psychological consequences, like anxiety, that men endure.\u00a0 ", "answer": 0}, {"article": "\u201cI\u2019m thinking, is this the way it\u2019s going to be for the rest of my life?\n\u201cI know we can do more.\u201d\n\nAlthough there\u2019s no direct evidence that heart patients who are screened fare better, depression can result in poorer outcomes and a poorer quality of life, the panel said.\nI would think, \u2018Is this a heart attack?\u2019\u201d\n\nA couple of months after she got home she called Mended Hearts, a group affiliated with the heart association that provides support to heart patients, and talked to someone who let her know depression was common in heart patients.\nIf the patient answers yes to one or both, a questionnaire is recommended to determine if the patient is depressed and the severity.\nIf depression is indicated, the patient may need to see a professional qualified in treating depression, the panel said, adding that treatment options include antidepressants, seeing a psychotherapist and exercise.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story does not mention any possible downsides of depression screening. While there are few risks, some of the harms could include: missing cases of mild depression, stigma,\u00a0mislabeling situational stress as an illness, not to mention barriers and difficulties involved in getting the appropriate follow-up care once diagnosed.", "answer": 0}, {"article": "Among the most dispensed: eat a healthy diet, keep a healthy weight, avoid alcohol and tobacco and stay away from certain medications, such as blood pressure and depression drugs.\n\u201cBut this is a much better done study than almost anything that\u2019s been done before on the subject.\u201d He notes that most previous studies did not randomly assign people to exercise groups and compare the outcome on sperm quality, but rather recorded sperm measures among men who reported their exercise habits after the fact.\nWhile it\u2019s not entirely clear why, part of the reason may have to do with the fact that extreme exercise generates body heat, which can be detrimental to sperm health; for marathoners and people training at intense levels, finding ways to dissipate body heat is a major concern.\n\u201cThis fits reasonably well with what we thought about the effects of exercise,\u201d says Dr. Peter Schlegel, vice president of the American Society of Reproductive Medicine and chairman of urology at New York Presbyterian/Weill Cornell Medical Center.\nIn the study, Behzad Maleki at Justus-Liebig University in Germany and his colleagues recruited 280 sedentary, middle-aged men and randomly assigned them to one of three exercise regimens, or to no exercise, and followed them for six months.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "There is no mention of potential harms in this story. Because one of the exercise interventions was high-intensity interval training (HIIT), a brief discussion of harms was needed (see safety concerns of this PDF).", "answer": 0}, {"article": "Shares of Sarepta nearly tripled on Wednesday, closing at $44.93.\nOne possible reason for skepticism is that two of the boys on a lower dose of the drug rapidly lost the ability to walk, even though the level of dystrophin in their muscles increased substantially.\nIt would also represent a success, after decades of setbacks, for the technology eteplirsen uses, called antisense, which is a way of turning off specific genes.\nAlso, eteplirsen would be appropriate for only about 13 percent to 15 percent of Duchenne patients, those with the particular genetic mutation the drug is meant to counteract.\nWhile the company excluded those boys from its analysis as outliers, the Food and Drug Administration might not do so.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story provided some limited information on what is known about the potential harms, \u201cIt is also unclear how long the effects of the drug would last or if safety issues would arise with longer treatment.\u201d\u00a0 \u201cEteplirsen, which Sarepta says has shown no side effects so far,\u2026\u201d\u00a0\nThe company\u2019s press release noted: \u201cThe safety profile of eteplirsen was evaluated across all subjects through 48 weeks and there were no treatment-related adverse events, no serious adverse events, and no discontinuations.\u00a0Furthermore, no clinically significant treatment-related changes were detected on any safety laboratory parameters, including several biomarkers for renal function. \u201d We think that this information should have been included in the story, as it would have provided more meaningful details to back up the sparse comments on harms that were published.\u00a0 No, we don\u2019t expect a story to read like a journal.\u00a0 But we do draw a line between what we think is meaningful explanation to readers and what isn\u2019t.", "answer": 0}, {"article": "Dr. Louis Jacques, director of the coverage and analysis group at the Centers for Medicare and Medicaid Services, said cost was not a factor and that the agency had reviewed products approved by the F.D.A.\n\u201cI\u2019ve never seen anything like this.\u201d\n\nExelixis will now add many prostate cancer patients to the midstage clinical trial from which the results were drawn, said Michael M. Morrissey, the company\u2019s chief executive.\nThe 10 voting members, mainly doctors and health policy experts, averaged 3.6 on the question of how much confidence they had that there was adequate evidence to conclude that Provenge significantly prolongs survival.\nThe drug was approved by the Food and Drug Administration in April after a clinical trial showed that those getting the drug had a median survival of about 26 months, four months longer than those in a control group.\nOne criticism of the drug was filed by a law firm, Willkie Farr & Gallagher, on behalf of a client who the law firm said wanted to remain anonymous because of the \u201cpublic vilification of anyone that questions Provenge.\u201d\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "There was no mention of any possible harms associated with XL184 even though information available from the company indicates that fatigue, diarrhea, nausea, high blood pressure, rash, \u2018hand-foot syndrome\u2019, and cough have been seen in the small cohort of men treated with XL 184 for 6 weeks or more.\nAnd while indicating that Provenge helped men with advanced prostate cancer live 4 months longer, there was no mention of any harms associated with use of this drug.", "answer": 0}, {"article": "Rose Cooper, a microbiologist and honey expert at the University of Wales Institute at Cardiff, remains cautiously optimistic that the increased use of honey dressings will help better information to emerge.\nIn 2000, a World Health Organization report warned: \"Since 1970, no new classes of antibacterials have been developed to combat infectious diseases.\"\nThe company, which has been developing manuka products since 2005, buys medical-grade honey from Comvita, which receives unprocessed honey from beekeepers in New Zealand.\nOn average, the report said, \"research and development of anti-infective drugs takes 10 to 20 years.\"\nToday, according to the CDC, \"nearly all significant bacterial infections in the world are becoming resistant to the most commonly prescribed antibiotic treatments.\"\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story does not mention any harms of using honey. Reports indicate that topical use of honey can cause a burning or stinging sensation and there is some concern about infection.", "answer": 0}, {"article": "Most bills do allow parents to opt out, because the question remains: Where to make this decision - at the statehouse ... or your house.\nBut some worry that may sends a mixed signal by protecting girls against a sexually transmitted disease while at the same time telling them they shouldn't have sex.\n\"Even if you think you aren't at risk, you are,\" adds Audrey.\nThe vaccine promises to reduce the number of HPV related cervical cancers by more than 70 percent, CBS News correspondent Cynthia Bowers reports.\nNot yet,\" Alexander says.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story does not describe any potential harms of the vaccine.", "answer": 0}, {"article": "Doctors and patients\u2019 advocates urged women considering the procedure to go for counseling and take their time before making a decision, noting that other risk-reducing options were available, like tamoxifen therapy for estrogen receptor-positive breast cancer and the use of more sensitive magnetic resonance imaging screening for earlier detection.\n\u201cFewer women are having just one breast removed.\u201d\n\nYounger women, white women and women with a previous cancer diagnosis were more likely to opt for a contralateral prophylactic mastectomy, the study found, as were women who had lobular histology, meaning the cancer started in the lobules or milk-making glands of the breast.\nThough all women with breast cancer are at risk of developing a second cancer in the uninvolved breast, the risk is slightly greater with lobular histology, Dr. Tuttle said, and white women may be more likely to carry genetic mutations associated with an increased risk of developing cancer in the contralateral breast.\nBut our job is to make sure they have all the accurate information.\u201d\n\nThe study used data from cancer surveillance registries covering about a quarter of the United States to identify 152,755 patients whose cancer was diagnosed in one breast from 1998 to 2003.\n\u201cFor the vast majority of our patients, this does not impact the chances of dying of breast cancer, and that\u2019s the key thing here,\u201d said Dr. Julie R. Gralow, the chairwoman of the communications committee of the American Society of Clinical Oncology and an associate professor of medical oncology at the University of Washington and the Fred Hutchinson Cancer Research Center in Seattle.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The focus of the story discusses the recent increase in bilateral mastectomy after the diagnosis of cancer in one breast.\u00a0 This may be overtreatment for some women.\u00a0 The story notes that physicians should provide women with accurate information about the survival benefit of all treatments, including less invasive options for reducing the risk of a recurrence. ", "answer": 1}, {"article": "The results were presented Thursday at the American College of Neuropsychopharmacology annual meeting in Hollywood, Fla.\n\"We saw a robust, rapid-acting, long-lasting effect,\" said lead researcher Joseph Moskal, a research professor of biomedical engineering at Northwestern's McCormick School of Engineering and Applied Science and director of the school's Falk Center for Molecular Therapeutics.\nThe new drug -- called GLYX-13 -- is so far given in an intravenous form and was recently tested in patients who had not responded to other antidepressants.\nAn advantage is that the drug doesn't have the side effects of other drugs that target these same areas, such as hallucinations and schizophrenia-like symptoms, the researchers noted.\n\"Because it's so quick it would be a huge advantage over our current medications all of which take six to eight weeks for the full effect and at least three to four weeks to start working for most people,\" Bruno said.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The lead researcher is quoted as saying, \u201cIn addition, we have shown little or no side effects with our compound.\u201d And the story does caution that many unknowns remain about GLYX-13, including its long-term effects and the effects of stopping its use. The story also adds that the drug does not display side effects of hallucinations and schizophrenia-like symptoms.\nHowever, here\u2019s why we rule this one unsatisfactory on the harms criterion:\u00a0 A single dose of a medication (which appears to be the design here) can\u2019t establish harms.\u00a0 The story should have been less accepting of the statement that there were no side effects.\u00a0 The compare-and-contrast to other drugs targeting the same receptors and the apparent lack of short-term and severe side effects (e.g., hallucinations) was useful but not close to the whole story.", "answer": 0}, {"article": "He was not involved in the study.\nOver-the-counter multivitamins typically contain 15 to 25 IU of vitamin E.\n\nThe newly-released Physicians Health Study showed an 8 percent reduction in total cancer occurrence for participants taking a multivitamin, but no benefit was seen for rates of prostate cancer, the most common cancer seen among the participants in the study.\n\u201cOur trial took a very commonly used multivitamin that has basically low levels of all the different essential vitamins and minerals.\u201d\n\nThe findings suggest that the biggest health benefit may come from a broad combination of dietary supplements, he said.\n\u201cIt suggests that a balanced multivitamin approach is probably more beneficial than increasing to high levels any one vitamin.\u201d\n\nAbout half of U.S. adults take at least one daily dietary supplement - the most popular being a multivitamin, according to the U.S. Centers for Disease Control and Prevention.\nLOS ANGELES (Reuters) - Swallowing a daily multivitamin can reduce the risk of cancer by at least eight percent in middle-aged and older men and appears to have no dangerous side-effects, according to the first large-scale, randomized study on the subject.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story said that taking a multivitamin \u201cappears to have no dangerous side-effects,\u201d\u00a0which we\u2019ll call good enough for a satisfactory. In addition, it describes the results of previous studies that have suggested harm from other vitamin formulations. However, it didn\u2019t emphasize that the study was conducted in relatively healthy non-smoking\u00a0men, and that\u00a0certain vitamins may cause problems for people who\u00a0smoke or who are taking medications. The AP explained this nuance.", "answer": 1}, {"article": "Officials at St. Andrew's Episcopal School in Potomac gently suggested that the high school sophomore get a mental health screening.\nThe idea of a psychiatric evaluation sent chills down the spine of Caroline's mother, Mathy Milling Downing, who believed that her younger daughter, Candace, had committed suicide because of an adverse reaction linked to a psychiatric drug -- the antidepressant Zoloft.\nDowning's family offers a powerful case study into the pros and cons of new guidelines recommending widespread screening of adolescents for mental disorders: Last month, the U.S. Preventive Services Task Force, a federal group that makes public health recommendations, said that all adolescents between ages 12 and 18 should be screened for major depression.\nThe very different experiences of the two sisters illustrate the paradox at the heart of screening recommendations: What matters is not whether screening is done but how it is done and how screening information gets used.\nBy contrast, she said, the multiple screenings that Caroline received carefully evaluated the child as an individual and homed in on the kind of therapy that was best for her.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "While indicating that the use of SSRI medication by adolescents has been associated with increased risk of suicide, the story provided no quantitative information about how likely this is to occur. \u00a0The story did mention the potential for over-prescribing of antidepressants. \u00a0However, it did not mention other potential harms such as stigma, mis-diagnosis, distracting from more important health problems, and treatment without adequate follow-up potentially leading to net harm.", "answer": 0}, {"article": "The item you've requested, /cgi-bin/article.cgi?f=/n/a/2006/03/12/national/a131601S24.DTL&type=health, was not found.\n\u2022 the item no longer exists, or\n\u2022 there has been an error on the site.\n\nIf you feel the address you entered is correct you can contact us, mentioning the error message received and the item you were trying to reach.\n\nWe apologize for any inconvenience. From here, you can:\n\u2022 use the menu bar above\n\u2022 select an item from our site index below", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "No harms associated with this treatment were mentioned; only that it was \u201csafer\u2019 than \u201cwater pills\u201d (as opposed to the IV diuretic to which it was compared.) While no harms were mentioned, the article did mention that patients did not report feeling any better.", "answer": 0}, {"article": "Jason Dragoo\u2019s Stanford University research team gets 100 to 200 inquiries every day from people interested in joining its clinical trial studying the use of stem cells to treat knee injuries.\n\nThe interest highlights a growing demand for the use of stem cells derived from a person\u2019s own bone marrow or fat to treat orthopedic injuries. Osteoarthritis, a degenerative joint disease where the protective tissue or cartilage around a joint wears down, is a particular focus of inquiry.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "This story does not clearly state the harms involved with either conventional therapy for osteoarthritis nor the injection of stem cells into the knee joint.", "answer": 0}, {"article": "Guyuron, chair of plastic surgery at University Hospitals Case Medical Center in Cleveland, went on to identify four common \"trigger sites\" and publish studies showing that, in selected patients, surgical decompression of nerves in one or more of these sites provides lasting migraine relief. He has also taught 250 plastic surgeons around the world (none in the Philadelphia area) to perform the outpatient operation, which costs an average of $10,000 and is not covered by many insurers.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story makes a passing reference to harms. It says, \u201cLast week, following Boston media stories about migraine surgery, the headache society issued a warning: \u2018No convincing or definitive data show its long-term value,\u2019 it may cause irreversible side effects, and it can be \u2018extremely expensive.'\u201d It also lists some of the side effects seen in the small studies conducted by the surgeon who is the focus of the story. Given how serious the decision is to undergo surgery for a migraine headache, we think a much fuller discussion of side effects and harms was warranted, including quantifying what\u2019s been observed.", "answer": 0}, {"article": "(That\u2019s a high dose; a 3 oz.\nWhat\u2019s more, the people who showed the highest blood levels of the omega-3 fats (people absorb it at different rates) showed the greatest reduction in scarring \u2014 13% \u2014 compared to those with the lowest levels.\n\u201cThe omega-3 fatty acids seem to be preventing scarring of the otherwise healthy muscle that now has to overwork because of the heart attack,\u201d says Kwong.\nIt\u2019s the first encouraging strategy for protecting the heart a heart attack; the more remaining healthy tissue that can be saved, the stronger the heart will be.\nThe remaining healthy tissue starts to compensate for the compromised tissue, but has to work harder to maintain the heart\u2019s normal pumping function.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Harms should have been included.\nAs made clear in a New York Times story, Dr. James Stein of the preventive cardiology department at the University of Wisconsin Hospital and Clinics explained that \u201cfish oil can be hazardous when combined with aspirin or other blood thinners.\u201d This seems particularly pertinent here as post heart-attack patients are often\u00a0recommended to take aspirin.", "answer": 0}, {"article": "Forty percent have heart disease, and half will die from it.\nNow, more are getting open-heart surgery, with remarkable survival rates rivaling those of much younger people, new studies show.\nThe answer: Average survival was roughly six years \u2014 almost the same as similarly aged people who do not have heart disease.\nIn Florida, Dr. Paul Kurlansky led a study of 1,062 octogenarians who had heart bypass surgery at Mount Sinai Medical Center in Miami Beach from 1989 through 2001.\nEven more impressive: 65 percent survived without any long-term complications \u2014 a \u201cvery, very remarkable\u201d result, Kurlansky said.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story made short shrift of harms that might be associated with the treatment. \u00a0It mentioned that older patients want to decide for themselves whether to take the risk but then never detailed what risk was being alluded to. \u00a0The story also mentioned that 65% of the patients had no long term complications, but again \u2013 there was no discussion about what complications were seen to affect 35% of patients studied.", "answer": 0}, {"article": "Although the company selling Xiaflex will be Auxilium Pharmaceuticals of Malvern, Pa., the F.D.A.\nWe don\u2019t have to pay for manufacturing.\u201d\n\nThe Wegman family \u2014 the two sons and the founder\u2019s 75-year-old wife, Toby \u2014 controls about 25 percent of the company\u2019s stock.\nWhile collagenase itself is not patented, the companies do have patents on the use of the enzyme to treat Dupuytren\u2019s and Peyronie\u2019s.\nThe enzyme, called collagenase, breaks down collagen, a major component of the body\u2019s connective tissue that is found in skin, tendons, cartilage and other organs.\n\u201cIt was to me just like a miracle.\u201d\n\nXiaflex is an enzyme produced by a gangrene-causing bacterium, Clostridium histolyticum, which uses it to eat away the tissues of its victims.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The sidebar mentions that Xiaflex can rupture tendons \"in rare circumstances\" and that the injections\u00a0\"often\" cause temporary pain\u00a0and bruising and \"sometimes\" cause allergic reactions.\u00a0\u00a0We wish that the story had been a bit more precise in its quantification of these adverse effects,\u00a0but we feel the descriptions provided are\u00a0enough to paint a reasonably accurate portrait of the drug\u2019s potential harms.", "answer": 1}, {"article": "\"Off-label\" refers to the practice of prescribing medicines to treat conditions not been specifically approved by the FDA.\nCyclobenzaprine, marketed in higher doses by others as Amrix, Fexmid, and Flexeril, is already widely used ''off-label'' for patients with fibromyalgia, Lederman says.\nThe results of the study are published online in The Journal of Rheumatology.\nHowever, a rheumatologist not connected to the study does not expect the new drug to be a ''game-changer.\"\nAbout 5 million Americans have fibromyalgia.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "\n\n\nThe story does report that some participants had headaches, dry mouth and drowsiness, and that this drug sometimes makes people drowsy during the day. However, since there were only 18 participants who took the active ingredient, the story would have been better if it had alerted readers that much larger numbers of patients would need to be studied in order to quantify the likelihood of less common adverse events. ", "answer": 1}, {"article": "\"Getting double-blind clinical studies like this one published helps to bring credibility to parental reports.\"\n\"All the data seem to suggest that manipulating the oxytocin system has a powerful effect on the core symptoms of autism,\" said Eric Hollander, director of the compulsive, impulsive and autism spectrum disorders program at the Montefiore Medical Center in New York.\nThe study, involving 13 adults with either a high-functioning form of autism or Asperger syndrome, a mild form of the disorder, found that when the subjects inhaled the hormone oxytocin, they scored significantly better on a test that involved recognizing faces and performed much better in a game that involved tossing a ball with others.\n\"This is the first study that looked at whether oxytocin has an effect on social behavior, which is a major deficit in autism,\" said Angela Sirigu, who directs the National Center for Scientific Research in France and led the study, published online by the Proceedings of the National Academy of Sciences.\n\"If you can find someone who appears to have deficits in oxytocin biology, giving them what you might argue would be replacement oxytocin may be helpful,\" Parker said.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The study was of relatively short duration and no side effects were reported. The story does note that more research in children particularly is needed on the safety of oxytocin.\u00a0However, the story could have noted that oxytocin is not without side effects based on usage in adults. ", "answer": 1}, {"article": "\"Experimental studies suggest that fructans may be beneficial in diabetes, obesity, stimulating the immune system of the body, decreasing levels of disease-causing bacteria in the intestine, relieving constipation and reducing the risk of colon cancer,\" Mercedes Lopez, of the National Polytechnic Institute in Guanajuato, said in the news release.\nThe fructans turn into alcohol when agave is processed into tequila, they said.\nBut drinking tequila won't help, the study authors noted.\nCompared to other mice, those fed agave fructans absorbed more calcium from food, excreted less calcium in their feces, and had a 50 percent increase in levels of a protein associated with the build-up of new bone tissue.\n\"They can be used in many products for children and infants to help prevent various diseases, and can even be used in ice cream as a sugar substitute.\"\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Not a word about potential harms.\u00a0 ", "answer": 0}, {"article": "Tamoxifen, a generic drug, is already approved for reducing the risk of breast cancer.\nAs for the data on vaginal and vulvar cancer prevention, they came from combining data from three trials used to test the ability of the vaccine, Gardasil, made by Merck & Company, to prevent cervical cancer.\nWhile both drugs reduced cases of breast cancer by about half from what would have been expected for the women in the study, raloxifene caused fewer cases of blood clots, cataracts and uterine cancers, making it initially appear the winner.\nSo, in response to the cancer institute's announcement two months ago, some experts quickly declared that raloxifene was not clearly superior, leaving women in a quandary.\nThe editorial in the journal said the new data \"still may not be enough to convince primary care physicians to be more aggressive than they have been to date in breast cancer chemoprevention.\"\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "While the story lists the possible side effects and harms of the study medications, it does not mention how often these problems happened, nor how much they bothered women who had them. The article distorts the findings of the study by focusing on the quality of life data while downplaying or misrepresenting the data on outcomes for serious or life-threatening problems such as uterine cancer and blood clots. ", "answer": 0}, {"article": "The blood test, which is not without its own ouch factor, measures levels of circulating IgE.\n\u201cBut Hugh Sampson\u2019s work may turn the tide.\u201d\n\nAs for Sarah Marcus, starting last summer she was weaned from allergy shots so she would no longer need them when she went away to college, at the University of Pennsylvania.\nDiagnosing requires a thorough medical history and interpreting the test results within that context; generalists may lack the time to do a complete history, especially under the pressures of managed care.\nBut skin-testing results can vary from one allergist to the next, and most allergists don\u2019t rely on a prior allergist\u2019s results when a patient switches practices.\nBecause the test comes with a small risk of a serious reaction, it should not be performed in very young children and pregnant women, among others.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story only mentions one harm of the blood test \u2013 getting the blood drawn itself. The story should have mentioned other harms such as what happens with false positive or negative results or how the results may be misinterpreted by non-allergy specialist clinicians.", "answer": 0}, {"article": "Doctors said Thursday that the increased risk did not outweigh the benefits of the drugs.\nThe drugs, which include Depakote, Lamictal, Topamax, Keppra, Lyrica and Neurontin, are sometimes prescribed for chronic pain and headaches, as well.\n\u201cWhat\u2019s really important to say is that bipolar disorder is very difficult to treat, the burden is enormous, and these medications help keep people free of mood and anxiety symptoms and allow them to function,\u201d said Andrew A. Nierenberg, medical director of the bipolar clinic and research program at Massachusetts General Hospital.\nThe Food and Drug Administration undertook a combined analysis of 199 clinical trials with 43,892 patients and found 4 suicides and 105 reports of suicidal symptoms among the 27,863 patients who were given the drugs compared to no suicides and 35 reports of suicidal symptoms among the 16,029 patients treated with placebos.\nDrugs for epilepsy, bipolar illness and mood problems double the risks of suicidal thoughts and behavior, and patients taking them should be watched for sudden behavioral changes, drug regulators have said.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The focus of the story is a potential harm of treatment, namely, an increased risk of suicidal thoughts or behaviors. The story notes the risks are greater for epileptics than for those taking\u00a0 the same medications for psychiatric conditions or for chronic pain. The story does not note other, less serious harms of these drugs, which can include weight gain, mental confusion and an upset stomach. Discussion of other side effects would be useful information if patients are considering the full risks and benefits of taking this class of medication over the long-term. ", "answer": 1}, {"article": "The surgery she's upset about may be archaic - but it's very common.\nAbout 600,000 of them are done every year in this country.\nHysterectomy is the surgical removal of the uterus.\nLiterally, no pain.\"\nAnd right away, she wanted to go home.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story does not mention the harms of surgery.", "answer": 0}, {"article": "By far, the lowest incidence of colorectal cancers was seen in pesco-vegetarians, people who eat fish at least once a month but eschew all other types of meat. Compared to omnivores, pesco-vegetarians were 43% less likely to be diagnosed with these cancers during the course of the study.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "There are really no harms to discuss when addressing these dietary changes, particularly given the extremely broad definitions of the vegetarian diet in the relevant study. Not applicable.", "answer": 2}, {"article": "Servan-Schreiber offered more words of wisdom to LaPook -- words he says doctors rarely impart to their patients -- and LaPook discussed with co-anchor Harry Smith on The Early Show Friday why he thinks it is that cancer survivors aren't offered more guidance by the medical establishment:\n\nServan-Schreiber appears in the joint CBS, NBC, ABC special \"Standing Up To Cancer\" Friday night.\nAnd if you do these things, which are very simple, you're greatly increasing your chance of beating the odds.\"\n\"There's tremendous evidence that physical exercise helps prevent cancer, and also helps people who already have cancer prevent a recurrence,\" he says.\nHe has penned the best-selling book, \"Anti-Cancer: A New Way of Life,\" about his past and on-going battle, and offers suggestions to fellow cancer patients.\nAccording to Servan-Schreiber, herbs and spices such as garlic, turmeric, rosemary, thyme, mint, and green tea help make the body less fertile for cancer.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story rightly points out that there are few drawbacks to adopting a healthy lifestyle.", "answer": 1}, {"article": "MONDAY, Nov. 16, 2015 (HealthDay News) -- Breast-feeding a premature infant may help reduce the risk of a serious eye problem known as retinopathy of prematurity (ROP), new research suggests.\nThe studies included more than 2,200 preterm infants, comparing how often babies had been fed human milk or formula, and whether or not they developed ROP.\nThe takeaway from this study, Llanos said, is to breast-feed as long as possible, if possible.\nIn re-evaluating the studies, Chen's team found that breast-feeding in any amount appeared to reduce the risk of ROP.\nHowever, the new analysis only showed an association between breast milk and a reduced risk of ROP.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "In the framework of our criteria, the intervention in this study is the feeding\u00a0of human milk. The potential harms of human milk do not seem to warrant a discussion in this article however.", "answer": 2}, {"article": "There were, however, wide variations in individual responses, the team noted.\n\"I really want to encourage clinical trials in this area because of its potential significance, but we have to be very careful in terms of safety data,\" Lajonchere said.\nIt's almost like a designer drug, a drug which has a selective effect on a behavior in the normal range,\" said Keith Young, vice chairman of research in psychiatry and behavioral science at the Texas A&M Health Science Center College of Medicine in Temple and the neuroimaging and genetics core leader at the VA Center of Excellence for Research on Returning War Veterans at the Central Texas Veterans Health Care System.\nWhile there are drugs for the secondary symptoms of autism, such as irritability and aggression, doctors have nothing yet for the core symptoms in the areas of language, social interaction and intellectual deficits.\nMONDAY, Feb. 15, 2010 (HealthDay News) -- People with high-functioning autism or Asperger's syndrome were better able to \"catch\" social cues after inhaling the hormone oxytocin, new research shows.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "While harms are not quantified in the\u00a0published study\u00a0itself, this story does well to emphaszie the importance \u2014 and current lack \u2014 of safety data for an alluded-to use of oxytocin in children with autism. \nWe do know a good deal about the toxicity of oxytocin when given to women to induce labor and for a few hours. In addititon to possible severe allergic reactions, water intoxication is an important side effect.", "answer": 1}, {"article": "Christian\u2019s team studied 676 school-age children whose mothers had been in a clinical trial in which some got iron and folic acid supplements and other nutrients while they were pregnant.\nAbout 80 percent of the children \u2014 aged 7 to 9 \u2014 were enrolled in school.\n\u201cWhat we showed is prenatal iron and folic acid supplementation had a significant impact on the offspring\u2019s intellectual level and motor ability and ability during school age, which was a very exciting finding,\u201d she said.\n\u201cWe had the opportunity to follow the offspring of women who had participated in a randomized trial of iron and folic acid and other micronutrients to assess neurocognitive function and outcomes,\u201d Christian said in a telephone interview.\nThe World Health Organization estimates that in developing countries, every other pregnant woman is anemic and about 40 percent of preschool children are anemic.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Any vitamin supplement taken in very high doses can be harmful and some acknowledgment of this should have been made here. Even citing the author or another expert about a lack of observed or known harm would have been sufficient.", "answer": 0}, {"article": "That accounts for a small percentage of people.\nMore: Breast cancer: Study finds tumor risk increased by use of oral contraceptives\n\nBut \u201cit has a lot of caveats,\u201d warned Donald St. Pierre, acting director of the FDA's Office of In Vitro Diagnostics and Radiological Health.\nThe prescription-free test is the first to report on three specific BRCA1 and BRCA2 breast cancer gene mutations, according to the FDA.\nStill, the company, which already tests DNA for other health risks as well as ancestry, said this cancer test is \"a step in the right direction.\"\nThese tests might help with prevention, but cannot diagnose cancer and cannot rule out your chances of getting cancer, 23andMe said.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "There are questions about accuracy that will be discussed under quality of evidence, but we think it\u2019s worth addressing potential harm associated with any screening test: false results. The Mayo Clinic notes that testing positive for a BRCA mutation can cause \u201cFeelings of anxiety, anger, sadness or depression\u201d; \u201cDifficult decisions about preventive measures that have long-term consequences\u201d; and \u201cFeelings of inevitability that you\u2019ll get cancer.\u201d Those are serious stresses associated with accurate diagnoses. Those same stresses can occur if someone is inaccurately told that they have a relevant gene mutation \u2014 and that\u2019s a potential harm that is worth mentioning.\nAnother potential harm is if a patient is found to have a \u201cVUS\u201d \u2013 variant of uncertain significance. This is an abnormality in the gene which may or may not be harmful. When patients undergo genetic testing under the care of their physician or genetic counselor, the possibility and implications of a VUS are explained prior to and after testing. As the 23andMe testing kit is available to the consumer without a prescription and without a requirement for pre-test education or counseling, patients may be further confused if the results reveal a VUS.", "answer": 0}, {"article": "A birth-control pill that eliminates women's monthly periods could hit pharmacy shelves later this year, marking the latest effort by a drug company to expand a contraceptive's features beyond preventing pregnancy.\n\nSince \"The Pill\" was introduced nearly a half-century ago, most regimens have mimicked a woman's cycle by having a pill-free week each month when women can have bleeding and other symptoms.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Harms of \u201call\u201d birth control pills are noted, but no numbers provided. The story doesn\u2019t mention whether these harms happened to similar numbers of women in trials of the new pill. The story would have been more balanced if it had quoted an independent expert discussing the real or perceived potential harms.", "answer": 0}, {"article": "Outside of heart attacks, doctors are often too quick to use a common $20,000 procedure to treat patients suffering from coronary artery disease, a new study suggests.\n\nAbout 600,000 angioplasty procedures, which almost always involve placement of a tiny metal tube called a stent, are done in the U.S. each year. Roughly 70% of these procedures are performed on patients suffering symptoms of a heart attack and aren't medically controversial. But the remainder are done on stable patients who are suffering mild symptoms or no symptoms...", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "As good as this story was, there was no direct discussion of harms, although the harm of inappropriate use should be clear.\u00a0 However, patients who undergo cardiac catheterization face well known risks including kidney damage and failure, damage to blood vessels in the groin, sometimes requiring surgery. There is also a risk of heart damage and risks associated with the antiplatelet drugs used to prevent blood clots from forming. All of these risks are balanced out by the benefit in the right patients.", "answer": 0}, {"article": "NEW YORK (Reuters Health) - Minimally invasive surgery for a burst appendix appears to be more successful and less costly in the long run than the traditional operation, a new study hints.\n\u201cIn healthy individuals, the death rate is very (small) for all groups of patients.\nPeople who had the laparoscopic procedures also had lower death rates, at 0.07 percent versus 0.17 percent, fewer readmissions and a slightly shorter stay at the hospital.\n\u201cOverall, this study shows benefit from laparoscopy on every aspect, including cost,\u201d he told Reuters Health.\nDoctors say this type of operation hurts patients less afterward than the conventional \u201copen\u201d method, which involves one long incision in the abdomen of up to 12 inches.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Good job comparing death rate, readmission rate and hospital stays between the two procedures.", "answer": 1}, {"article": "Sabourin Lussier, born with spina bifida, faced the possibility of kidney failure when she was just 19 years old. Her bladder, damaged by the devastating birth disorder, leaked uncontrollably and often backed urine up into her kidneys.\n\nA conventional surgery to reconstruct her bladder with intestinal tissue threatened further health complications. So in May 2000, Ms. Lussier and her mother, Gail Johnston, agreed to an experiment under which she and eight other patients with spina bifida would receive partial, laboratory-built...", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "No mention of the potential harms of the new man-made bladder. ", "answer": 0}, {"article": "Red and purple fruits owe their colors to...\nAlthough it's a challenge to eat the raw fruit without getting a mouthful of seeds and astringent pith, pomegranates are everywhere now in the form of juice, concentrates and extracts, all heavily promoted for better health.\nThe juice is a beautiful wine-red color and tastes delicious.\nMuch of the popularity is the work of a California-based company, Pom Wonderful.\nIt pays researchers to study the benefits of pomegranate juice, gives doctors information on positive studies and, of course, sells pomegranate products.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "This article failed to mention any harms or ill-effects that might be associated with ingestion of pomegranate or pomegranate-containing products. There are several case reports of pomegranate allergies in the medical literature.", "answer": 0}, {"article": "\u201cThe length of statin use, both greater than six months and greater than five years of use was associated with reduction in colorectal cancer risk.\u201d\n\nThe group of statins that showed the greatest effect in reducing risk are classified as lipophilic: atorvastatin (Lipitor), fluvastatin (Lescol), lovastatin (Altocor, Altoprev, Mevacor), pitavastatin (Livalo), and simvastatin (Zocor),\n\nColorectal cancer is the third most common type of cancer in the U.S.; 102,900 new cases of colon cancer are diagnosed in men and women every year, and about 39,670 new cases of rectal cancer are diagnosed annually.\n\u201cThis effect was largely consistent across study design with both case control and cohort studies showing a strong correlation,\u201d he says in a news release.\nAlso, the longer patients used statin drugs, the greater their reduction in risk for colorectal cancer.\nThe relationship between statins and cancer is unclear, but other research exploring the impact of statins at the molecular level suggests that these cholesterol-lowering drugs may help control the development of tumor, as well as tumor growth.\n\u201cObservational studies have suggested that long-term use of statins is associated with reduced risk of several cancers, including breast, prostate, lung, pancreas and liver,\u201d says Samadder in the news release.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "\u00a0There was no mention of potential harms associated with the use of statin medication.\u00a0 That\u2019s a significant omission.\u00a0", "answer": 0}, {"article": "Urba is a co-author of the\n\non ipilimumab published in the New England Journal of Medicine Saturday.\nStill, the study stands as \"a major landmark in cancer immunotherapy,\" says Dr. Bernard Fox, president of the International Society for Biological Therapy of Cancer.\nThe 47-year-old pre-school teacher from Eugene was stunned when her biopsy came back positive for melanoma \u2013the most life-threatening form of skin cancer.\nWhile far from a cure, the treatment is the first to improve survival in people with melanoma that has spread, or metastasized, says Dr. Walter Urba, director of cancer research at the Providence Cancer Center.\nFor now, federal regulators have authorized\n\nto people who have serious or immediately life-threatening, inoperable melanoma that has spread, who have no alternative treatment options, and whose physicians believe the drug is appropriate.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Good job on harms as well \u2013 \"Serious side effects also became clear. Nearly two-thirds of patients on ipilimumab experienced side effects caused by over-active immunity, such as severe itching, intestinal irritation and diarrhea. Researchers linked 14 deaths to the study drugs, half caused by immune-system reactions.\"", "answer": 1}, {"article": "Compared with the 16% of people who didn't drink coffee at all, those who downed two or more cups each day were about 18% less likely to have died during the study period. In addition, those who drank just one to six cups of coffee per week were 12% less likely to die. Both of these figures were calculated after taking into account known risk factors for early death, such as smoking (which is often paired with coffee drinking), diet and body mass index.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Coffee does have adverse effects, such as insomnia, increasing anxiety, and triggering reflux in certain people. However, the story made no mention of coffee\u2019s downsides.", "answer": 0}, {"article": "We are excited to announce that FibromyalgiaTreating.com is now part of RedOrbit.com. All of the same great people, writers and editors but now with more firepower. We now have access to an enormous amount of additional research information from doctors and scientists. We can now extend to other conditions that may be part of your everyday lives and help you on a broad level if that is what you need. We are here for you and now, better than ever so sit back and enjoy the new Fibromyalgia Treating by RedOrbit!", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story mentions that the newer technology may result in over treatment as there are more false positives with the CAD technology vs. radiologists' analysis alone. In a recent study published in the New England Journal of Medicine, there was 20% increase in biopsy rates after mammographers used the CAD software.", "answer": 1}, {"article": "WEDNESDAY, July 13, 2011 (HealthDay News) -- For men who have prostate cancer that's considered \"intermediate risk,\" radiation plus four months of hormone therapy appears to improve survival, a new study finds.\nThe hormone therapy is known as androgen deprivation therapy.\nThe hormone therapy started two months before radiation.\nMen with high-risk cancer need long-term hormone therapy.\nIt could be four months, six months or longer.\"\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The harms associated with male hormone therapy were listed.", "answer": 1}, {"article": "Despite popular lore, agency won't allow labels to say drink is good for consumers' hearts\n\nWASHINGTON - There is no credible scientific evidence that drinking green tea reduces the risk of heart disease, federal regulators said last week in rejecting a petition that sought to allow tea labels to make that claim.\nNonetheless, the belief that drinking green tea confers health benefits has driven its popularity over the past decade, the Tea Association of the United States has said.\nIto En Ltd., a Japanese company that bills itself as the world's largest green tea company, and its U.S. subsidiary, Ito En (North America) Inc., petitioned the FDA in June, seeking to make the claim that drinking at least five ounces of green tea a day may reduce the risk of heart disease.\n\"There is no credible evidence to support qualified health claims for green tea or green tea extract and a reduction of a number of risk factors associated with (cardiovascular disease),\" the FDA said on its Web site last week.\nA health claim, in the language of the FDA, characterizes the relationship between a substance and a reduction in the risk of contracting a particular disease.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "This article reports that consumption of green tea is not an effective means for reducing risk of heart disease. However, it failed to mention potential harms of consuming green tea. It can be harmful for people with heart problems for whom consumption of caffeine is restricted. ", "answer": 0}, {"article": "The requested URL /usnews/health/articles/070603/11back.htm was not found on this server.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story notes that surgery has risks, but does not explain what the risks are, whether the patients enrolled in the studies were harmed by the treatments they received, or whether other research has documented potential long-term harms not reported in the current studies. For example, fusion eliminates movement in the fused segment of the spine. This not only reduces instability (as intended), but can add extra stress to the segments above and below the fused segment. This added stress often creates its own problems and may trigger additional fusions. ", "answer": 0}, {"article": "This clinical trial was funded by Merck.\nThe UK currently uses Gardasil which protects against four HPV types and offers about 70 per cent protection against cervical cancer, and also significantly reduces the risk of other types of cancer and genital warts.\nHowever, other types are high risk, causing cervical cancer (and less commonly vulvar, vaginal, penile, anal, and throat cancers).\nThe new vaccine, Gardasil 9, is not only safe but will offer greatly improved protection against cervical and other cancers.\nUntil late last year, there were two available vaccines to protect against HPV related disease (Cervarix and Gardasil).\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The only mention of potential harms from the new vaccine come from a study author who says, \u201cThis is a significant achievement. The new vaccine, Gardasil 9, is not only safe but will offer greatly improved protection against cervical and other cancers.\u201d \u00a0Indeed, the vaccine appears to be safe, but we think that a complete disclosure of the adverse events observed in the study would have been helpful.\u00a0The conclusion in the research notes, \u201cAdverse events related to injection site were more common in the 9vHPV group than in the qHPV group.\u201d So yes, the vaccine is safe, but appears to have more issues at the injection site than the existing vaccines. This is important because not all girls carry through with all three vaccinations; the lack of follow-through may be related to pain on injection.", "answer": 0}, {"article": "The key to making the therapy work?\nThe only treatment is a bone-marrow transplant \u2014 if a compatible donor can be found \u2014 or a transplant with cord blood, if it was saved at birth.\nThe disease strikes about one in 20,000 boys; symptoms first occur at an average age of 7.\nFor the first time, doctors have used gene therapy to stave off a fatal degenerative brain disease, an achievement that some experts had thought impossible.\nThe patients were children who had inherited a mutated gene causing a rare disorder, adrenoleukodystrophy, or ALD.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Potential adverse effects were not adequately addressed. The story did do a good job of highlighting concerns about gene therapies in general, pointing to problems that have cropped up in previous, unrelated gene therapy trials. And it mentioned that bone marrow transplants have risks. However, it didn\u2019t address potential harms associated with this study in particular. According to a supplement of the journal article, side effects ranged from fever and seizures to gastroenteritis. The side effects listed in the supplement also included those for one patient (2018), whose ALD symptoms worsened significantly after treatment began. It\u2019s not clear what effect, if any, the treatment had on the relevant patient.", "answer": 0}, {"article": "An experimental treatment for prostate cancer tumors using high-intensity focused ultrasound (HIFU) shows promise as an effective treatment with fewer side effects than existing therapies.\nIn this study, after 12 months, it\u2019s a 9-in-10 chance.\u201d\n\nThe men in the study were aged 45 to 80 with medium- to high-risk cancer, and would likely have undergone surgery or radiotherapy down the line.\nWhile the initial results were promising, they need to be replicated; HIFU also needs to be studied long-term and compared with other therapies.\nIf the technology holds up, it could also work for other cell-based cancers like breast, thyroid, pancreas and liver, Ahmed said.\nAhmed told Bloomberg that HIFU may also be cheaper than other standard treatments, noting that the cost of the MRI and mapping was an estimated $2,400, plus about $1,600 for HIFU; in comparison, removing the prostate costs about $7,100.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story stated that \u201cNone of the patients reported urinary incontinence a year after treatment, and only 1 in 10 suffered from poor erections.\u201d Again, this was not the whole story.\u00a0 17% of men developed urinary tract infections after the procedure and men required catheters for an average of 8 days.", "answer": 0}, {"article": "In 2012, a federally funded panel of experts on preventive care concluded there are more risks than benefits to screening American men for prostate cancer with the PSA test. And in April 2017, the U.S. Preventive Services Task Force dumped the decision squarely into the laps of patients and their doctors. Some men between 55 and 69 years of age might well decide to get their PSA checked, the task force said. After hearing the ledger of pros and cons, however, others in that age bracket might just as reasonably skip the screening test, the panel concluded.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story warns of overdiagnosis and overtreatment, and then specifically notes harms to \u201csexual function, urination and bowel movements.\u201d The story also quotes an expert who notes that \u201cthe way screening has been implemented in the United States leaves much to be desired\u201d and that the debate should be about \u201cwhether we can change our behavior so that it does more good than harm.\u201d\nHowever, while the headline and lead paragraphs focus on the claim that PSA screening saves lives, the first mention of overdiagnosis and overtreatment does not appear until more than halfway into the story.", "answer": 1}, {"article": "It is the first shingles vaccine to combine a non-live antigen with a specifically designed adjuvant.\nMany vaccines are made from a weakened form of the virus, but Shingrix is made from just a single protein--known as glycoprotein E--that comes from the outer shell of the herpes zoster virus.\n\"The efficacy is approximately 90% for all age groups--even for those over 70 years of age.\nThe research, published in the Journal of Infectious Diseases, shows that Shingrix offers protection for up to four years, but Professor Cunningham believes it will last much longer.\n\"Our research shows that the vaccine stimulates your immune system to produce more antibodies and it generates a 24-fold increase in T cells.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "There\u2019s no information on harms. Most people had pain around the injection site, and a variety of other symptoms such as muscle plain, headache and nausea were reported during clinical trials.", "answer": 0}, {"article": "These results have helped eliminate pre-term birth and hospitalizations for pre-term labor, and patients and families have better outcomes, he added.\n\u201cThey\u2019ve lost family members generation after generation after generation, or they\u2019ve had family members who\u2019ve suffered from chronic disease that\u2019s totally preventable.\u201d\n\nThese procedures not only help limit the passing on of diseases\u2014 they may also help couples get pregnant faster.\n\u201cWhen we do pre-implantation genetic screening, we can ensure that the embryos are chromosomally normal before transferring them back to the intended mother\u2019s uterus, and that increases the likelihood of implantation,\u201d Dr. Jared Robbins, an associated professor in obstetrics and gynecology-reproductive endo & infertility at Northwestern University Feinberg School of Medicine, told Fox News.\nAccording to the Centers for Disease Control and Prevention (CDC), birth defects caused by genetic disorders affect one in every 33 births in the United States.\nSpecialists now have a way to test the parents-to-be that may not only increase their chances of getting pregnant but also reduce the risk of them passing on certain genetic diseases.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story doesn\u2019t address potential harms. A 2011 article in the journal Nursing for Women\u2019s Health addresses the issue nicely: \u201cThe limitations of [preliminary genetic diagnosis] should be discussed with the couple, too. These include informing the couple about the possibility of misdiagnosis and also the possibility that genetic mutation-free embryos may not be identified.\u201d Those are risks that can\u2019t be overlooked.", "answer": 0}, {"article": "Ralph Sacco and Tatjana Rundek of the University of Miami in an accompanying editorial.\nThe researchers also found that the one-year stroke risk doubled when multiple blood vessel clogs were seen with brain imaging, a large artery was narrowed by heart disease and the patient scored a 6 or 7 on a seven-point scale that assesses stroke risk factors.\nThe findings, reported in the New England Journal of Medicine, are more evidence of the benefits of sending someone to a hospital even if muscle weakness or slurred speech has only lasted for a few seconds, lead author Dr. Pierre Amarenco of Bichat Hospital in Paris told Reuters Health by phone.\nBut in the new study, Amarenco and his colleagues found stroke risks of 1.5 percent at two days, 2.1 percent at seven days and 3.7 percent at 90 days when mini-strokes were treated aggressively.\nIt didn\u2019t include a comparison group, which would offer the best evidence, but it \u201chelps build the evidence base for the importance of getting in for early treatment,\u201d said Dr. Donna Arnett, dean of public health at the University of Kentucky and past president of the American Heart Association.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The study doesn\u2019t appear to discuss harms or side effects from this newer type of specialized stroke care for TIA patients, nor does the story. However, that doesn\u2019t mean any exist. Aggressively treating\u00a0TIAs carries risks and side effects.", "answer": 0}, {"article": "Adamas is also testing the drug to treat walking impairment in patients with multiple sclerosis.\nThe main ingredient of Gocovri, amantadine, has been available in the market as an antiviral drug for several decades.\nA majority of patients diagnosed with Parkinson\u2019s are treated with levodopa, whose use often leads to dyskinesia - involuntary movements that are non-rhythmic, purposeless and unpredictable.\nAn estimated 90 percent of levodopa-treated patients, about 200,000 people in the United States, suffer from LID, the company said.\nAdamas\u2019 Gocovri, previously ADS-5102, is the first drug cleared by the FDA to control levodopa-induced dyskinesia (LID).\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "None of the harms related to amantadine are mentioned in this release. One has to be especially cautious of the drug\u2019s effects on the central nervous system, including nervousness, anxiety, agitation, insomnia, difficulty in concentrating, and exacerbations of pre-existing seizure disorders.", "answer": 0}, {"article": "Is that a good thing?\n\"Oxygen is different, because it has a direct biological effect on brain tissue,\" said Paul G. Harch, a physician in New Orleans who over the past three decades has used hyperbaric oxygen to treat hundreds of people with chronic brain injury as well as stroke.\nFor the past 50 years, hyperbaric therapy has been approved by the Food and Drug Administration as a treatment for non-healing wounds, carbon monoxide poisoning, burns and decompression sickness.\n\"These patients don't have enough oxygen to heal the injured parts of their brains,\" said Shai Efrati, a researcher and physician at Tel Aviv University in Israel and a leading hyperbaric scientist.\nWhile in the chamber, patients breathe in pure oxygen, typically pressurized to about twice the density of sea-level air; in this environment, the lungs take in about 10 times as much oxygen as under normal conditions.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The\u00a0 risks and complications of hyperbaric treatment are not mentioned.\nAccording to Johns Hopkins Health Library these risks include (but are not limited to) lung damage, middle ear trauma, visual changes, and seizures. Many of these are dose-related, which means that the risks increase with duration of therapy and degrees of pressurization.\nFurthermore, there are certain groups of people (like those with chronic lung, middle ear, sinus, or seizure disorders) who may not be good candidates.", "answer": 0}, {"article": "\u201cSo this is a possible fringe benefit.\u201d\n\nResearchers studied 2,447 men over 12 years, examining them every other year.\nTaking aspirin every day may lower the risk for prostate enlargement, a new study has found.\n\u201cWe were pretty surprised by the strong association with objective things like the 49 percent reduction,\u201d he said.\nOther nonsteroidal anti-inflammatory drugs, or Nsaids, like naproxen (Aleve) or ibuprofen (Advil or Motrin), have the same effect.\nStill, he said, he was impressed.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The article does not mention any harms of using daily aspirin (like bleeding). ", "answer": 0}, {"article": "Sept. 17, 2010 -- The FDA has approved Krystexxa (pegloticase) for the treatment of gout.\nThe drug is associated with some serious side effects.\nThe condition is associated with obesity, high blood pressure, high cholesterol, and diabetes.\nThe drug is administered to patients every two weeks as an intravenous infusion.\nKrystexxa is for adults with long-standing chronic gout who do not improve with or cannot tolerate other treatments.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story did explain: ", "answer": 1}, {"article": "University of Miami cardiologists last week reported success in a small, preliminary human clinical trial of a new stem cell therapy they hope some day will routinely mend human hearts and reduce the need for lifelong medication, even for transplants.\n\u201cAlmost certainly, I would be deceased or in much worse shape had I not had the opportunity to be in this program.\u201d\n\nHare stressed that the current trial is only a small, run-up phase of extensive testing that will take up to five years and involve dozens of hospitals and hundreds of patients before winning U.S. Food and Drug Administration approval for routine use.\n\u201cThat's the Holy Grail, the quest the whole field has been pursuing for close to a decade, and this is evidence we're on the right track,\u201d said Dr. Joshua Hare, director of the University of Miami Medical School's Interdisciplinary Stem Cell Institute.\nThe reduction was up to 25 percent, while current therapies including medication and pacemakers typically reduce the size by only about 5 percent, he said.\nMax Eaton, the 68-year-old direct-buy franchise owner who was patient No.1 in the eight-person trial, said Wednesday he's thankful he was part of the trial, adding that he had just completed a 2.8-mile, 41-minute walk around his neighborhood in Lauderdale-by-the-Sea, Fla.\n\n\u201cI feel very grateful,\u201d he said.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "As the story indicates, none of the participants experienced \u201csignificant side effects,\u201d but it would have been helpful to define what \u201csignificant\u201d means. For example, the study authors define serious side effects as death, non-fatal heart attack or stroke, hospitalization for worsening heart failure, blood flow compromise, or atrial fibrillation. While none of the subjects experienced these more serious side effects, the study did report that people had other issues such as premature ventricular complex, increased heart rhythm, and fluid buildup around the heart. Even when describing a study this small, the story should quantify the harms.\n", "answer": 0}, {"article": "Two new just-released studies offer fresh insights into the best way to lose weight and keep it off. Jennifer Corbett Dooren has details on The News Hub. Photo: Bloomberg\n\nA diet based on healthy carbohydrates\u2014rather than a low-fat or low-carbohydrate diet\u2014offers the best chance of keeping weight off without bringing unwanted side effects, a study published Tuesday in the Journal of the American Medical Association suggests.\n\nStudy participants following a low-glycemic-index diet, which is similar to a Mediterranean diet and focuses on fish, fruit, vegetables, nuts and whole grains, also saw improved cholesterol levels and other important markers that lower the risks of developing heart disease...", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story mentioned that despite burning more calories, the low-carb group had increases in some markers of cardiovascular disease.", "answer": 1}, {"article": "\"What we've had available the last 16, 17 years has made a big difference,\" Richert says, \"and what we have coming onboard now, these are going to make even a larger difference.\nThe new pills also appear to be more effective than most current drugs.\nThe main benefit of the pills will be that they are easier to take.\n\"People will be more prone to take them early, more prone to stay on the drugs,\" Richert says.\nIt was later reintroduced with strict monitoring requirements.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Potential\u00a0 harms were listed but not quantified.\u00a0 How often do they occur?\u00a0 ", "answer": 0}, {"article": "Patients who continued treatment for 24 weeks had further decreases in insulin doses, and lost an average of 10 pounds.\n\"Some patients have now been treated for up to a year, and the effect is as good as it was at the beginning,\" Dandona said at a news conference webcast from Boston.\nAt the annual meeting of the Endocrine Society in Boston, Dandona reported the results of a study in which 14 adults, whose type 1 diabetes was well controlled with insulin given via an insulin pump, received once-daily Victoza for either one week or 24 weeks.\nJune 7, 2011 - People with well-controlled type 1 diabetes had even better sugar control, used less insulin, and lost an average of 10 pounds in six months when taking the type 2 diabetes drug Victoza in a small clinical study.\nTheir average dose of mealtime insulin decreased by seven units (30%) and their need for all-day insulin dropped by eight units (32%).\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story pays appropriate attention to potential harms. It notes that the weight loss caused by the drug could be detrimental to thin patients, and that the drug causes\u00a0abdominal pain, nausea, and vomiting.\u00a0\u00a0The study author notes\u00a0that adverse effects cause about 5% of type 2 diabetes patients to stop taking the drug. The story probably should have mentioned that the drug is administered by injection, something which can\u2019t be very appealing to type 1 diabetics who\u00a0may already be giving themselves multiple injections daily or, as in this study, are using insulin pumps that only require a needle to be inserted every few days.", "answer": 1}, {"article": "Four people taking curcumin, and two taking placebos, experienced mild side effects such as abdominal pain and nausea.\nThe research, published online Jan. 19 in the American Journal of Geriatric Psychiatry, examined the effects of an easily absorbed curcumin supplement on memory performance in people without dementia, as well as curcumin\u2019s potential impact on the microscopic plaques and tangles in the brains of people with Alzheimer\u2019s disease.\nIt also has been suggested as a possible reason that senior citizens in India, where curcumin is a dietary staple, have a lower prevalence of Alzheimer\u2019s disease and better cognitive performance.\nThe study was supported by the Ahmanson Foundation, the Marshall and Margherite McComb Foundation, the McMahan Foundation, Bob and Marion Wilson, the Fran and Ray Stark Foundation Fund for Alzheimer\u2019s Disease Research, the U.S. Department of Energy and the National Institutes of Health.\nNewswise \u2014 Lovers of Indian food, give yourselves a second helping: Daily consumption of a certain form of curcumin \u2014 the substance that gives Indian curry its bright color \u2014 improved memory and mood in people with mild, age-related memory loss, according to the results of a study conducted by UCLA researchers.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release notes that four volunteers taking the curcumin supplement experienced abdominal pain and nausea \u2014 a potential harm of turmeric use. But the published study notes that six volunteers dropped out of the study due to \u201cgastrointestinal distress.\u201d This should have been noted in the release as well.\nAs we have reported before in our reviews related to health claims made about curcumin, the active ingredient of tumeric:\nNeither turmeric nor curcumin has been extensively studied in clinical trials, but\u00a0animal studies have shown\u00a0that chronic use could lead to stomach ulcers. In addition, the American Herbal Products Association classifies turmeric as a menstrual stimulant.\u00a0Turmeric should be avoided\u00a0in patients with bleeding disorders and bile duct obstruction.\nExperts believe tumeric is generally safe, although the quality of the available clinical studies is questionable.", "answer": 0}, {"article": "MS is an autoimmune neurodegenerative disorder that affects nearly 2.5 million people worldwide.\nThat myelin increases the speed of neural transmission is one of the most well-established concepts in neurobiology, and combined with the clear evidence from Chan's preclinical research showing that clemastine fumarate promotes myelin formation, myelin regeneration is the only plausible explanation for the VEP results, the authors said.\nThe drug tested in the trial, clemastine fumarate, was first identified as a candidate treatment for MS in 2013 by UCSF's Jonah R. Chan, PhD, Debbie and Andy Rachleff Distinguished Professor of Neurology, vice chief of the Division of Neuroinflammation and Glial Biology, and senior author of the new study.\nIn light of previous laboratory studies of the antihistamine compound at UCSF, the researchers said, the drug most likely exerted its effect by repairing damage MS had inflicted on myelin, an insulating membrane that speeds transmission of electrical signals in the nervous system.\nIt's not a cure, but it's a first step towards restoring brain function to the millions who are affected by this chronic, debilitating disease,\" said the trial's principal investigator, Ari Green, MD, also Debbie and Andy Rachleff Distinguished Professor of Neurology, chief of the Division of Neuroinflammation and Glial Biology, and medical director of the UCSF Multiple Sclerosis and Neuroinflammation Center.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "Most common side effects associated with clemastine include transient drowsiness, sedation, dizziness and disturbed coordination. Other adverse effects include rash, low blood pressure, vomiting, difficulty urinating and wheezing.\nParticipants did not experience serious adverse effects during the trial, according to the published journal article (page 5). Some patients experienced fatigue, which resulted in a patient modifying his/her dose, and a small number of patients showed increased levels of triglycerides, a type of fat found in blood.\nSince harms are not addressed in the news release, we rate it Not Satisfactory.", "answer": 0}, {"article": "That was not statistically significant.\nJanuvia, an oral medication known chemically as sitagliptin that helps lower blood sugar levels, had sales of about $4 billion in 2014, plus another $1.8 billion for the related combination product Janumet\n\nOn the study\u2019s main focus, after about three years 11.4 percent of Januvia patients had experienced cardiovascular death, non-fatal heart attack, non-fatal stroke or hospitalization for unstable angina versus 11.6 percent in the placebo group.\nThe detailed results also showed no increase in hospitalization for heart failure, which had been a particular concern with DPP-4 inhibitors, the class to which Januvia belongs.\n(Reuters) - Details of a large heart safety study presented on Monday appear to give Merck and Co\u2019s diabetes drug Januvia a clean bill of health, possibly setting the stage for a return to sales growth for the drugmaker\u2019s biggest product.\nThere were 228 such hospitalizations for Januvia and 229 in the placebo group, according to data also published in the New England Journal of Medicine.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story is focused on the potential harms of the drug and it does a fairly good job explaining the differences between the risks for different bad outcomes from the drug and from a placebo. We give very high marks to the story for providing both comparisons using percentages but also using absolute numbers throughout. So, for example, the story said,\u201dThere were 228 such hospitalizations for Januvia and 229 in the placebo group, according to data also published in the New England Journal of Medicine.\u201d\nIt also does a nice job of explaining, at least in one instance, that some of the comparisons between the drug and placebo are not statistically significant. For example, the story said that, \u201cThere was also no significant difference between Januvia and placebo in infections, cancer, kidney failure or severe hypoglycemia, which is dangerously low blood sugar, researchers reported.\u00a0Acute pancreatitis, a concern with some diabetes drugs, was uncommon but higher with Januvia, 23 versus 12. That was not statistically significant.\u201d\nWith that being said, we wish the story had mentioned that three-year follow up may not be long enough to catch some potential harms. And while the pancreatitis issue was downplayed, a larger and longer study might have shown the concern to be statistically significant if the trend continued. An independent expert analyst may well have commented on such concerns, but no such expert was quoted.", "answer": 1}, {"article": "Merck & Co. and Schering-Plough Corp. said a long-awaited trial showed their cholesterol drug Vytorin failed to slow progression of heart disease better than a cheaper drug, threatening the companies' $5 billion-a-year cholesterol-fighting franchise.\n\nSchering-Plough's shares fell 8% to $25.52 and Merck declined 1.3% to $59.78 at 4 p.m. in New York Stock Exchange composite trading.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "There was really no mention of the harms of treatment other than that the combination medication studied failed to provide greater reduction of cardiovascular risk than from a statin alone. This is where reporting on unpublished data is troublesome.\u00a0 What harms surfaced in this trial? ", "answer": 0}, {"article": "WASHINGTON (Reuters) - A new, longer-lasting \u201cmorning-after\u201d pill to prevent unwanted pregnancy appears to work with no unexpected side effects, U.S. health regulatory staff said in documents released on Tuesday.\nIf it is approved, it should be clearly labeled as an abortifacient, which would limit its distribution, the American Association of Pro Life Obstetricians & Gynecologists said in a letter to the FDA earlier this month.\n\u201cThere is a medical need for an efficient emergency contraceptive product which acts consistently over a prolonged time period,\u201d HRA Pharma said in a separate document released by the FDA.\n\u201cThere is no doubt that ulipristal acts an abortifacient because the drug blocks progesterone receptors at three critical areas,\u201d an action that \u201cinterferes with the hormone action of progesterone to prepare the endometrium for implantation and to support the early pregnancy,\u201d the group wrote.\nFor ella, \u201cwhile you\u2019re going to have to go and get a prescription for it, it gives you a little bit more leeway in terms of putting your ability to put your life on hold and get this healthcare need taken care of,\u201d said Amy Allina, program and policy director for the National Women\u2019s Health Network.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story mentions that the FDA found no unexpected adverse events and describes the side effects of the drug including nausea, headache and abdominal pain as \"common.\" The package insert for EllaOne describes these side effects as affecting more than 10% of users. It would have been helpful if the story had cited that stat. ", "answer": 1}, {"article": "(CNN) -- The use of mammograms has dipped since a medical task force made controversial recommendations that women in their 40s may not need to get breast cancer screenings every year, according to one of three small studies to be presented Monday.\nThe studies suggest that fewer physicians are recommending annual mammograms for women in their 40s, fewer patients in that age group are getting screened and that tumors found through routine mammography are more likely to be detected in early stages of cancer.\nAlthough the task force concluded that the net benefit of mammography in the 40s is small, Hardesty said: \"If you're the one person we find your cancer, it's the world to you.\"\nAfter the guidelines, that rate decreased to 20%, and 56% of the clinicians reported they were discussing the risks and benefits of screening with patients.\nThat decrease, Hardesty said, \"is a statistically significant difference,\" but it also showed more doctors were discussing mammograms with patients.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "We wouid have like to have seen more discussion of the potential harms in 85% of biopsies being non-cancerous.\u00a0 But since the story did actually quantify the number of false positives, we\u2019ll give it the benefit of the doubt on this criterion.", "answer": 1}, {"article": "The average age was 53 when the study began.\nDuring the next seven years, the cancer returned in 256 women (16.7 percent) in the special diet group and 262 women (16.9 percent) in the comparison group.\nThe government study found no benefit from a mega-veggie-and-fruit diet over the U.S. recommended serving of five fruits and vegetables a day -- more than most Americans eat.\nHopes that a diet low in fat and chock-full of fruit and vegetables might prevent the return of breast cancer have been dashed by a seven-year experiment in more than 3,000 women.\nThe study appears in today's Journal of the American Medical Association.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story only provided the information that the two groups did not differ in terms of rates for breast cancer recurrence, not survival. The story did mention that neither of the groups lost more weight, so such a high-fiber diet is not a guarantee for weight loss.\u00a0 The story does not mention any harms of a diet high in fiber and low in fat. Possible \"side effects\" of such a diet might include bloating, gas, and diarrhea or loose stools.\u00a0 \n\u00a0\n", "answer": 0}, {"article": "For more information about deep brain stimulation, visit the American Association of Neurological Surgeons\nThe study adds to other recent research focused on neuromodulation, which harnesses the power of electrical impulses in the body for therapeutic benefit.\nIn the case study, a 55-year-old man was implanted with a deep brain stimulator to treat severe pain stemming from a stroke.\n\"It's a really interesting paper,\" said Dr. Nicholas D. Schiff, director of the Laboratory of Cognitive Neuromodulation at New York-Presbyterian Hospital/Weill Cornell Medical Center.\nThe finding introduces the possibility that deep brain stimulation -- a surgical implant that delivers electrical pulses to the brain -- might one day become a treatment for drug-resistant hypertension or lead to clues about the brain's role in regulating blood pressure.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story makes passing reference to risks, but it doesn\u2019t mention any specific problems and doesn\u2019t discuss how commonly they occur with DBS. This is, after all, brain surgery, and there are a host of things that can go wrong, ranging from obvious problems such infections,\u00a0bleeding, and strokes,\u00a0to more subtle effects such as cognitive impairment. The story should have explored these. The competing WebMD story, while failing to quantify the harms, at least listed quite a few of the potential problems.", "answer": 0}, {"article": "Researchers said they had identified a family of retroviruses in patients with chronic fatigue syndrome, opening up a potentially promising new avenue of treatment for a debilitating disease that afflicts as many as four million Americans and 17 million people world-wide.\n\nThe finding will likely spur patients with the condition to seek treatment with drugs used to fight HIV, the virus that causes AIDS. Although HIV and the newly identified virus group are different, they are both retroviruses.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "", "answer": 0}, {"article": "Watch Chief Medical Correspondent Dr. Sanjay Gupta's CNN Special Report \"Weed 4: Pot vs.\n\"There is a great deal of movement in the Northeast, with New Hampshire and New Jersey being well-positioned to legalize adult use,\" Moore said.\nBut unlike opioids, marijuana has little addiction potential, and virtually no deaths from marijuana overdose have been reported in the United States, according to Bradford.\n'This crisis is very real'\n\n\"We have had overuse of certain prescription opioids over the years, and it's certainly contributed to the opioid crisis that we're feeling,\" he added.\n\"We saw a 9% or 10% reduction (in opioid prescriptions) in Colorado and Oregon,\" Wen said.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The article didn\u2019t explain that marijuana can be addictive and has side effects. These include an increased heart rate, which can increase the risk of a heart attack, especially in older people with heart problems. In some people, long-term use can cause intense nausea and vomiting. In addition, high doses of marijuana can cause psychosis, delusions or hallucinations. When smoked, marijuana can cause breathing problems and increase a person\u2019s risk of developing a lung infection.", "answer": 0}, {"article": "For more information, visit www.idri.org.\n\"While previous attempts have used vaccines primarily developed for other diseases, this is the first totally defined vaccine candidate developed specifically for leprosy, using the latest technologies and offering no less than those exposed to leprosy deserve,\" said Steven Reed, Ph.D., IDRI President, CEO & Founder.\n\"We are thrilled that after 15 years and an investment of over $5.1 million, made possible by our faithful donors and partners, a leprosy-specific vaccine is beginning a Phase I clinical trial,\" says Bill Simmons, President and CEO of American Leprosy Missions.\nIn addition to IDRI and American Leprosy Missions, a variety of partners are taking part in efforts to eliminate leprosy, including Novartis and the Novartis Foundation.\n\"The vision and support of American Leprosy Missions has been tremendous as we've worked with them throughout the years, moving from our work in developing a leprosy diagnostic to our current focus on a successful leprosy vaccine,\" he said.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The whole goal of a phase 1 trial is to determine what, if any, potential harms are associated with a given treatment. The release makes note of this, which is why we give it a satisfactory rating. That said, if animal trials turned up any potential harms that may be relevant to human subjects, those should have been mentioned here. And even if animal trials didn\u2019t turn up any potential harms, the release would have been stronger if it had mentioned that.", "answer": 1}, {"article": "\u201cNow it\u2019s, like, \u2018When do we get this here?\nTeichner asked Brad and Amy Price, \u201cYou keep using the word \u2018miracle.\u2019 In what way is all of this a miracle?\u201d\n\n\u201cOur son\u2019s still with us, and Cecilia as well,\u201d they replied.\nAnd when Kefalis learned about the Italian trial, and the fact that Amy Price had to keep going back to Milan with Giovanni and Ceci, it was clear she would use the money to help families get to Italy.\nTell me what you need me to do.\u2019\u201d\n\nUntil then, she continues to fight her battles one cupcake at a time -- the Price children, Giovanni and Cecilia, proof to her the war can be won.\nAmy recalled: \u201cShe\u2019s sitting on the bed in her tutu and her colorful sweater, and they\u2019re telling me she\u2019s gonna die.\u201d\n\nMany children with the disorder are dead by the age of 6.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The\u00a0mention of gene therapy\u2019s difficult past, including deaths in clinical trials, is valuable\u00a0context for the reader to understand the potential risks of experimental treatments, so we\u2019re glad the story mentioned that.\nHowever, there should have been some discussion of the potential harms of this new treatment. (If there are none, which is unlikely, that is also important and valuable information to the reader.)", "answer": 0}, {"article": "Lustig and his colleagues think they\u2019ve produced the \u201chard and fast data that sugar is toxic irrespective of its calories and irrespective of weight.\u201d\n\nMORE: FDA Wants Nutrition Labels to Include More Detail on Added Sugars\n\nLustig\u2019s confidence comes from the unique study, described in , of 43 Hispanic or African-American children aged eight to 18 years old.\nThe only difference in the nine-day diet was that most of the sugar the children ate was replaced by starch \u2014 the overall number of calories remained the same.\n\u201cWe know that a healthy diet and weight loss cause good metabolic changes, and although this study tries to attribute its effects to low fructose, in fact it is impossible to do that because of the study design.\u201d\n\nSome experts are concerned for other reasons.\nBut I worry that people are going to hang everything on this when we still need to reduce consumption.\u201d\n\nLustig hopes that won\u2019t happen as more data emerges that details how sugar is altering the body in unhealthy ways outside of its caloric contribution.\nWhile there has been a lot of attention on the presence of belly fat and its connection to metabolic syndrome, the fact that the children saw improvements in the amount of fat in their liver suggests that might be an important way that sugar is contributing to chronic disease.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "It\u2019s\u00a0hard to say what \u201charms\u201d or risks would result from cutting sugar from childrens\u2019 diets. We\u2019ll rate this Not Applicable.", "answer": 2}, {"article": "A compound in raspberries is being touted as the next new fat burner. But people looking to lose a few pounds may not want to go running to the produce aisle just yet. Scientists say there are no major human studies to support the idea that a berry holds the secret to weight loss.\n\nRaspberry ketones, the organic compounds that give raspberries their aroma, raised hopes as a weight-loss aid after a 2005 study by Japanese researchers found the ketones boosted fat-burning processes in rat cells in a laboratory as long as those...", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story mentions an unpublished manufacturer-funded\u00a0safety study which purportedly found no side effects from one raspberry ketone product. However, it\u00a0emphasizes the\u00a0fact that neither the study author nor the funding company would provide a copy of the paper, suggesting that the results wouldn\u2019t hold up to scrutiny. The story also warns that people with\u00a0cardiac issues or high blood pressure should avoid these supplements, which may produce stimulant effects.\u00a0It could have mentioned that dietary supplements\u00a0are not well regulated, and\u00a0that many products \u2014 especially weight loss products \u2014 have been shown to contain undeclared drugs and other potentially dangerous ingredients.\n\u00a0", "answer": 1}, {"article": "Erenumab, a laboratory-made antibody that blocks a neural brain pathway called CGRP, is the first drug in 20 years proven to prevent migraine attacks.\nLead investigator Prof Peter Goadsby, from King\u2019s College hospital, London, said: \u201cStrive \u2026 represents an incredibly important step forward for migraine understanding and migraine treatment.\u201d\n\nThe findings, reported in the New England Journal of Medicine, clearly showed that blocking the CGRP pathway could reduce the impact of migraine, he said.\nThe research revealed that by months four to six, at least a 50% reduction in mean migraine days per month was achieved for just over 43% of patients injected under the skin with 70-mg of erenumab each month, while half of patients injected with the higher dose of 140-mg had such results.\n\u201cPlacebo responses [in migraine studies] are quite high and I think that is partly due to the subjective nature of pain and because of the strong psychological effects that being treated have on that experience of pain and those symptoms,\u201d he said, adding that injections generally result in an even stronger placebo effect than tablets.\nThe trial, called Strive, compared patients taking erenumab for six months with others given a non-active placebo dummy drug.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story teases us with the tidbit that erenumab may come with fewer side effects, yet not one of them or their potential frequency is established. The reported adverse event numbers are important: About 63% of the placebo group experienced at least one, compared to 55.5%-57.3% of the drug groups.", "answer": 0}, {"article": "I would be in my 60s when I had to do this again, and who wants to have surgery unnecessarily when you are 60 something?\"\nIt also turns out that the longer a woman has the implants, the more likely she is to experience these complications.\nAs many as half of patients will need to have additional surgeries or have the implants removed in the first decade.\nWhat's more, he says few of them follow the recommendations to get routine MRIs to screen for leaks.\nBut complications from implants are frequent \u2014 things like hardening of the skin around the implant; ruptured, wrinkled, or lopsided implants; scarring, pain and infection.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story discussed common problems, but was silent on:\nHalf the story on harms just isn\u2019t good enough in this case.\n", "answer": 0}, {"article": "Researchers collected data on occurrence and severity of respiratory symptoms, breastfeeding status and genotyping was performed.\nIt is already known that environmental factors have a modifying effect on specific genetic risk, so the aim of this new study was to find out whether this could also be true for breastfeeding and this specific gene related to asthma with the respect to respiratory symptoms in early infancy.\nThis is the first time that we were able to show the effect of the 17q21 variants on respiratory symptoms during the 1st year of life, depending on breastfeeding status.\n\"Our study is the first to show that breastfeeding can modify the effect of asthma-related genetic profiles on respiratory symptoms in the first year of life\", commented Dr Olga Gorlanova, from the University Children's Hospital Basel (UKBB), and the University of Basel, Basel, Switzerland.\nFindings revealed that during the weeks that infants were breastfed, those carrying the asthma risk genotypes, had a 27% decreased relative risk of developing respiratory symptoms.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "Harms associated with breastfeeding are admittedly few and far between. Infrequently, a mother may transfer environmental contaminants to a breastfeeding infant. However, the risks associated with genetic testing in general and the association between the\u00a0chromosomal variant\u00a0on chromosome 17, called 17q21, and the risk of the development of asthma are not covered. How reliable is the test?\u00a0 Is over- or under-diagnosis a risk factor? How likely is it that the child may eventually develop asthma? How many children with the variant develop asthma?", "answer": 0}, {"article": "\"We found that the combination of two anticytokines containing extra-low doses of antibodies against TNF\u03b1 and IFN?\nIn patients with hypertension, target blood pressure was reached in 71% of those taking the combination of anticytokines compared to just 32% of patients on standard therapy alone.\nPatients with active disease have an increase in molecules that promote inflammation, which has been associated with an increased risk of cardiovascular disease.\nPatients taking the combination of anticytokines had a lower rheumatoid arthritis disease activity score, as measured by the DAS28,2 and more dramatic decreases in IL-1, IL-6 and TNF\u03b1 than the group on standard therapy alone.\n\"Rheumatoid arthritis is an autoimmune disease in which cytokines such as tumour necrosis factor (TNF) and interferon (IFN), which normally protect the body, attack healthy cells,\" said Professor Babaeva.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "No mention of harms, and there are known rare, but serious, adverse effects associated with all of the biologic drugs used to treat rheumatoid arthritis.", "answer": 0}, {"article": "Available from: http://www.\nAround 180 million people globally have chronic HCV infection,1 including approximately 15 million people in the EU.2 The prevalence of HCV infection in children varies from 0.05%-0.36% in the United States and Europe and up to 1.8%-5.8% in some developing countries.3 While direct-acting antivirals have been used to treat and cure adult patients with HCV,4-7 until now children have been mainly treated for 24 to 48 weeks with pegylated interferon plus ribavirin (RBV), an older treatment which causes severe side effects.8\n\n\"Direct-acting antivirals have transformed the treatment of adults with chronic HCV, however, studies of these new therapies in children are required,\" said Dr Karen Murray, University of Washington School of Medicine and Seattle Children's, Seattle, United States, and lead author of the study.\nILC 2017: The study evaluated the use of a direct-acting antiviral treatment in children aged 6 to 11, for whom the standard of care has been pegylated interferon plus ribavirin\n\nApril 21, 2017, Amsterdam, The Netherlands: A study presented today that evaluated an investigational dosage of once-daily ledipasvir 45 mg/sofosbuvir 200 mg (LDV/SOF) in children aged six to 11 years infected with the Hepatitis C virus (HCV), found that 99% of children (n=89/90) had undetectable levels of HCV-RNA 12 weeks after treatment.\n\"This study is a breakthrough for the management of children aged six to 11 years old with Hepatitis C, demonstrating that the new DAA regimen is highly efficacious and, more importantly, safe in this group of HCV-infected children\", said Prof Frank Tacke, University Hospital Aachen, Germany, and EASL Governing Board Member.\nThe study, presented at The International Liver Congress\u2122 2017 in Amsterdam, The Netherlands, also showed that the fixed-dose combination of LDV/SOF was well-tolerated, and no patients experienced a serious adverse event considered related to the study drug.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The news release does an adequate job, stating that the combination therapy \u201cwas well-tolerated, and no patients experienced a serious adverse event considered related to the study drug.\u201d It adds: \u201cThe most common side effects reported in 10% or more of patients were headache, fever, abdominal pain, diarrhea, vomiting, cough, fatigue, sore throat and nausea.\u201d\nBut one important caveat wasn\u2019t mentioned: Often negative effects aren\u2019t apparent until after a drug goes on the market and is used by a large and diverse population of patients. For example, if the drug resulted in a fatal complication in 2 out of 100 children, this small study could easily have missed that. It\u2019s risky to call a drug \u201csafe\u201d until it\u2019s been used in a very large number of patients.\nThis is particularly true when drugs are fast-tracked for approval by the FDA, as Harvoni\u2019s use in children is expected to be. As HealthNewsReview.org reported in January, Harvoni is among the new generation of hepatitis C drugs that are generating serious adverse effects that warrant further scrutiny. Hence, there could be unknown risks in extending this therapy to kids.", "answer": 1}]